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1.1 Sepsis 
1.1.1 Definition 
Before 1992 terms like ‘bacteraemia’, ‘septicaemia’ and ‘sepsis syndrome’ were used 
interchangeably and ‘sepsis syndrome’ was considered synonymous with ‘severe infection’. 
However, it is generally the response of the host characterised by a marked inflammatory 
response, rather than the infectious agent itself, that portends a dismal prognosis.1 The 
inflammatory host’s response can also occur under non-infectious conditions such as trauma, 
burns or pancreatitis and has been labelled as SIRS (Systemic Inflammatory Response 
Syndrome). Sepsis can be considered as SIRS caused by an infectious agent. In 1992, the 
American College of Chest Physicians and Society of Critical Care Medicine (ACCP/SCCM) 
organised a consensus conference with the goal to define sepsis and organ failure. They 
agreed that sepsis should be defined as a systemic response to infection and that this 
systemic response is manifested by two or more of the following conditions as a result of 
infection: temperature >38° or < 36°, heart rate > 90 beats/min, respiratory 
rate > 20 breaths/min or PaCO2 < 32 Torr (<4.3 kPa), white blood cells > 12,000 cells/mm
3 or 
< 4,000 cells/ mm3, or >10% immature (band) forms. Sepsis associated with organ 
dysfunction, hypoperfusion, or hypotension (a systolic blood pressure of < 90 mmHg or a 
reduction of > 40 mmHg from baseline in the absence of other causes for hypotension) was 
defined as severe sepsis, and septic shock was defined as sepsis with hypotension despite 
adequate fluid resuscitation, along with the presence of perfusion abnormalities that may 
include, but are not limited to, lactic acidosis, oliguria or an acute alteration in mental 
status.2 
This definition has created a lot of controversy because the SIRS criteria are overly sensitive 
and not specific, meaning that most ICU patients would qualify for them. Also, these criteria 
are not of utility in diagnosing a cause for the syndrome or in identifying a distinct pattern of 
host response.3;4 They are descriptive rather than mechanistic and describe clinical 
syndromes, rather than specific pathophysiological processes.5 In 2001, a broadly supported 
consensus meeting evaluated the 1992 definition and although they decided evidence did 
not support a change in the original definition, they did expand the list of potential signs and 
symptoms of sepsis reflecting clinical bedside experience and thus providing tools that 
should alert clinicians for a potential diagnosis of sepsis (Table 1). 6;7 
Table 1: Diagnostic tools for diagnosing sepsis 6;7 
Infection, documented or suspected and some of the following: 
General variables 
 Fever (>38.3°C) 
 Hypothermia (core temperature <36°) 
 Heart rate >90/min or more than two SD above the normal value for age 
 Tachypnoe 
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 Altered mental state 
 Significant edema or positive fluid balance (>20ml/kg over 24h) 
 Hyperglycemia (plasma glucose >140mg/dl or 7.7 mmol/l in the absence of diabetes) 
Inflammatory variables 
 Leucocytosis (>12000/µl) 
 Leukopenia (<4000/µl) 
 Normal WBC count with greater than 10% immature forms 
 Plasma C-reactive protein more than two SD above the normal value 
 Plasma  pro calcitonine more than two SD above the normal value 
Hemodynamic variables 
 Arterial hypotension (SBP <90mmHg, MAP<70mmHg or a SBP decrease >40mmHg in 
adults or more than 2 SD below normal for age) 
Organ dysfunction variables 
 Arterial hypoxemia (PaO2/FIO2<300) 
 Acute oliguria (urine output < 0.5 ml/kg/h for at least 2 hours despite adequate fluid 
resuscitation) 
 Creatinine increase >0.5mg/dl or 44.2 µmol/l 
 Coagulation abnormalities (INR>1.5 or aPTT>60sec) 
 Ileus (absent bowel sounds) 
 Thrombocytopenia (platelet count <100,000/µl)  
 Hyperbilirubinemia (>4mg/dl or >70µmol/l) 
Tissue perfusion variables 
 Hyperlactatemia (>1mmol/l) 
 Decreased capillary refill or mottling    
 
1.1.2 Epidemiology 
About  37% to 75% of admissions in medical and surgical ICU’s is related to sepsis.8-12 In a 
multicenter study in French ICU’s, the yearly incidence rate of severe sepsis was estimated at 
0.95 episodes per 1000 inhabitants and the total annual number of episodes in ICU’s at 
56,540.13 Compared with previous studies from the same group in 1993, these data suggest 
a 75% increase in the incidence rate of severe sepsis.14 The increasing incidence in sepsis and 
severe sepsis in the last decades has been corroborated by several other groups in the 
United States and Europe (Table 2). It is likely that multiple factors contribute to this rapid 
increase in incidence. First, the population is aging with an increasing burden of chronic 
disease. Second, there is also an increased use of invasive procedures and 
immunosuppressive drugs, chemotherapy and transplantation. Last, there is an increasing 
microbial resistance.15  Although the increase in the incidence of sepsis is universal, there is 
still a wide variability between and even within countries (Table 2). This is most likely due to 
differences in documentation of sepsis and hospital coding practices. In large databases the 
ICD-9 (International Statistical Classification of Disease) codes are used to capture patients 
with severe sepsis by coupling codes for infection and for organ dysfunction. Differences in 
Chapter 1 
19 
the methodology to use these codes can explain the variability in epidemiological data.15 The 
total number of sepsis related deaths is consistently  increasing over the various studies and 
septicemia has become the 11th leading cause of death in the US (Centers for Disease 
Control/National Health Service). However, the mortality in patients with sepsis or case 
fatality rate is decreasing (Table 2). The latter is probably explained by improvements in care 
for patients with sepsis due to greater awareness of the condition, more rapid 
administration of antibiotics and  better organisation of ICU care.16-21  
 
1.1.3 Costs and quality of life 
In a time where health care resources are being cut down, the discussion on health-
economics and whether treatment for sepsis patients is cost-effective, cannot be avoided. 
The costs associated with sepsis treatment and research are immense, reaching up to 16.7 
billion$  yearly in the US.22 Treating patients with sepsis costs more than treating general ICU 
patients. Edbrook et al23 demonstrated that patients with severe sepsis or early septic shock 
spent prolonged periods of time in the ICU and were significantly more expensive to treat 
than non sepsis ICU patients. In their study, the cost of treating a sepsis patients  varied from 
twice to eleven times more than a non septic ICU patient. Weycker et al24 showed that per 
sepsis patient the cost for the index admission was on average 44.600$. If patients survived 
to hospital discharge, costs went up to 78.500$ at 1 year and 118.800$ at 5 years, per 
patient. In a Canadian retrospective study, Letarte et al25 studied 100 patients with severe 
sepsis and septic shock and found that the mean cost was 11.474$ per episode per case or 
1064$ per day. For survivors after day 28 through year 1, the cost was 27,481$. The total 
cost came to 36.4 to 72.9 million$ per year but was higher if patients survived after day 28, 
indicating that not only the sepsis episode itself, but also revalidation and re-integration 
afterwards, are expensive.  In Germany, the costs associated with sepsis related admissions 
go up from 3.6 to 7.7 billion € yearly.26  
In the last decade, several initiatives to improve the care for patients with sepsis were taken. 
In 2004, an international group of experts in the diagnosis and management of infection and 
sepsis, representing 11 organizations, published the first internationally accepted guidelines 
that the bedside clinician could use for management of severe sepsis and septic shock.27 
These guidelines were converted into ‘sepsis bundles’, defined as selected sets of 
interventions or processes of care, that, when implemented as a group provide a more 
robust picture of the quality of care provided.28 Although implementing an integrated sepsis 
protocol resulted in a mean increase in cost of 8,800$ per patient, largely driven by 
increased ICU Length of Stay (LOS), life expectancy and quality adjusted life years were 
higher in the group receiving the protocol vs those who did not receive it.29 The protocol was 
associated with an incremental cost of 11,274 per quality adjusted life years gained.29 
Surviving ICU without regaining a meaningful Quality of Life (QOL) is not a desirable goal of 
the critical care process30, which makes mortality an insufficient measure of ICU outcome.31 
Even if sepsis patients survive up to hospital discharge, they often present with residual 
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organ dysfunction which may result in invalidating symptoms such as dyspnoe, fatigue, 
impaired function status and reduced health related quality of life in comparision with the 
general population.32-36 However, it remains controversial whether this is specifically due to 
the sepsis syndrome rather than being related to any form of critical illness. In the latter case, 
this persistent ‘dysfunction’ could also be attributed to age and underlying comorbidity. 
Granja et al34 compared the post discharge quality of life in critically ill patients with versus 
without sepsis, by using the EQ5D (Euro Col 5 Dimensions) questionnaire. Patients in the 
sepsis group had a higher mortality, higher APACHE II score and longer LOS vs the non-sepsis 
group. There was no difference in QOL between both groups except for ‘anxiety’ and 
‘depression’, two conditions that appeared to be less prevalent in the sepsis group. 
Several other studies37-44 demonstrated a decrement in QOL in sepsis survivors. However 
they mostly did not report on QOL pre sepsis and compared with population norms which 
might confound the relationship between reduced QOL and sepsis.  
Overall, there is an increasing interest in quality of life and the (potential) advantages of post 
discharge care in sepsis patients to improve health related quality of life, as indicated by 
several trials currently underway on these topics.45;46  
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Table 2: Main studies on the incidence of sepsis over time. 
 Time period Setting Sepsis definition Incidence Mortality Costs 
Angus et al22 1995 
compared to 
1993-1994 
Non-federal hospitals (n=847)  
in 7 US states 
Severe sepsis, 
documented infection 
and acute organ 
dysfunction (ICD-9-CM) 
- 192,980/6,621,559; 
yielding national estimates 
of 751,000 cases 
- 3 cases/1000 population 
- 2.26 cases/100 hospital 
discharges 
- 1.5% increase per year 
 
Overall hospital 
mortality 
28.6%=251,000 deaths 
annually 
Average cost 
per case: 
22,100$ 
annual, total 
cost:16.7 
billion$ 
Martin et al47 1997-2000 Non-federal acute care 
hospitals including 
approximately 500 hospitals 
with equal representation of all 
geographic regions 
Several ICD-9-CM codes 
for sepsis, bacteremia 
and fungal infections 
Organ failure was 
defined by a 
combination of ICD-9-
CM and CPT  codes 
 
- 10,319,418 cases of 
sepsis/750 million 
hospitalizations 
- 82.7/100,000 in 1997 vs 
240.4/100,000 in 2000 
 
- Hospital mortality 
1979-1984: 27.8% 
- Hospital mortality 
1995-2000: 17.9% 
NA 
Wang et al48 2001-2004 Emergency department 
NHAMCS  
Suspected severe sepsis 
Combination of ICD-9 ED 
admission codes, triage 
vital signs and clinical 
interventions 
2,282,000 cases 
/331,500,000 admissions 
=571,000/year 
or 0.69% 
NA NA 
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Dombrovskiy et 
al49 
1993-
2003 
US community hospitals from 
the NIS=20% sample of US non-
federal short term hospitals 
Sepsis ICD-9-CM codes 
for septicemia and 
major organ 
dysfunction 
- Sepsis: 8,403,766 (=2.15% of all 
hospitalizations) 
- Severe sepsis:2,857,476 (=0.73% 
of all hospitalizations and 34% of all 
hospitalizations for sepsis) 
- Percentage of severe sepsis: 
25.6% in 1993 vs 43.8% in 2003 
- Annual increase of 8.3% in 
hospitalizations for severe sepsis 
(64.7/100,000 in 1993 vs 
134.6/100,000 in 2003) 
- Mortality rate severe 
sepsis from 30.3% in 
1993 to 49.7% in 2003 
- Case fatality rate from 
45% in 1993 to 37.7% in 
2003 
- Annual increase in age 
adjusted mortality for 
severe sepsis:5.6% 
- Annual decrease in 
case fatality rate:1.4% 
 
NA 
Wilhelms et al50 1987-
2005 
ICD-9 and ICD-10 according to 
previously published methods 
by Angus et al22, Martin et al47 
and Flaatten et al51 
Swedish hospital 
discharge Register 
recording all hospital 
admissions 
- Method 122: n=37,990; incidence 
increased from 0.10/1000 in 1987 
to 0.35/1000 in 2005 
- Method 247: n=27,655; incidence 
increased from 0.26/1000 in 1987 
to 0.43/1000 in 2005 
- Method 351: n=12,512; incidence 
increased from 0.03/1000 in 1987 
to 0.13/1000 in 2005 
 
Hospital Mortality 
- Method 122:22.1% 
- Method 247:22.4% 
- Method 351:29.2% 
NA 
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Lagu et al52 2003-
2007 
Severe sepsis 
ICD-9-CM codes according to 
Dombrovskiy et al49 and organ dysfunction 
US community 
hospitals from the 
NIS=20% sample of 
US non-federal 
short term 
hospitals 
200/100,000 in 2003 vs 
300/100,000 in 2007; annual 
increase of 17.8% per year 
- Overall mortality from 
75/100,000 in 2003 to 
87/100,000 in 2007 
- Case fatality rate from 
37% to 29% (2% per 
year decrease in 
hospital mortality for 
patients with severe 
sepsis) 
 
Total cost 
15.4 billion$ 
per year in 
2003 vs 24.3 
billion$ per 
year in 2007 
Gaieski et al15 2004-
2009 
Sever sepsis 
Documented infection including ICD-9 
code for sepsis or septic shock and the 
presence of new organ dysfunction or the 
ICD-9 code for severe sepsis + comparing 
four previous methods (Martin et al47, 
Wang et al48, Angus et al22 and 
Dombrovskiy et al49) 
NIS database 
containing hospital 
stays from 1050 
hospitals in 44 
states 
- Method 122:905/100,000 
- Method 248:1,031/100,000 
- Method 349:300/100,000 
- Method 447:369/100,000 
- Annual increase of 13-
13.3% depending on the 
method used 
- Mortality from 14.7% 
in 2004 to 29.9% in 
2009, depending on the 
method 
- For all methods22;47-49: 
decrease in case fatality 
rate 
NA 
Kaukonen et al21 2000-
2012 
Severe Sepsis with and without shock 
were defined by the presence of ≥2 SIRS 
criteria within the first 24h after ICU 
admission and either 1)APACHE III 
admission diagnosis consistent with sepsis 
or 2)APACHE admission diagnosis 
consistent with infection accompanied by 
organ failure 
Data from the 
ANZICS 
n=2,708/35,012 in 2000 and 
n=12,512/100,286 in 2012 
which means an increase 
from 7.2% in 2000 to 11.1% 
in 2012. 
Mortality in severe 
sepsis decreased from 
35% in 2000 to 18.4% in 
2012 with an average 
annual decrease of 1.3% 
NA 
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1.2 Septic Acute Kidney Injury 
1.2.1 AKI and RRT in sepsis and the critically ill 
Sepsis contributes to AKI in about  30-50% of all AKI cases.53;54 In a study by Bagshaw et al, 
comparing septic vs non septic AKI, sepsis was considered the cause of AKI in 47.5% of 
patients.53 Neveu et al corroborated this by demonstrating that ARF had a septic origin in 
45.5%.10 In another study by Bagshaw et al, sepsis contributed to early AKI (= in the first 24h 
of admission) in 32.4% of cases.55 Brivet el al found 48% of ARF (Acute Renal Failure) to be 
associated with sepsis in critically ill patients.56 In a large study in critically ill patients, Uchino 
et al found that septic shock was the most common contributing factor to ARF.57 Septic 
Acute Kidney Injury (AKI) associates with a greater severity of illness than non- septic AKI, 
which translates in higher mortality rates.53;58;59 In a study by Ali et al, sepsis was a 
precipitating factor in 47% of AKI cases and the incidence of AKI  and Acute on Chronic Renal 
Failure were 18.1 and 33.6 per 100,000 population, respectively.60 The incidence of ARF in 
the critically ill (septic and non septic) varies between 3-25% according to the definition used 
and the population studied.54;56;57;61 In patients with AKI around 1.78 per 100 person years 
are treated with RRT vs 0.74 per 100 person years in those without AKI.62 Around 4-6% of 
critically ill patients are treated with RRT, depending on the inclusion criteria.12;57;63 In the 
general population, the estimated incidence of acute RRT need varies widely54;64-69, going 
from 2.2/100,00065 to 28.6/100,000 population years.54 This variability in incidence is 
explained by 1) the geographic location, 2) the availability of ICU beds, 3) location of RRT 
(either only ICU or both ICU and ward), 4) the epoch in which the incidence is estimated and 
5) the severity of illness of the included patients. 
 
1.2.2 Definition of AKI 
Reaching an agreement on a universally accepted definition of Acute Kidney Injury (AKI) has 
turned out to be one of the major challenges in the field of nephrology. Despite the 
advances in technology over the last decades, AKI is still associated with an unacceptable 
high morbidity and mortality and the absence of a universal definition is an impediment to 
progress in this domain. It hampers the comparison of epidemiological data between 
different studies and it results in widely different outcome data even within one specific 
setting (e.g. cardiac surgery or critically ill setting).  
In the last years, several efforts to uniformize the definition of AKI were published. In 2004, 
the Acute Dialysis Quality Initiative (ADQI) established the RIFLE criteria (Table 3).70  RIFLE is 
an acronym that stands for “Risk”, “Injury”, “Failure”, “Loss of Kidney Function” and “End 
Stage Renal Disease”. It consists of three severity stages (Risk, Injury and Failure) and two 
outcome stages and is based on both serum creatinine and urinary output criteria, 
classifying patients according to whichever criterion delivers the worst RIFLE classification 
(e.g. a patient with RIFLE “Risk” for serum creatinine and RIFLE “Failure” for urinary output 
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will have a final RIFLE classification as “Failure”).  In 2007, the Acute Kidney Injury Network71 
refined the RIFLE criteria by 1) eliminating the need for a baseline serum creatinine and 
using the admission value as a reference value, 2) removing the eGFR criteria (since eGFR 
should only be used in steady state conditions which AKI is not by definition) and adding an 
absolute increase in serum creatinine of 0.3 mg/dl next to a relative 1.5 fold increase (Table 
3). The addition of a 0.3 mg/dl increase in the definition relates to several reports on the 
association of even small increases of serum creatinine with worse outcome, mainly in the 
cardiac surgery setting72-79 and 3) including a 48 hours window for the serum creatinine 
increase to occur. Several studies have compared the AKIN and RIFLE criteria in different 
settings, mostly concluding that they were of equal value (Table 4). KDIGO finally assembled 
both the RIFLE and AKIN criteria in their definition80 which was followed by position 
statements by various associations in Europe and the United States.81-84 Since the 
publication of the KDIGO criteria for AKI, they have been validated in different clinical 
settings and compared to the existing classification criteria of RIFLE and AKIN, demonstrating 
good performance for diagnosing AKI (Table 4). In several studies the criteria themselves are 
still being applied differently which makes it difficult to compare studies that at first glance 
appear to use the same definitions, but in fact use (substantially) different interpretations of 
the same definition (Table 4). 
Most of these studies also report on outcome whereas  these  criteria were originally not 
intended to predict mortality. 
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Table 3: Comparison of the RIFLE, AKIN, KDIGO and ERBP criteria for AKI 
 RIFLE AKIN KDIGO ERBP 
Reference or baseline sCr  
value 
Historical baseline value 
If not available: estimated 
value according to ADQI 
Admission value Baseline value, unspecified Admission value 
sCr criterion: relative 
increases within severity 
stages 
Risk: sCr x 1.5-1.9 
Injury: sCr x 2-2.9 
Failure: sCr x 3 or if 
sCr>4mg/dl an acute 
increase of 0.5 mg/dl 
 
Stage 1: sCr x 1.5-2 
Stage 2: sCr x 2-3 
Stage 3: sCr x 3 or RRT or if 
sCr>4mg/dl an acute 
increase of 0.5 mg/dl  
 
Stage 1: sCr x 1.5-1.9 
Stage 2: sCr x 2-2.9 
Stage 3: sCr x 3 or RRT or 
acute rise in sCr>4 mg/dl 
Stage 1: sCr x 1.5-1.9 
Stage 2: sCr x 2-2.9 
Stage 3: sCr x 3 or RRT or 
acute rise in sCr>4 mg/dl 
sCr criterion: absolute 
increases within severity 
stages 
NA Stage 1 if 0.3mg/dl increase 
over 48h 
Stage 1 if 0.3mg/dl increase 
over 48h 
Stage 1 if 0.3mg/dl increase 
over 48h 
GFR criterion Risk: 25% decrease in GFR 
Injury: 50% decrease in GFR 
Failure: 75% decrease in GFR 
NA In patients < 18 years: 
eGFR<35 
ml/min/1,73m2=stage 3 
NA 
UO criterion within severity 
stages 
Risk: UO < 0.5 ml/kg/u 
during  6 hours 
Injury: UO < 0.5 ml/kg/u 
during  12 hours 
Failure: UO < 0.3 ml/kg/u 
during  24 hours or anuria 
during  12 hours 
Stage 1: UO < 0.5 ml/kg/u 
during  6 hours 
Stage 2: UO < 0.5 ml/kg/u 
during  12 hours 
Stage 3: UO < 0.3 ml/kg/u 
during  24 hours or anuria 
during  12 hours 
Stage 1: UO < 0.5 ml/kg/u 
during  6-12 hours 
Stage 2: UO < 0.5 ml/kg/u 
during ≥12 hours 
Stage 3: UO < 0.3 ml/kg/u 
during ≥24 hours or anuria 
during ≥12 hours 
Stage 1: UO < 0.5 ml/kg/u 
during a 6 hour block 
Stage 2: UO < 0.5 ml/kg/u 
during  two 6 hour blocks 
Stage 3: UO < 0.3 ml/kg/u 
during ≥24 hours or anuria 
during ≥12 hours 
     
Time span for AKI diagnosis within 7 days time windows of 48h within 
7 days 
0.3mg/dl increase over 48h 
or sCr x 1.5 within 7 days 
0.3mg/dl increase over 48h 
or sCr x 1.5 within 7 days 
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 RIFLE AKIN KDIGO ERBP 
Outcome stages -Loss: Persistent ARF. 
Complete loss of kidney 
function >4 weeks 
-End Stage Kidney Disease: 
RRT need ≥3 months 
NA NA NA 
Extra AKI should be sustained for 
at least 24 hours 
- Exlude obstruction  
- Staging should be done 
after fluid resuscitation to 
exclude prerenal factors 
The cause of AKI should be 
determined 
wheneverpossible. 
- The cause of AKI should be 
determined whenever 
possible. As a minimal work-
up, the presence of 
hypovolaemia, post-renal 
causes, low cardiac output, 
use of nephrotoxic agents, 
acute glomerulonephritis 
and renal micro-angiopathy 
as underlying contributors to 
AKI should be evaluated. 
- Urinary volume should be 
expressed using ideal body 
weight rather than real body 
weight when calculating 
urinary output in ml/kg/u 
- Urinary output can be 
collected in 6 hour blocks 
instead of hourly 
- eGFR should not be used  
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Alhough all these efforts are a major step forward, there are still some flaws and pitfalls 
when using these definitions. First, as stated above, these classification criteria are originally 
based on both serum creatinine and urinary output criteria70;71;80;81 but the latter are mostly 
omitted because data on hourly or six hourly urinary output are often lacking, especially in 
large administrative datasets.85-87 Second, the requirement of a historical baseline serum 
creatinine for defining absolute or relative serum creatinine increases in RIFLE, is not always 
satisfied. Using surrogate baseline values such as the admission value, a nadir value during 
the actual hospitalization or an estimated value by solving the MDRD equation assuming a 
GFR of 75 ml/min/1,73m2 as suggested by ADQI70 is susceptible for misclassifications in both 
directions (either over- or underestimation of AKI).88;89 Third, serum creatinine is an 
imperfect parameter for AKI diagnosis because it is influenced by several non-renal factors 
such as age, gender, race, muscle mass and in sepsis patients, volume status. Also, it is a 
functional parameter and it increases slowly after a renal insult so that there is a delay in 
diagnosis.90 The latter has made the search for new serum and urinary biomarkers that are 
only influenced by tubular damage, a top priority in the field of nephrology. The additional 
value of these biomarkers on top of currently used parameters such as  serum creatinine and 
urinary output remains controversial (see also section 1.3 on biomarkers). 
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Table 4: Studies comparing RIFLE, AKIN and KDIGO critera 
Study Study design Setting Included 
patients 
Comparison AKI criteria Baseline sCr Time span AKI 
diagnosis 
Outcome 
Bagshaw et 
al/2008/ NDT
85
 
retrospective critically ill n=120,123 RIFLE vs AKIN sCr and UO but 
modified UO 
criteria 
estimated 
according to 
ADQI 
first 24h after ICU 
admission 
AKI: 
- RIFLE:36.1% 
- AKIN:37.1% 
Hospital mortality: 
- RIFLE:AUC ROC 0.66 
- AKIN:AUC ROC 0.67 
Lopes et 
al/2008/Crit 
Care
91
 
retrospective critically ill n=662 RIFLE vs AKIN sCr and UO - RIFLE: 
estimated 
according to 
ADQI 
- AKIN: lowest 
value within 
24h after 
admission 
within ICU 
hospitalization 
AKI: 
- RIFLE:43.8% 
- AKIN:50.4% 
Hospital mortality: 
- RIFLE:AUC ROC 0.73 
- AKIN:AUC ROC 0.75 
 
Haase et 
 al /2009/ 
J Thorac 
Cardiovasc 
Surg
92
 
prospective cardiac 
surgery 
n=282 RIFLE vs AKIN sCr and UO NA RIFLE: within 7 days 
postoperatively 
AKIN: within 48h 
AKI: 
- RIFLE:45.8% 
- AKIN:44.7% 
Hospital mortality: 
- RIFLE:AUC ROC 0.91 
  (0.82-0.99) 
- AKIN:AUC ROC 0.94 
  (0.81-0.97) 
Joannidis et 
al/2009/ICM
86
 
retrospective critically ill n=16,784 RIFLE vs AKIN sCr and UO but 
modified UO 
criteria 
-RIFLE: 
estimated 
according to 
ADQI 
-AKIN: ICU 
admission value 
First 48h after 
admission 
AKI: 
- RIFLE:35.5% 
- AKIN:28.5% 
Hospital mortality: 
- RIFLE-R:OR 1.38(1.17-1.63)  
- RIFLE-I:OR 1.9(1.65-2.18) 
- RIFLE-F:OR 2.99(2.66-3.36) 
- AKIN st 1:OR 2.07(1.77-2.43) 
- AKIN st 2:OR 1.93(1.63-2.28) 
- AKIN st 3:OR 2.99(2.64-3.38) 
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Study Study design Setting Included 
patients 
Comparison AKI criteria Baseline sCr Time span AKI 
diagnosis 
Outcome 
Robert et 
al/2010/ 
Cardiac 
Surgery
93
 
retrospective cardiac 
surgery 
n=25,086 RIFLE vs AKIN sCr only the latest sCr 
value before 
surgery 
during hospitalization AKI: 
- RIFLE:31% 
- AKIN:30% 
Hospital mortality: 
- RIFLE:AUC ROC 0.78 
- AKIN:AUC ROC 0.77 
Yan et al/2010/ 
Eur J 
Cardiothorac 
Surg
94
 
retrospective post cardio- 
tomy on 
ECMO 
n=67 RIFLE vs AKIN sCr and UO the first value 
available for 
every patient 
hospitalized 
First 48h after ECMO AKI: 
- RIFLE:81% 
- AKIN:85% 
Hospital mortality: 
- RIFLE-F:AUC ROC 0.74 
- AKIN:AUC ROC 0.80 
Chang et  
al/2010/ 
Shock
95
  
retrospective critically ill n=291 RIFLE vs AKIN sCr and UO the first value at 
hospitalization 
or estimated 
according to 
MDRD in n=20 
NA AKI: 
- RIFLE:61% 
- AKIN:% 
Hospital Mortality: 
- RIFLE:AUC ROC 0.74 
- AKIN:AUC ROC 0.72 
Englberger et 
al/2011/Crit 
Care
96
 
retrospective cardiac 
surgery 
n=4,836 RIFLE vs AKIN sCr only the last value 
before surgery 
first 7 postoperative 
days 
AKI: 
- RIFLE:18.9% 
- AKIN:26.3% 
Hospital mortality: 
Increase with an OR of 4.5(3.6-
5.6) for every increase in RIFLE 
class vs 5.3(4.3-6.6) for AKIN 
Wang et 
al/2013/NDT
97
 
retrospective Adult in-
patients 
under- 
going ≥2 sCr 
measure-
ments 
n=19,878 KDIGO vs absolute 
sCr increase 
sCr only lowest of the 3 
first sCr values 
available 
during hospitalization AKI: 
- KDIGO:23.4% 
- Delta sCr discriminates the 
differences between adjacent 
AKI stages earlier 
In-patient Mortality: 
NRI between delta sCr and 
KDIGO for prediction of 
mortality was 9.7%(6.2-13.2%) 
Chapter 1 
31 
Study Study design Setting Included 
patients 
Comparison AKI criteria Baseline sCr Time span AKI 
diagnosis 
Outcome 
Roy et al/2013/ 
Cardiorenal 
Med
98
 
retrospective heart failure n=637 KDIGO vs 
RIFLE,AKIN,WRF 
sCr only estimated from 
the admission 
value (if within 
the normal 
range) or from 
another value 
within 6 months 
(whichever was 
lowest) 
- RIFLE: 1-7 days and 
sustained for at least 
24h 
- AKIN: 48h period 
during hospitalization 
- KDIGO: 1.5 increase 
over 7 days or 
0.3mg/dl increase over 
48h 
 
 
AKI: 
- KDIGO:36.7% 
- RIFLE:25.6% 
- AKIN:27.9% 
- WRF:33% 
Composite outcome (Heart 
Failure related readmission, 
RRT need or death)  
*30 days: 
- KDIGO:AUC ROC 0.74 
- RIFLE:AUC ROC 0.76 
- AKIN:AUC ROC 0.72 
- WRF:AUC ROC 0.72 
*1 year: 
- KDIGO:AUC ROC 0.67 
- RIFLE:AUC ROC 0.64 
- AKIN:AUC ROC 0.64 
- WRF:AUC ROC 0.65 
Rodrigues et 
al/2013/PLoS 
One
99
 
prospective post AMI n=1,050 KDIGO vs RIFLE sCr only admission sCr 7 days AKI: 
- KDIGO:36.6% 
- RIFLE:14.8% 
30 days mortality: 
- KDIGO:AHR 3.99(2.59-6.15) 
- RIFLE:AHR 3.51(2.35-5.25) 
1 year mortality: 
- KDIGO:AHR 2.43(1.62-3.62) 
- RIFLE:AHR 1.84(1.12-3.01) 
Bastin et 
al/2013/ 
J Crit Care
100
 
retrospective cardiac 
surgery 
n=1,881 KDIGO vs 
AKIN,RIFLE 
sCr only most recent sCr 
value either pre 
admission or 
upon admission 
first 7 days after 
admission 
AKI: 
- KDIGO:25.9% 
- RIFLE:24.9% 
- AKIN:25.9% 
Hospital mortality: 
- KDIGO: AUC ROC 0.86 
- RIFLE:AUC ROC 0.78 
- AKIN:AUC ROC 0.86 
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Study Study design Setting Included 
patients 
Comparison AKI criteria Baseline sCr Time span AKI 
diagnosis 
Outcome 
Zeng/ 
2014/CJASN
101
 
retrospective Hospita- 
lized 
patients 
n=31,970 KDIGO vs RIFLE, 
AKIN, CK kinetics 
model 
sCr only lowest during 
hospitalization 
or arithmic 
mean of all 
values in the 
outpatient 
setting (7-365 
days) and 
comparison 
with estimated 
values and 
values acquired 
by multiple 
imputation 
-KDIGO: 0.3mg/dl 
increase within 48h or 
sCr x 1.5 within 7 days 
- AKIN: within 48h 
- RIFLE: within 7 days 
AKI: 
-KDIGO:18.3% 
-RIFLE:16.1% 
- AKIN:16.6% 
- CK: 7% 
Hospital mortality: 
- KDIGO:OR 2.8(2.2-3.6) 
- RIFLE:OR 2.9(2.2-3.6) 
- AKIN:OR 2.6(2.0-3.3) 
- CK:OR 5.2(4.1-6.6) 
 
Fujii/2014/ 
CJASN
102
 
retrospective Hospita- 
lized 
patients 
n=49,185 KDIGO vs 
RIFLE,AKIN 
sCr only most recent 
value before 
admission or an 
estimated 
value, or the 
lowest sCr value 
within 7 days 
for the first 7 
days. After day 
8, the reference 
value was the 
lowest sCr value 
within the last 7 
days 
during hospitalization AKI: 
- KDIGO:11.6% 
- RIFLE:11% 
- AKIN:4.8% 
Hospital mortality: 
- KDIGO:AUC ROC 0.78  
- RIFLE:AUC ROC 0.77 
- AKIN:AUC ROC 0.69 
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1.2.3 Pathophysiology of septic AKI 
There is a lot of controversy about the pathogenesis of septic AKI and the role of renal 
hypoperfusion vs inflammation cascades in this phenomenon.8;103-114 Although sepsis is 
characterized by a hyperdynamic  state with high cardiac output, low vascular resistance and 
hypotension, it remains unknown how this translates to the kidney.115,116 Schrier et al117 
state that renal vasoconstriction is the hallmark of septic AKI (Figure 1), however several 
reports demonstrate an increase rather than a decrease in renal blood flow (RBF) in 
sepsis.118;119 Animal studies also show opposite findings.120;121 Langenberg et al 
demonstrated in a model of sustained hyperdynamic sepsis in Merino sheep that septic ARF 
was associated with a marked increase in RBF with renal vasodilatation.121 However, Benes 
et al induced sepsis in pigs and found opposite findings with an increase in renal vascular 
resistance, accompanied by a reduction in RBF.120 Overall, 2/3 of the animal studies reported 
a decrease in RBF whereas the remaining 38% reported no change or an increase in RBF.122  
The role of altered blood flow in the pathogenesis of septic AKI in humans remains difficult 
to characterize because of limitations associated with the measurement of renal blood flow 
during sepsis.123 Using PAH clearance to estimate RBF in sepsis is problematic since the PAH 
exctraction rate is decreased and renal vein sampling is an invasive technique, often not 
feasible in critically ill and unstable patients. To the best of our knowledge, only three 
studies measured renal blood flow in septic humans, all of them suggesting increased renal 
blood flow.118;119;124 Nevertheless, even when there is no decrease in RBF, there can still be a 
low perfusion pressure with a dysregulation of pre- en post glomerular capillary perfusion 
pressure, which determines renal vascular resistance. 
Figure 1: Hemodynamic factors in sepsis (adapted from Schrier et al.)117 
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More recently, Prowle et al used Cine phase-contrast magnetic resonance imaging125 to 
measure renal blood flow and cardiac output in 10 adult patients with established septic 
acute kidney injury (nine received RRT) and 11 normal volunteers.126 They found that renal 
blood flow was constantly reduced as a fraction of cardiac output in established acute kidney 
injury and lower than in normal individuals. Renal vascular resistance was generally 
increased, but remained significantly correlated with systemic vascular resistance. Authors  
found no correlation between RBF and GFR as estimated by CrCl.126  
However, in recent literature more and more emphasis is put on tubular damage caused by 
inflammatory cascades, oxidative stress, microcirculatory changes and immunological 
processes as the underlying pathophysiological mechanism for septic AKI as opposed to 
renal hypoperfusion.127-133  
 
1.2.4 Animal models 
The failure to successfully translate results from animals to humans134;135 has been 
attributed to specific disease characteristics of sepsis (complexity and heterogeneity), 
inappropriate clinical trials with inadequate trial designs and the use of animal models that 
do not fully mimic human sepsis. 
Animal models need to reproduce the complexity of human sepsis and its treatment in the 
ICU. Sepsis models can be divided into three categories: 1) injection of an exogenous toxin 
(e.g.LPS), 2) alteration of the animal’s endogenous protective barrier such as intestinal  
leakage (e.g. cecal ligation and puncture (CLP) or colon ascendens stent peritonitis (CASP) 
and 3) infusion or instillation of exogenous bacteria (Table 5). The problem with LPS injection 
is that it causes much earlier and higher peak levels of cytokine expression compared with 
levels observed in human sepsis. CLP induced sepsis models show a cytokine profile similar 
to that in human sepsis. CLP induced sepsis increases lymphocyte apoptosis, which mimics 
immunosuppression at the later phase of human sepsis. But although the standard CLP 
model encompasses more clinical features and drug responses of human sepsis than the LPS 
model, it is still missing some key features, especially kidney and lung injury. Also, models 
such als CLP or CASP are helpful in understanding polymicrobial sepsis but human sepsis may 
also be caused by a single pathogen. Opposite to CLP or CASP models, bacterial infusion 
models may also be caused by a single pathogen. They can approximate introduction of a 
single pathogen in a controlled manner, allowing reproducible infection and can be 
translated to larger animals for the study of systemic and organ-specific hemodynamics. 
Animal models of sepsis differ from human sepsis because of age, comorbidity and use of 
supportive therapy. Animals should receive treatment comparable to the supportive 
treatment that is standard for ICU patients. Clinical sepsis and sepsis induced AKI are 
dramatically influenced by underlying diseases, which partly explains why simple animal 
models of sepsis do not mimic human sepsis and thus are not able to predict human 
response to therapeutics.109  Studying septic AKI in animal models also requires that animals 
live long enough so that they can develop AKI. 
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Table 5: Different animals models of sepsis.109 
Animal model Advantage Disadvantage 
LPS Injection Simple, sterile; some 
similarities with human 
pathophysiology 
Early and transient increase in 
inflammatory mediators more 
intense than in human sepsis 
CLP or CASP Early silent period; moderate 
and delayed peak of mediators; 
multiple bacterial flora 
Age and strain variability; early 
hemodynamic period in some 
models 
Clinically relevant CLP Replication of clinical risk 
factors 
Difficulty in analyzing 
pathophysiological pathyways 
Infusion or instillation of 
exogenous bacteria 
Early hyperdynamic state No change in intrarenal 
microcirculation; need large 
animals; labor intensive 
 
Complex animal models of human sepsis may be pharmacologically more relevant than 
simple animal models for the testing of therapeutics, as they may ultimately predict human 
drug responsiveness more accurately. Despite a focus on the proinflammatory aspects of 
sepsis, most deaths in sepsis occur from nosocomial infections during a late prolonged 
immunosuppressed state, even in the face of succesful early, supportive therapies. Septic 
patients have defects in innate and adaptive immunity, including altered monocyte antigen 
presentation, decreased lymphocyte proliferation and responsiveness, and lymphocyte 
apoptosis and anergy. Simple CLP models demonstrate splenic apoptosis but animals 
generally die too early before late immunosuppression fully develops. More complex models, 
such as 2 hit models have therefore been developed. Other issues in model development to 
be considered include that host susceptibility to pathogenic factors is species dependent. For 
instance, rodents are much less sensitive to LPS than humans.  
 
1.2.5  Cost and Quality of life in patients with (septic) AKI  
AKI is associated with increased cost vs no-AKI across different settings. Chertow et al73 
demonstrated that, in hospitalized patients, a serum creatinine increase of 0.5 mg/dl was 
associated with a nearly 7,500$ increase in hospital costs across a broad spectrum of 
conditions. Kerr et al136 demonstrated that AKI is associated with QALY (Quality Adjusted Life 
Years)  loss and that the financial burden of AKI is substantial. Total postoperative costs after 
cardiac surgery were higher in patients with AKI compared to the matched controls and they 
increased progressively with the severity of AKI as determined by RIFLE stages.137 Also in 
general ICU costs are higher in patients whose course is complicated by AKI.138 In a study by 
Van Berendoncks et al, AKI hospital survivors were visited at home between 1 and 2 years 
after hospital discharge to determine morbidity, comorbidity and quality of life.139 Authors 
found  that the Physical Component Summary (PCS) declined and that the Mental 
Component Summary remained stable in relation to the US population. These results were 
also confirmed by comparing them to the general population values of the neighboring 
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countries.139 Apart from age, other parameters such as severity of disease and clinical 
parameters during hospitalization did not show any significant relationship with the 
summary scores, suggesting that Health Related Quality of Life is difficult to predict from 
data available at the time of acute illness, as was found by others.140 The need to take into 
account the prehospitalisation Health Related Quality of Life when examining outcomes in 
critically ill patients was also demonstrated by Iribarren-Diarasarri et al and Wehler et 
al.141;142 Some studies have reported reduced quality of life after RRT 143-145 while others 
have reported no difference in long-term quality of life between RRT and no-RRT 
patients.69;146 In a retrospective study of 979 ARF patients treated with RRT, 77.7% of 
hospital survivors responded to a questionnaire about their quality of life. 57% appeared to 
be self-sustaining and 49% stated that their quality of life had improved.147 Loss of energy 
and limitations of physical mobility assessed by the Nottingham Health Profile were the most 
frequently reported complaints at six months in patients treated with RRT during their 
hospital stay. Functional ability as assessed by the Daily Living score was fairly good at six 
months.67 Gopal et al found that in the majority of patients who survived to be discharged 
from hospital after combined acute multiple organ and renal failure, the overall state of 
health and quality of life seemed acceptable.31 In a retrospective cohort of 24,906 critically ill 
patients, Vaara et al found that at six months, patients treated with RRT (6.8%) perceived 
their health as good as non-RRT patients by VAS (visual analogue scale).69 Although Johansen 
et al found a more unfavorable Healt Related Quality of Life compared with previous reports, 
this might be attributed to the fact that Quality of Life was only assessed at 60 days and that 
included patients were generally sicker.148 The cost per ARF survivor in the study by Korkeila 
et al67 was estimated at 80,000$ per patient and in the study by Gopal et al31, the cost for 
each year of survival was estimated at 50,000$ per patient.149 Most patients felt that their 
treatment was worthwhile and that they would undergo the same treatment again if 
necessary31, which was confirmed by several other studies.140;143;150;151 Hamel et al estimated 
the cost  per QALY at 128,200$ in ARF patients treated with RRT.145 In a study by Ahlström et 
al the total costs of hospital treatment were 28,000$ per ARF patient treated with RRT and 
222,000$/QALY for the first year.143 Laukkanen et al152 showed that the cost utility of acute 
RRT is generally poor. However, it seems to be acceptable in patients with renal recovery 
who survive over a year, and in 5 year survivors the cost utility ratio was around 20,000 
€/QALY. However, the cost utility decreased with increasing age exceeding 1 million€/QALY 
in the older groups.152 Thus cost utility of acute RRT was good in patients who had no 
chronic renal disease before hospitalization and whose renal function recovered.152 There is 
controversy on the economic burden of CRRT (Continuous Renal Replacement Therapy) 
versus IRRT (Intermittent Renal Replacement Therapy) with most studies concluding that 
continuous techniques are more expensive without significant improve in QALY.153-155 Etghen 
et al 156 however, concluded that initial CRRT is cost effective compared to IRRT by reducing 
the rate of long-term dialysis dependence among critically ill AKI survivors. However, a 
recent Cochrane review157 does not demonstrate a benefit of CRRT over IRRT. Cost 
consideration also varies among centers, mainly due to differences in nurse staffing, use of 
fluids, anticoagulation and extracorporeal circuit. 158 
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Altogether, these findings suggest that the cost and effort associated with RRT and ICU care 
in these patients are high but broadly comparable to those associated with the care of other 
serious illnesses.67;149 
1.3 Biomarkers 
1.3.1  Definition 
A biomarker can be defined as a measurable or assessable entity that provides diagnostic, 
prognostic or treatment orienting information which can drive patient care.159 An ideal 
validated biomarker should be able to detect a disease or condition non-invasively and has 
to be specific for the corresponding disease, and therefore should unambiguously 
discriminate it from disease-related changes or other disease entities.160 An ideal biomarker 
should come from a readily attainable source and the result of the biomarker assessment 
should lead to a noticeable benefit for the patient through intervention based on the 
interpretation of the biomarker value, such as survival or quality of life improvement.159 
 
1.3.2 Use of biomarkers in different settings 
The search for biomarkers is a top priority research item in many settings such as 
cardiovascular diseases161, oncology162;163, infectious diseases164 and renal diseases.165;166 
The aim is to allow for earlier diagnosis, even in a stage where the disease is subclinical 
and/or to monitor evolution under treatment.  
Renal diseases are ideally suited for biomarker research given that urine is an easy accessible 
biofluid and its protein content is derived mainly from the kidney.167 There has been 
extensive research to find new biomarkers in several domains of kidney diseases such as 
diabetic nephropathy, lupus nephritis, FSGS, membranous glomeronephritis, IgA 
nephropathy, allograft rejection in kidney transplants and Acute Kidney Injury. 165;166 
The goal of biomarker research in kidney disease is to allow for 1) earlier diagnosis of kidney 
injury and/or dysfunction which is particularly important because the currently used markers, 
such as serum creatinine, are unreliable and delay diagnosis, 2) differentiation between 
distinct pathological entities, 3) selection of patients who would benefit from 
immunosuppressive therapy, 4) selection of patients who need more RAS blockade.167 
Especially in the field of AKI there has been an increasing interest in serum and urinary 
biomarkers. Serum creatinine, currently used to diagnose AKI, is an imperfect parameter 
that is influenced by several non-renal factors such as age, gender, race and muscle mass 
and only increases slowly after a renal insult causing a delay in diagnosis.90 The potential 
interest of new biomarkers not only lays in earlier diagnosis but also in he differentiation 
between so called ‘prerenal azotemia’, a condition assumed not to be associated with 
tubular injury and ‘intrinsic AKI’, which is associated with tubular injury. Serum creatinine is 
a functional parameter that does not directly relate to tubular injury. This has made the 
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search for urinary biomarkers only influenced by tubular damage, a top priority in the field 
of nephrology (Table 6). 
Table 6: Summary of the most studied biomarkers for diagnosis of AKI and their main source 
Acronym/abbreviation Legend Main source 
AP alkaline phosphatase Liver, bone, intestine, placenta, 
brush border proximal convoluted 
tubules 
α1MG alpha 1 microglobulin Liver. Reabsorption by renal 
proximal tubular cells 
α1acidGP alpha 1 acid glycoprotein Liver. Reabsorption by renal 
proximal tubular cells 
AST Aspartate aminotransferase Liver, heart, muscle, brain, red 
blood cells, kidney 
Β2MG beta 2 microglobulin All nucleated cells. Reabsorption 
by renal proximal tubular cells 
Cystatin C Cystatin C All nucleated cells. Reabsorption 
by renal proximal tubular cells 
FENA Fractional Excretion of Sodium NA 
FEUrea Fractional Excretion of Urea NA 
GGTP Gamma glutamyl transpeptidase All cells except myocytes. Mainly 
liver and kidney (brush border 
proximal convoluted tubules and 
loop of Henle) 
GST-α Alpha glutathione S transferase Expressed in almost all tissues. 
Kidney: Proximal tubular cells 
(cytoplasmatic) 
GST-π Pi glutathione S transferase Expressed in almost all tissues. 
Kidney: Distal tubular cells 
(cytoplasmatic) 
HGF  Hepatocyte Growth Factor Mesenchymal cells 
ICAM-1 Intracellular Adhesion Molecule 1 Endothelial cells, leukocytes 
IL-6 Interleukin 6 T lymphocytes, macrophages, 
endothelial cells, monocytes 
IL-8 Interleukin 8 Monocytes, macrophages, 
epithelial cells, endothelial cells 
IL-10 Interleukin 10 Monocytes, lymphocytes, 
macrophages 
IL-18 Interleukin 18 Monocytes, dendritic cells, 
macrophages and epithelial cells 
KIM-1 Kidney Injury Molecule 1 Kidney: Proximal tubular cells 
LDH Lactate dehydrogenase Heart, liver, red blood cells, 
muscle, brain, lung. Kidney: 
proximal tubular cells 
(cytoplasmatic) 
LFABP Liver type Fatty Acid Binding Protein Hepatocytes, Kidney: proximal 
tubular cells 
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Acronym/abbreviation Legend Main source 
NGAL Neutrophil Gelatinase Associated 
Lipocalin 
Leucocytes, loop of Henle and 
collecting ducts 
NAG N Acetyl beta Glucosaminidase Several tissues (Liver, brain, 
spleen,…). Kidney: Proximal 
tubular cells (lysosomal) 
PAI-1 Plasminogen Activator Inhibitor 1 Endothelium 
PCX Podocalyxin Podocytes 
RBP Retinol Binding Protein Liver. Reabsorption by renal 
proximal tubula cells 
sTNFR-I Soluble Tumor Necrosis Factor 
Receptor I 
Most cells and tissues (cytotoxic, 
apoptotic and proinflammatory 
effects) 
sTNFR-II Soluble Tumor Necrosis Factor 
Receptor II 
Most cells and tissues 
(proliferative and anti-apoptotic 
effects) 
TNFα Tumor Necrosis Factor alpha Macrophages, lymfoïd cells, renal 
parenchymal cells 
11k-TXB2 11-keto-Thromboxane B2 Platelets 
vWF Von Willebrand Factor Endothelium, megakaryocytes, 
subendothelial connective tissue 
 
Although initial results with new biomarkers were promising168;169, these succesful results 
were mainly obtained in specific settings with a known timing of renal injury (e.g. cardiac 
surgery) and in homogenous patient populations with little comorbidities (e.g. paediactrics). 
Results are far less promising in adult heterogenous populations even when the timing of 
the renal event is known170 but especially when the latter is unknown, multifactorial or 
repetitive (e.g. sepsis, critically ill).171  Many of these markers are also influenced by other 
disease states such as inflammation172 which can explain the important overlap in biomarker 
levels between AKI and no AKI, limiting their use as a discriminatory tool in the individual 
patient and questioning their additional role on top of currently used parameters such as a 
serum creatinine and urinary output. 
 
1.3.3 Proteomics 
Proteomics refers to the large scale study of proteins and their function and structure with 
the objective to find biomarkers than can help to discriminate healthy from disease affected 
individuals. Proteomics can potentially capture dynamic changes in protein expression, 
integrating both genetic and epigenetic factors.173 Commonality in the excretion patterns of 
certain proteins or their fragments in various diseases offer critical insights into the default 
mechanisms of pathological processes. 
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Multiple distinct protein isoforms can be created from the same gene (thus genomics are 
not helpful in the differentiation of these isoforms, which might have different functions) 
and also, proteins can be susceptible to posttranslational modificatons.167 
Both protein isoforms and posttranslational modifications are only detectable by studying 
the protein directly and can be indicative of diverse protein functions.167 Proteomic studies 
can be either discovery based or targeted. Discovery based proteomics are either broad 
(comparison of 2 types of samples, qualitative or quantitative) or focused (protein-protein 
interactions). Targeted proteomic studies are based on previous knowledge of the candidate 
proteins of interest, and consists of different types of samples, using SR (Selected Reaction) 
or MR (Multiple Reaction) monitoring.167  
Mass spectrometry (MS) is widely used as a method for protein identification. There are two 
main components of a mass spectrometer, namely, the ionization technique (to volatilize 
and ionize proteins and peptides for mass analysis with high sensitivity and specificity) and 
the mass analyzer. The most commonly used ionization techniques are Matrix-Assisted Laser 
Desorption Ionization (MALDI) and electrospray ionization (ESI). There are four different 
types of mass analyzers: Time of Flight (TOF), quadrupole (Q), ion trap (IT), and Fourier 
transform ion cyclotron resonance (FTICR).174  
However, several caveats should be kept in mind with proteomic research. Serum 
proteomics is hampered by the complexity of the serum proteome containing proteins with 
concentration varying over 12 orders of magnitude. Therefore blood samples must be 
depleted of high-abundance proteins. In urinary proteomics, the high salt content and 
changing physicochemical properties and cellular components affect its protein 
concentration and the stability of proteins.160 Sample collection and preparation should be 
standardized. Often, there is a lack of uniform method for sample collection and analysis. 
However, urine composition is influenced by diet, timing of collection, exercise, sex and age 
and therefore, differences in the timing of collection, the methodology used for urine 
concentration (specific gravity or urinary creatinine) and protein isolation, will yield distinct 
proteins. Also, there are still some unresolved technical issues such as the wide 
concentration range, the expense and the fact that it is time-consuming. Not taking into 
account these factors might result in observing protein differences that reflect technical bias 
and not a disease state. An additional problem with the novel renal biomarkers is that the 
urine contains a large dynamic range of protein concentrations and that the majority of 
discovered proteins is within the high abundance  range and thus are not specific to one 
condition.173  
 
1.4  Aim of the project 
The aim of the current project was to: 1) compare different ways to calculate serum 
creatinine increase and assess whether small increases in serum creatinine are also 
associated with worse outcome in sepsis, as is the case in the cardiac surgery setting, 2) 
systematically review the value of new serum and urinary biomarkers in the diagnosis of AKI 
in different clinical settings (paediatrics, cardiac surgery, critically ill patients, emergency 
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department and contrast induced AKI), 3) explore the use of biomarkers such as NGAL, 
fractional excretion of sodium (FENa) and fractional excretion of urea (FEUrea) in the 
differentiation between transient and intrinsic septic AKI, 4) investigate the correlation 
between urinary and serum NGAL since serum NGAL levels are known to be influenced by 
inflammatory states and 5) investigate the role of renal hypoperfusion as a 
pathophysiological pathway in septic AKI.  
To answer these questions, we prospectively included 195 patients with sepsis, severe sepsis 
or septic shock, admitted to the Intensive Care Unit  (ICU) of the Ghent University Hospital.  
 
1.5  Reference List 
 1.  Matot I, Sprung CL. Definition of sepsis. Intensive Care Med 2001; 27 Suppl 1: S3-S9 
 2.   American College of Chest Physicians/Society of Critical Care Medicine Consensus 
Conference: definitions for sepsis and organ failure and guidelines for the use of innovative 
therapies in sepsis. Crit Care Med 1992; 20: 864-874 
 3.  Vandijck D, Decruyenaere JM, Blot SI. The value of sepsis definitions in daily ICU-practice. 
Acta Clin Belg 2006; 61: 220-226 
 4.  Vincent JL, Martinez EO, Silva E. Evolving concepts in sepsis definitions. Crit Care Clin 2009; 
25: 665-75 
 5.  Abraham E, Matthay MA, Dinarello CA et al. Consensus conference definitions for sepsis, 
septic shock, acute lung injury, and acute respiratory distress syndrome: time for a 
reevaluation. Crit Care Med 2000; 28: 232-235 
 6.  Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines 
for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637 
 7.  Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis 
Definitions Conference. Crit Care Med 2003; 31: 1250-1256 
 8.  Groeneveld AB. Pathogenesis of acute renal failure during sepsis.Nephrology Dialysis 
Transplantation 1994; 9 Suppl 4: 47-51 
 9.  Jochimsen F, Schafer JH, Maurer A, Distler A. Impairment of renal function in medical 
intensive care: predictability of acute renal failure. Crit Care Med 1990; 18: 480-485 
 10.  Neveu H, Kleinknecht D, Brivet F, Loirat P, Landais P. Prognostic factors in acute renal failure 
due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute 
Renal Failure. Nephrology Dialysis Transplantation 1996; 11: 293-299 
 11.  Schafer JH, Maurer A, Jochimsen F et al. Outcome prediction models on admission in a 
medical intensive care unit: do they predict individual outcome? Crit Care Med 1990; 18: 
1111-1118 
Chapter 1 
 
 12.  Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the 
SOAP study. Crit Care Med 2006; 34: 344-353 
 13.  Brun-Buisson C, Meshaka P, Pinton P, Vallet B, EPISEPSIS Study Group. EPISEPSIS: a 
reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. 
Intensive Care Medicine 2004; 30: 580-588 
 14.  Brun-Buisson C, Doyon F, Carlet J et al. Incidence, risk factors, and outcome of severe sepsis 
and septic shock in adults. A multicenter prospective study in intensive care units. French ICU 
Group for Severe Sepsis. JAMA 1995; 274: 968-974 
 15.  Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of 
severe sepsis in the United States. Crit Care Med 2013; 41: 1167-1174 
 16.  Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe 
sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377 
 17.  Castellanos-Ortega A, Suberviola B, Garcia-Astudillo LA et al. Impact of the Surviving Sepsis 
Campaign protocols on hospital length of stay and mortality in septic shock patients: results 
of a three-year follow-up quasi-experimental study. Crit Care Med 2010; 38: 1036-1043 
 18.  Ferrer R, Artigas A, Suarez D et al. Effectiveness of treatments for severe sepsis: a 
prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180: 861-866 
 19.  Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective 
antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care 
Med 2006; 34: 1589-1596 
 20.  Levy MM, Dellinger RP, Townsend SR et al. The Surviving Sepsis Campaign: results of an 
international guideline-based performance improvement program targeting severe sepsis. 
Crit Care Med 2010; 38: 367-374 
 21.  Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and 
septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 
2014; 311: 1308-1316 
 22.  Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of 
severe sepsis in the United States: analysis of incidence, outcome, and associated costs of 
care. Crit Care Med 2001; 29: 1303-1310 
 23.  Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM. The patient-related 
costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit 
Care Med 1999; 27: 1760-1767 
 24.  Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term mortality and medical care 
charges in patients with severe sepsis. Crit Care Med 2003; 31: 2316-2323 
 25.  Letarte J, Longo CJ, Pelletier J, Nabonne B, Fisher HN. Patient characteristics and costs of 
severe sepsis and septic shock in Quebec. J Crit Care 2002; 17: 39-49 
Chapter 1 
43 
 26.  Moerer O, Burchardi H. [The cost of sepsis]. Anaesthesist 2006; 55 Suppl 1: 36-42 
 27.  Dellinger RP, Carlet JM, Masur H et al. Surviving Sepsis Campaign guidelines for management 
of severe sepsis and septic shock. Crit Care Med 2004; 32: 858-873 
 28.  Levy MM, Pronovost PJ, Dellinger RP et al. Sepsis change bundles: converting guidelines into 
meaningful change in behavior and clinical outcome. Crit Care Med 2004; 32: S595-S597 
 29.  Talmor D, Greenberg D, Howell MD, Lisbon A, Novack V, Shapiro N. The costs and cost-
effectiveness of an integrated sepsis treatment protocol. Crit Care Med 2008; 36: 1168-1174 
 30.  Capuzzo M, Moreno RP, Jordan B, Bauer P, Alvisi R, Metnitz PG. Predictors of early recovery 
of health status after intensive care. Intensive Care Med 2006; 32: 1832-1838 
 31.  Gopal I, Bhonagiri S, Ronco C, Bellomo R. Out of hospital outcome and quality of life in 
survivors of combined acute multiple organ and renal failure treated with continuous 
venovenous hemofiltration/hemodiafiltration. Intensive Care Med 1997; 23: 766-772 
 32.  Fletcher SN, Kennedy DD, Ghosh IR et al. Persistent neuromuscular and neurophysiologic 
abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003; 31: 
1012-1016 
 33.  Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia JL et al. Critical illness 
polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. 
Intensive Care Med 2001; 27: 1288-1296 
 34.  Granja C, Dias C, Costa-Pereira A, Sarmento A. Quality of life of survivors from severe sepsis 
and septic shock may be similar to that of others who survive critical illness. Crit Care 2004; 8: 
R91-R98 
 35.  Semmler A, Widmann CN, Okulla T et al. Persistent cognitive impairment, hippocampal 
atrophy and EEG changes in sepsis survivors. J Neurol Neurosurg Psychiatry 2013; 84: 62-69 
 36.  Tennila A, Salmi T, Pettila V, Roine RO, Varpula T, Takkunen O. Early signs of critical illness 
polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. 
Intensive Care Med 2000; 26: 1360-1363 
 37.  Haraldsen P, Andersson R. Quality of life, morbidity, and mortality after surgical intensive 
care: a follow-up study of patients treated for abdominal sepsis in the surgical intensive care 
unit. Eur J Surg Suppl 2003; 23-27 
 38.  Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA. Long-term health-related quality of 
life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related 
quality of life. Crit Care Med 2000; 28: 3599-3605 
 39.  Hofhuis JG, Spronk PE, van Stel HF, Schrijvers GJ, Rommes JH, Bakker J. The impact of critical 
illness on perceived health-related quality of life during ICU treatment, hospital stay, and 
after hospital discharge: a long-term follow-up study. Chest 2008; 133: 377-385 
Chapter 1 
 
 40.  Karlsson S, Varpula M, Ruokonen E et al. Incidence, treatment, and outcome of severe sepsis 
in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 2007; 33: 435-443 
 41.  Korosec JH, Jagodic K, Podbregar M. Long-term outcome and quality of life of patients 
treated in surgical intensive care: a comparison between sepsis and trauma. Crit Care 2006; 
10: R134 
 42.  Longo CJ, Heyland DK, Fisher HN, Fowler RA, Martin CM, Day AG. A long-term follow-up 
study investigating health-related quality of life and resource use in survivors of severe sepsis: 
comparison of recombinant human activated protein C with standard care. Crit Care 2007; 11: 
R128 
 43.  McLauchlan GJ, Anderson ID, Grant IS, Fearon KC. Outcome of patients with abdominal sepsis 
treated in an intensive care unit. Br J Surg 1995; 82: 524-529 
 44.  Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected 
gram-negative sepsis. JAMA 1995; 274: 338-345 
 45.  Paratz JD, Kenardy J, Mitchell G et al. IMPOSE (IMProving Outcomes after Sepsis)-the effect 
of a multidisciplinary follow-up service on health-related quality of life in patients postsepsis 
syndromes-a double-blinded randomised controlled trial: protocol. BMJ Open 2014; 4: 1-6 
 46.  Schmidt K, Thiel P, Mueller F et al. Sepsis survivors monitoring and coordination in outpatient 
health care (SMOOTH): study protocol for a randomized controlled trial. Trials 2014; 15: 283 
 47.  Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States 
from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554 
 48.  Wang HE, Shapiro NI, Angus DC, Yealy DM. National estimates of severe sepsis in United 
States emergency departments. Crit Care Med 2007; 35: 1928-1936 
 49.  Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and 
mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit 
Care Med 2007; 35: 1244-1250 
 50.  Wilhelms SB, Huss FR, Granath G, Sjoberg F. Assessment of incidence of severe sepsis in 
Sweden using different ways of abstracting International Classification of Diseases codes: 
difficulties with methods and interpretation of results. Crit Care Med 2010; 38: 1442-1449 
 51.  Flaatten H. Epidemiology of sepsis in Norway in 1999. Crit Care 2004; 8: R180-R184 
 52.  Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK. Hospitalizations, 
costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012; 
40: 754-761 
 53.  Bagshaw SM, Uchino S, Bellomo R et al. Septic acute kidney injury in critically ill patients: 
clinical characteristics and outcomes. Clinical Journal of The American Society of Nephrology: 
CJASN 2007; 2: 431-439 
Chapter 1 
45 
 54.  Prescott GJ, Metcalfe W, Baharani J et al. A prospective national study of acute renal failure 
treated with RRT: incidence, aetiology and outcomes. Nephrol Dial Transplant 2007; 22: 
2513-2519 
 55.  Bagshaw SM, George C, Bellomo R. Early acute kidney injury and sepsis: a multicentre 
evaluation. Crit Care 2008; 12: 1-9 
 56.  Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute renal failure in intensive care units--
causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter 
study. French Study Group on Acute Renal Failure. Crit Care Med 1996; 24: 192-198 
 57.  Uchino S, Kellum JA, Bellomo R et al. Acute renal failure in critically ill patients: a 
multinational, multicenter study. JAMA 2005; 294: 813-818 
 58.  Carl DE, Grossman C, Behnke M, Sessler CN, Gehr TW. Effect of timing of dialysis on mortality 
in critically ill, septic patients with acute renal failure. Hemodial Int 2010; 14: 11-17 
 59.  Chou YH, Huang TM, Wu VC et al. Impact of timing of renal replacement therapy initiation on 
outcome of septic acute kidney injury. Crit Care 2011; 15: 1-9 
 60.  Ali T, Khan I, Simpson W et al. Incidence and outcomes in acute kidney injury: a 
comprehensive population-based study. J Am Soc Nephrol 2007; 18: 1292-1298 
 61.  Brochard L, Abroug F, Brenner M et al. An Official ATS/ERS/ESICM/SCCM/SRLF Statement: 
Prevention and Management of Acute Renal Failure in the ICU Patient: an international 
consensus conference in intensive care medicine. Am J Respir Crit Care Med 2010; 181: 1128-
1155 
 62.  Wald R, Quinn RR, Adhikari NK et al. Risk of chronic dialysis and death following acute kidney 
injury. Am J Med 2012; 125: 585-593 
 63.  Bellomo R, Cass A, Cole L et al. Intensity of continuous renal-replacement therapy in critically 
ill patients. N Engl J Med 2009; 361: 1627-1638 
 64.  Cole L, Bellomo R, Silvester W, Reeves JH. A prospective, multicenter study of the 
epidemiology, management, and outcome of severe acute renal failure in a "closed" ICU 
system. Am J Respir Crit Care Med 2000; 162: 191-196 
 65.  Feest TG, Round A, Hamad S. Incidence of severe acute renal failure in adults: results of a 
community based study. BMJ 1993; 306: 481-483 
 66.  Khan IH, Catto GR, Edward N, MacLeod AM. Acute renal failure: factors influencing 
nephrology referral and outcome. Qjm 1997; 90: 781-785 
 67.  Korkeila M, Ruokonen E, Takala J. Costs of care, long-term prognosis and quality of life in 
patients requiring renal replacement therapy during intensive care. Intensive Care Medicine 
2000; 26: 1824-1831 
Chapter 1 
 
 68.  Liano F, Junco E, Pascual J, Madero R, Verde E. The spectrum of acute renal failure in the 
intensive care unit compared with that seen in other settings. The Madrid Acute Renal 
Failure Study Group. Kidney Int Suppl 1998; 66: S16-S24 
 69.  Vaara ST, Pettila V, Reinikainen M, Kaukonen KM. Population-based incidence, mortality and 
quality of life in critically ill patients treated with renal replacement therapy: a nationwide 
retrospective cohort study in Finnish intensive care units. Crit Care 2012; 16: 1-8 
 70.  Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, 
outcome measures, animal models, fluid therapy and information technology needs: the 
Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) 
Group. Crit Care 2004; 8: R204-R212 
 71.  Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to 
improve outcomes in acute kidney injury. Crit Care 2007; 11: 1-8 
 72.  Brown JR, Cochran RP, Dacey LJ et al. Perioperative increases in serum creatinine are 
predictive of increased 90-day mortality after coronary artery bypass graft surgery. 
Circulation 2006; 114: I409-I413 
 73.  Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, 
length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365-3370 
 74.  Gottlieb SS, Abraham W, Butler J et al. The prognostic importance of different definitions of 
worsening renal function in congestive heart failure. J Card Fail 2002; 8: 136-141 
 75.  Lassnigg A, Schmid ER, Hiesmayr M et al. Impact of minimal increases in serum creatinine on 
outcome in patients after cardiothoracic surgery: do we have to revise current definitions of 
acute renal failure? Crit Care Med 2008; 36: 1129-1137 
 76.  Loef BG, Epema AH, Smilde TD et al. Immediate postoperative renal function deterioration in 
cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc 
Nephrol 2005; 16: 195-200 
 77.  Newsome BB, Warnock DG, McClellan WM et al. Long-term risk of mortality and end-stage 
renal disease among the elderly after small increases in serum creatinine level during 
hospitalization for acute myocardial infarction. Arch Intern Med 2008; 168: 609-616 
 78.  Ryckwaert F, Alric P, Picot MC, Djoufelkit K, Colson P. Incidence and circumstances of serum 
creatinine increase after abdominal aortic surgery. Intensive Care Med 2003; 29: 1821-1824 
 79.  Smith GL, Vaccarino V, Kosiborod M et al. Worsening renal function: what is a clinically 
meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003; 9: 
13-25 
 80.   Kidney disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. 
KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2: 1-138 
Chapter 1 
47 
 81.  Fliser D, Laville M, Covic A et al. A European Renal Best Practice (ERBP) position statement on 
the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute 
kidney injury: part 1: definitions, conservative management and contrast-induced 
nephropathy. Nephrol Dial Transplant 2012; 27: 4263-4272 
 82.  James M, Bouchard J, Ho J et al. Canadian Society of Nephrology commentary on the 2012 
KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 2013; 61: 673-685 
 83.  Lewington A, Kanagasundaram S. Renal Association Clinical Practice Guidelines on acute 
kidney injury. Nephron Clin Pract 2011; 118 Suppl 1: c349-c390 
 84.  Palevsky PM, Liu KD, Brophy PD et al. KDOQI US commentary on the 2012 KDIGO clinical 
practice guideline for acute kidney injury. Am J Kidney Dis 2013; 61: 649-672 
 85.  Bagshaw SM, George C, Bellomo R. A comparison of the RIFLE and AKIN criteria for acute 
kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23: 1569-1574 
 86.  Joannidis M, Metnitz B, Bauer P et al. Acute kidney injury in critically ill patients classified by 
AKIN versus RIFLE using the SAPS 3 database. Intensive Care Med 2009; 35: 1692-1702 
 87.  Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic 
review. Kidney Int 2008; 73: 538-546 
 88.  Siew ED, Matheny ME, Ikizler TA et al. Commonly used surrogates for baseline renal function 
affect the classification and prognosis of acute kidney injury. Kidney Int 2010; 77: 536-542 
 89.  Zavada J, Hoste E, Cartin-Ceba R et al. A comparison of three methods to estimate baseline 
creatinine for RIFLE classification. Nephrol Dial Transplant 2010; 25: 3911-3918 
 90.  Endre ZH, Pickering JW, Walker RJ. Clearance and beyond: the complementary roles of GFR 
measurement and injury biomarkers in acute kidney injury (AKI). Am J Physiol Renal Physiol 
2011; 301: F697-F707 
 91.  Lopes JA, Fernandes P, Jorge S et al. Acute kidney injury in intensive care unit patients: a 
comparison between the RIFLE and the Acute Kidney Injury Network classifications. Crit Care 
2008; 12: R110 
 92.  Haase M, Bellomo R, Matalanis G, Calzavacca P, Dragun D, Haase-Fielitz A. A comparison of 
the RIFLE and Acute Kidney Injury Network classifications for cardiac surgery-associated 
acute kidney injury: a prospective cohort study. J Thorac Cardiovasc Surg 2009; 138: 1370-
1376 
 93.  Robert AM, Kramer RS, Dacey LJ et al. Cardiac surgery-associated acute kidney injury: a 
comparison of two consensus criteria. Ann Thorac Surg 2010; 90: 1939-1943 
 94.  Yan X, Jia S, Meng X et al. Acute kidney injury in adult postcardiotomy patients with 
extracorporeal membrane oxygenation: evaluation of the RIFLE classification and the Acute 
Kidney Injury Network criteria. Eur J Cardiothorac Surg 2010; 37: 334-338 
Chapter 1 
 
 95.  Chang CH, Lin CY, Tian YC et al. Acute kidney injury classification: comparison of AKIN and 
RIFLE criteria. Shock 2010; 33: 247-252 
 96.  Englberger L, Suri RM, Li Z et al. Clinical accuracy of RIFLE and Acute Kidney Injury Network 
(AKIN) criteria for acute kidney injury in patients undergoing cardiac surgery. Crit Care 2011; 
15: 1-9 
 97.  Wang HE, Jain G, Glassock RJ, Warnock DG. Comparison of absolute serum creatinine 
changes versus Kidney Disease: Improving Global Outcomes consensus definitions for 
characterizing stages of acute kidney injury. Nephrol Dial Transplant 2013; 28: 1447-1454 
 98.  Roy AK, Mc GC, Treacy C et al. A Comparison of Traditional and Novel Definitions (RIFLE, AKIN, 
and KDIGO) of Acute Kidney Injury for the Prediction of Outcomes in Acute Decompensated 
Heart Failure. Cardiorenal Med 2013; 3: 26-37 
 99.  Rodrigues FB, Bruetto RG, Torres US, Otaviano AP, Zanetta DM, Burdmann EA. Incidence and 
mortality of acute kidney injury after myocardial infarction: a comparison between KDIGO 
and RIFLE criteria. PLoS One 2013; 8: 1-8 
 100.  Bastin AJ, Ostermann M, Slack AJ, Diller GP, Finney SJ, Evans TW. Acute kidney injury after 
cardiac surgery according to Risk/Injury/Failure/Loss/End-stage, Acute Kidney Injury Network, 
and Kidney Disease: Improving Global Outcomes classifications. J Crit Care 2013; 28: 389-396 
 101.  Zeng X, McMahon GM, Brunelli SM, Bates DW, Waikar SS. Incidence, outcomes, and 
comparisons across definitions of AKI in hospitalized individuals. Clin J Am Soc Nephrol 2014; 
9: 12-20 
 102.  Fujii T, Uchino S, Takinami M, Bellomo R. Validation of the Kidney Disease Improving Global 
Outcomes criteria for AKI and comparison of three criteria in hospitalized patients. Clin J Am 
Soc Nephrol 2014; 9: 848-854 
 103.  Bock HA. Pathophysiology of acute renal failure in septic shock: from prerenal to renal failure. 
[Review] [37 refs]. Kidney International - Supplement 1998; 64: S15-S18 
 104.  Bougle A, Duranteau J. Pathophysiology of sepsis-induced acute kidney injury: the role of 
global renal blood flow and renal vascular resistance. Contributions to Nephrology 2011; 174: 
89-97 
 105.  Wan L, Bellomo R, Di GD, Ronco C. The pathogenesis of septic acute renal failure. Curr Opin 
Crit Care 2003; 9: 496-502 
 106.  Badr KF. Sepsis-associated renal vasoconstriction: potential targets for future therapy. Am J 
Kidney Dis 1992; 20: 207-213 
 107.  Chawla LS, Dommu A, Berger A, Shih S, Patel SS. Urinary sediment cast scoring index for 
acute kidney injury: a pilot study. Nephron 2008; 110: c145-c150 
 108.  Di G, May CN, Bellomo R. Vital organ blood flow during hyperdynamic sepsis. Chest 2003; 124: 
1053-1059 
Chapter 1 
49 
 109.  Doi K, Leelahavanichkul A, Yuen PS, Star RA. Animal models of sepsis and sepsis-induced 
kidney injury. J Clin Invest 2009; 119: 2868-2878 
 110.  Perazella MA, Coca SG, Kanbay M, Brewster UC, Parikh CR. Diagnostic value of urine 
microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am 
Soc Nephrol 2008; 3: 1615-1619 
 111.  Perazella MA, Parikh CR. How can urine microscopy influence the differential diagnosis of AKI? 
Clinical Journal of The American Society of Nephrology: CJASN 2009; 4: 691-693 
 112.  Perazella MA, Coca SG, Hall IE, Iyanam U, Koraishy M, Parikh CR. Urine microscopy is 
associated with severity and worsening of acute kidney injury in hospitalized patients. 
Clinical Journal of The American Society of Nephrology: CJASN 2010; 5: 402-408 
 113.  Thijs A, Thijs LG. Pathogenesis of renal failure in sepsis. Kidney Int Suppl 1998; 66: S34-S37 
 114.  Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol 2011; 22: 999-1006 
 115.  Badr KF. Novel mediators of sepsis-associated renal failure. Semin Nephrol 1994; 14: 3-7 
 116.  Kelleher SP, Robinette JB, Conger JD. Sympathetic nervous system in the loss of 
autoregulation in acute renal failure. American Journal of Physiology 1984; 246: F379-F386 
 117.  Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351: 159-169 
 118.  Lucas CE, Rector FE, Werner M, Rosenberg IK. Altered renal homeostasis with acute sepsis. 
Clinical significance. Archives of Surgery 1973; 106: 444-449 
 119.  Rector F, Goyal SC, Rosenberg IK, Lucas CE. Renal hyperemia in association with clinical sepsis. 
Surgical Forum 1972; 23: 51-53 
 120.  Benes J, Chvojka J, Sykora R et al. Searching for mechanisms that matter in early septic acute 
kidney injury: an experimental study. Critical Care (London, England) 2011; 15: 1-14 
 121.  Langenberg C, Wan L, Egi M, May CN, Bellomo R. Renal blood flow in experimental septic 
acute renal failure. Kidney International 2006; 69: 1996-2002 
 122.  Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S. Renal blood flow in sepsis. Crit 
Care 2005; 9: R363-R374 
 123.  Prowle JR, Ishikawa K, May CN, Bellomo R. Renal blood flow during acute renal failure in man. 
Blood Purif 2009; 28: 216-225 
 124.  Brenner M, Schaer GL, Mallory DL, Suffredini AF, Parrillo JE. Detection of renal blood flow 
abnormalities in septic and critically ill patients using a newly designed indwelling 
thermodilution renal vein catheter. Chest 1990; 98: 170-179 
 125.  Prowle JR, Molan MP, Hornsey E, Bellomo R. Cine phase-contrast magnetic resonance 
imaging for the measurement of renal blood flow. Contributions to Nephrology 2010; 165: 
329-336 
Chapter 1 
 
 126.  Prowle JR, Molan MP, Hornsey E, Bellomo R. Measurement of renal blood flow by phase-
contrast magnetic resonance imaging during septic acute kidney injury: a pilot investigation. 
Crit Care Med 2012; 40: 1768-1776 
 127.  Le Dorze M., Legrand M, Payen D, Ince C. The role of the microcirculation in acute kidney 
injury. Curr Opin Crit Care 2009; 15: 503-508 
 128.  Frithiof R. Sepsis-induced acute kidney injury-is there a lack of energy? Intensive Care Med 
2012; 38: 735-737 
 129.  Heemskerk S, Pickkers P, Bouw MP et al. Upregulation of renal inducible nitric oxide synthase 
during human endotoxemia and sepsis is associated with proximal tubule injury. Clin J Am 
Soc Nephrol 2006; 1: 853-862 
 130.  Himmelfarb J, McMonagle E, Freedman S et al. Oxidative stress is increased in critically ill 
patients with acute renal failure. Journal of the American Society of Nephrology 2004; 15: 
2449-2456 
 131.  Wang Z, Holthoff JH, Seely KA et al. Development of oxidative stress in the peritubular 
capillary microenvironment mediates sepsis-induced renal microcirculatory failure and acute 
kidney injury. American Journal of Pathology 2012; 180: 505-516 
 132.  Wu L, Gokden N, Mayeux PR. Evidence for the role of reactive nitrogen species in 
polymicrobial sepsis-induced renal peritubular capillary dysfunction and tubular injury. J Am 
Soc Nephrol 2007; 18: 1807-1815 
 133.  Zarjou A, Agarwal A. Sepsis and acute kidney injury.  Journal of the American Society of 
Nephrology 2011; 22: 999-1006 
 134.  Allgren RL, Marbury TC, Rahman SN et al. Anaritide in acute tubular necrosis. Auriculin 
Anaritide Acute Renal Failure Study Group. N Engl J Med 1997; 336: 828-834 
 135.  Hirschberg R, Kopple J, Lipsett P et al. Multicenter clinical trial of recombinant human insulin-
like growth factor I in patients with acute renal failure. Kidney Int 1999; 55: 2423-2432 
 136.  Kerr M, Bedford M, Matthews B, O'Donoghue D. The economic impact of acute kidney injury 
in England. Nephrol Dial Transplant 2014; 29: 1362-1368 
 137.  Dasta JF, Kane-Gill SL, Durtschi AJ, Pathak DS, Kellum JA. Costs and outcomes of acute kidney 
injury (AKI) following cardiac surgery. Nephrol Dial Transplant 2008; 23: 1970-1974 
 138.  Vandijck DM, Oeyen S, Decruyenaere JM, Annemans L, Hoste EA. Acute kidney injury, length 
of stay, and costs in patients hospitalized in the intensive care unit. Acta Clin Belg Suppl 2007; 
341-345 
 139.  Van Berendoncks AM, Elseviers MM, Lins RL. Outcome of acute kidney injury with different 
treatment options: long-term follow-up. Clin J Am Soc Nephrol 2010; 5: 1755-1762 
 140.  Maynard SE, Whittle J, Chelluri L, Arnold R. Quality of life and dialysis decisions in critically ill 
patients with acute renal failure. Intensive Care Med 2003; 29: 1589-1593 
Chapter 1 
51 
 141.  Wehler M, Geise A, Hadzionerovic D et al. Health-related quality of life of patients with 
multiple organ dysfunction: individual changes and comparison with normative population. 
Crit Care Med 2003; 31: 1094-1101 
 142.  Iribarren-Diarasarri S, Aizpuru-Barandiaran F, Munoz-Martinez T et al. Health-related quality 
of life as a prognostic factor of survival in critically ill patients. Intensive Care Med 2009; 35: 
833-839 
 143.  Ahlstrom A, Tallgren M, Peltonen S, Rasanen P, Pettila V. Survival and quality of life of 
patients requiring acute renal replacement therapy. Intensive Care Med 2005; 31: 1222-1228 
 144.  Desai AA, Baras J, Berk BB et al. Management of acute kidney injury in the intensive care unit: 
a cost-effectiveness analysis of daily vs alternate-day hemodialysis. Arch Intern Med 2008; 
168: 1761-1767 
 145.  Hamel MB, Phillips RS, Davis RB et al. Outcomes and cost-effectiveness of initiating dialysis 
and continuing aggressive care in seriously ill hospitalized adults. SUPPORT Investigators. 
Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann 
Intern Med 1997; 127: 195-202 
 146.  Landoni G, Zangrillo A, Franco A et al. Long-term outcome of patients who require renal 
replacement therapy after cardiac surgery. Eur J Anaesthesiol 2006; 23: 17-22 
 147.  Morgera S, Kraft AK, Siebert G, Luft FC, Neumayer HH. Long-term outcomes in acute renal 
failure patients treated with continuous renal replacement therapies. American Journal of 
Kidney Diseases 2002; 40: 275-279 
 148.  Johansen KL, Smith MW, Unruh ML, Siroka AM, O'Connor TZ, Palevsky PM. Predictors of 
health utility among 60-day survivors of acute kidney injury in the Veterans Affairs/National 
Institutes of Health Acute Renal Failure Trial Network Study. Clin J Am Soc Nephrol 2010; 5: 
1366-1372 
 149.  Gopal I, Bhonagiri S, Ronco C, Bellomo R. Out of hospital outcome and quality of life in 
survivors of combined acute multiple organ and renal failure treated with continuous 
venovenous hemofiltration/hemodiafiltration. Intensive Care Med 1997; 23: 766-772 
 150.  Delannoy B, Floccard B, Thiolliere F et al. Six-month outcome in acute kidney injury requiring 
renal replacement therapy in the ICU: a multicentre prospective study. Intensive Care Med 
2009; 35: 1907-1915 
 151.  Rimes-Stigare C, Awad A, Martensson J, Martling CR, Bell M. Long-term outcome after acute 
renal replacement therapy: a narrative review. Acta Anaesthesiol Scand 2012; 56: 138-146 
 152.  Laukkanen A, Emaus L, Pettila V, Kaukonen KM. Five-year cost-utility analysis of acute renal 
replacement therapy: a societal perspective. Intensive Care Med 2013; 39: 406-413 
 153.  Manns B, Doig CJ, Lee H et al. Cost of acute renal failure requiring dialysis in the intensive 
care unit: clinical and resource implications of renal recovery. Crit Care Med 2003; 31: 449-
455 
Chapter 1 
 
 154.  De Smedt DM, Elseviers MM, Lins RL, Annemans L. Economic evaluation of different 
treatment modalities in acute kidney injury. Nephrol Dial Transplant 2012; 27: 4095-4101 
 155.  Klarenbach S, Manns B, Pannu N, Clement FM, Wiebe N, Tonelli M. Economic evaluation of 
continuous renal replacement therapy in acute renal failure. Int J Technol Assess Health Care 
2009; 25: 331-338 
 156.  Ethgen O, Schneider AG, Bagshaw SM, Bellomo R, Kellum JA. Economics of dialysis 
dependence following renal replacement therapy for critically ill acute kidney injury patients. 
Nephrol Dial Transplant 2014; 
 157.  Rabindranath K, Adams J, MacLeod AM, Muirhead N. Intermittent versus continuous renal 
replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev 2007; 1-51 
 158.  Srisawat N, Lawsin L, Uchino S, Bellomo R, Kellum JA. Cost of acute renal replacement 
therapy in the intensive care unit: results from The Beginning and Ending Supportive Therapy 
for the Kidney (BEST Kidney) study. Crit Care 2010; 14: 1-10 
 159.  Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G. Proteomics as a tool for biomarker 
discovery. Dis Markers 2007; 23: 411-417 
 160.  Kienzl-Wagner K, Pratschke J, Brandacher G. Proteomics--a blessing or a curse? Application of 
proteomics technology to transplant medicine. Transplantation 2011; 92: 499-509 
 161.  Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular 
risk prediction. Circulation 2011; 123: 551-565 
 162.  Bichsel VE, Liotta LA, Petricoin EF, III. Cancer proteomics: from biomarker discovery to signal 
pathway profiling. Cancer J 2001; 7: 69-78 
 163.  Hanke JH, Webster KR, Ronco LV. Protein biomarkers and drug design for cancer treatments. 
Eur J Cancer Prev 2004; 13: 297-305 
 164.  Chen SC, Kontoyiannis DP. New molecular and surrogate biomarker-based tests in the 
diagnosis of bacterial and fungal infection in febrile neutropenic patients. Curr Opin Infect Dis 
2010; 23: 567-577 
 165.  Fliser D, Novak J, Thongboonkerd V et al. Advances in urinary proteome analysis and 
biomarker discovery. J Am Soc Nephrol 2007; 18: 1057-1071 
 166.  Goligorsky MS, Addabbo F, O'Riordan E. Diagnostic potential of urine proteome: a broken 
mirror of renal diseases. J Am Soc Nephrol 2007; 18: 2233-2239 
 167.  Konvalinka A, Scholey JW, Diamandis EP. Searching for new biomarkers of renal diseases 
through proteomics. Clin Chem 2012; 58: 353-365 
 168.  Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a 
biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238 
Chapter 1 
53 
 169.  Parikh CR, Mishra J, Thiessen-Philbrook H et al. Urinary IL-18 is an early predictive biomarker 
of acute kidney injury after cardiac surgery. Kidney Int 2006; 70: 199-203 
 170.  Parikh CR, Coca SG, Thiessen-Philbrook H et al. Postoperative biomarkers predict acute 
kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol 2011; 22: 
1748-1757 
 171.  Siew ED, Ikizler TA, Gebretsadik T et al. Elevated urinary IL-18 levels at the time of ICU 
admission predict adverse clinical outcomes. Clin J Am Soc Nephrol 2010; 5: 1497-1505 
 172.  Giasson J, Li GH, Chen Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new 
biomarker for non--acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets 2011; 10: 
272-282 
 173.  Mischak H, Apweiler R, Banks RE et al. Clinical proteomics: A need to define the field and to 
begin to set adequate standards. Proteomics Clin Appl 2007; 1: 148-156 
 174.  Wu J, Chen YD, Gu W. Urinary proteomics as a novel tool for biomarker discovery in kidney 
diseases. J Zhejiang Univ Sci B 2010; 11: 227-237 
 
 
  
  
 
 
 
 
 
CHAPTER 2:  
PROGNOSTIC ROBUSTNESS OF CURRENT AKI DEFINITIONS IN 
PATIENTS WITH SEPSIS. 
 
 
Jill Vanmassenhove, MD.1, Norbert Lameire, MD, PhD 1, Annemieke Dhondt, MD, PhD.1, 
Raymond Vanholder, MD, PhD.1, Wim Van Biesen, MD, PhD.1 
 
1Renal Division, Ghent University Hospital 
 
Paper currently under submission 
  
 
Chapter 2 
57 
2.1  Abstract 
Objective: To evaluate whether modifications in the definitions of how to calculate change of 
serum creatinine (sCr) and in the cut-off value, alter the prognostic value of AKI for 
prediction of mortality at 3 months, 1 and 2 years. 
Design: A prospective observational cohort study in patients admitted to ICU with sepsis. 
Setting: Single-centre university hospital. 
Patients: 195 septic patients were included between 12/01/2010 and 27/03/2011. The 
prognostic value of the diagnosis "AKI" was evaluated by using three different methods to 
calculate the change of sCr: either focusing on the onset status  by determining the 
difference between the highest value in the 24 hours after ICU admission and a pre-
admission historical baseline value (ΔHIS) or an estimated baseline value (ΔEST), or by 
subtracting the value after 24 hours of ICU from the admission value (ΔADM). For each of 
these definitions, different cut-off levels of sCr increase (0.1, 0.2, 0.3, 0.4 and 0.5 mg/dl), 
were evaluated.  
Interventions: none 
Measurements and main results: Mortality at 3 months, 1 and 2 years in AKI defined as 
ΔADM>0.3mg/dl was 48.1%, 63.0% and 63.0% vs 27.7%,39.8% and 47.6% in no AKI 
respectively (OR(95%CI):2.42(1.06-5.54),2.58(1.11-5.97) and 1.87(0.81-4.33); 0.3 mg/dl was 
the lowest cut-off value that was discriminatory. When AKI was defined as ΔHIS>0.3mg/dl or 
ΔEST>0.3mg/dl, there was no significant difference in mortality between AKI and no AKI. 
After adjusting for severity of illness, even ΔADM>0.3mg/dl was no longer independently 
associated with mortality.  
Conclusion: To predict mortality in sepsis patients, the AKI diagnostic criterion of an increase 
of sCr>0.3mg/dl should be calculated referring to the ICU admission value, allowing to 
incorporate the impact of initial therapy, rather than as the difference between the highest 
Scr and a known or estimated historical baseline value.  
 
2.2 Introduction 
There is growing evidence that Acute Kidney Injury (AKI) is an independent predictor for 
mortality rather than an innocent bystander. It has been demonstrated, especially in cardiac 
surgery, that even small increases in serum creatinine (sCr) are associated with increased 
mortality risk.1-4 It is however unclear whether this also applies to more complex 
multifactorial conditions such as sepsis where the impact of AKI might be overwhelmed by 
the severity of the underlying disease. In such circumstances, AKI  could rather be a marker 
of severity of illness than a cause of negative outcome. About 45 to 70% of AKI in the 
Intensive Care Unit (ICU) is associated with sepsis and septic AKI can be considered as a 
separate clinical entity with a largely unknown pathophysiology, and possibly different 
prognosis from non-septic AKI.5  
Despite recent advances in the uniformisation of the definition of AKI, there is continuing 
debate on the exact interpretation of the definitions6-9, and different definitions, incorrectly 
presented as being KDIGO or AKIN, continue to appear in the literature.10-13 The most 
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important issue in this debate relates to the method to calculate the increase of sCr. The 
currently proposed practice to use the highest creatinine value in a certain time-period after 
ICU admission does not take into account the evolution of sCr after starting therapeutic 
interventions. As such, the current definitions do not allow to distinguish the potential 
difference in prognosis for an AKI patient who is admitted with a high, but decreasing sCr 
value, e.g. a traditionally called prerenal AKI, and a patient who’s sCr increases progressively 
despite therapy. This might be problematic for the interpretation of future randomised 
controlled trials exploring interventions to prevent or treat AKI, as they might become false 
negative by including a mix of patients with a different prognosis.   
Also, the cut off value of a sCr increase  of 0.3mg/dl, as proposed by AKIN, KDIGO and ERBP 
6;8;9, has not previously been validated in a specific cohort of sepsis patients.  
In this prospective cohort study we wanted to assess short and longer term mortality in a 
cohort of sepsis patients admitted to the ICU in the Ghent University Hospital. We evaluated 
the impact on the prognostic value of AKI, the latter diagnosed by three different ways to 
calculate the change of sCr. The first took into account the evolution of sCr in the first 24 
hours after initiation of therapy, whereas the two others followed the more classical 
approach. In addition we intended to explore the robustness of the currently proposed 
increase in sCr of 0.3mg/dl as cut-off in sepsis, by comparing it’s predictive value to that of 
either smaller or larger increases. 
 
2.3 Materials and methods 
One hundred and ninety five consecutive adult patients (age ≥ 17 years) with sepsis 
admitted to the intensive care unit (ICU) of the Ghent University Hospital between 
12/01/2010 and 27/03/2011 were included. Sepsis, severe sepsis and septic shock were 
defined according to the American College of Chest Physicians/Society of Critical Care 
Medicine Consensus Conference guidelines.14 Exclusion criteria were: a history of liver 
and/or kidney transplantation, ICU stay less than 24 hours and patients treated with chronic 
hemodialysis.  
The criterion of increase of sCr as definition of AKI was modified by all possible combinations 
of two interventions:  
1° by using three different ways to calculate the change of sCr: either A/ as the highest 
value within 24 hours after ICU admission minus the value of a pre-admission historical 
baseline (ΔHIS); B/ as the highest value 24 hours after ICU admission minus an 
estimated baseline value obtained by solving the MDRD equation assuming a GFR of 75 
ml/min/1.73m², as suggested by ADQI7 (ΔEST); C/ as the value at 24 hours after 
admission minus the value at ICU admission (ΔADM), thus capturing the evolution of sCr 
after start of therapy; of note, the first two calculations by definition cannot capture a 
potential decrease of Scr by therapeutic interventions.  
2° by changing the absolute value of the increase of sCr (0.1, 0.2, 0.3, 0.4, and 0.5 mg/dl), 
to assess the robustness of the 0.3 mg/dl increase criterion in this sepsis population. 
Blood samples for measuring sCr were collected during the first five days after ICU 
admission, centrifuged immediately and frozen at -80° for later batch analysis, using an 
Isotope Dilution Mass Spectroscopy traceable method (Roche Diagnostics®). 
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Survival status was ascertained based on hospital records, or by a telephone interview with 
the family practitioner performed by JV.  
Statistical analysis: Results are reported as medians and interquartile ranges (IQR) for 
continuous variables, unless otherwise specified. Discrete variables are reported as numbers 
and/or percentages. All statistical analyses were performed using SPSS® 19.  
Chi square was used to asses a difference in prevalence in case of a dichotomous outcome. 
Results are reported as Odds ratio with 95% confidence intervals (OR;95%CI). Student t test 
was used to compare the means of normally distributed continuous variables whereas non 
parametric tests  were used to compare the medians of not normally distributed  continuous 
variables.  
Logistic regression (3 months) and Cox regression (1 and 2 year) were performed in forward 
and backward mode, presenting age, gender, presence of pre-existing renal insufficiency 
(eGFR<60ml/min)(CKD), APACHE II score and need for ventilation to the model as potential 
predictors for mortality.  As additional parameter, AKI according to the above specified 
definitions with different cut offs (0.1, 0.2, 0.3, 0.4 and 0.5 mg/dl) of increase of sCr  and 
different ways to calculate the increase of sCr (ΔADM, ΔHIS and ΔEST)  was added as a 
dummy code to the model. The effect of adding a small increase of sCr on predictive 
performance of mortality was assessed by comparing AUC ROC analysis of the different 
models with and without the different definitions of AKI, as applied in this study. 
For the short term (3 month) mortality, we used a logistic regression model, as in this case, 
actual duration of survival was not considered relevant and mortality was approached in a 
dichotomous way. For the longer term survival (1 and 2 year), we considered survival time as 
a continuous variable rather than a dichotomous one, and therefore, in that setting, Cox 
regression was performed.  
 
2.4 Results 
Descriptive patient data 
In this study, 195 consecutive patients with sepsis, severe sepsis and septic shock and 
admitted to ICU between 12/01/2010 and 27/03/2011 were included. Nine (4.6%), 63 
(32.3%) and 123 (63.1%) had sepsis, severe sepsis and septic shock, respectively. Overall 
mortality rates at the ICU, at three months, 1 year and 2 years after admission, were 23.1%, 
31.3%, 43.6% and 50.3%, respectively. Of the patients who needed RRT during their ICU stay 
(n=27(13.8%)), cumulative mortality rate during ICU stay was 55.6% (OR 5.75(2.44-13.53). 
Eighty-three percent of patients who were treated with RRT and survived ICU (n=10/12), 
survived up to two years. One  patient died at three months and another died at year 1.  
Demographics and relevant data for AKI vs no AKI according to the three different definitions 
(ΔADM>0.3, ΔHIS>0.3 and ΔEST>0.3) are presented in Table 1.  
The prevalence of AKI varied according to the definition used. Based on ΔADM>0.3 vs 
ΔHIS>0.3 and ΔEST>0.3, 27(13.8%) vs 98(50.3%) and 89(45.6) patients were labelled as AKI 
(p<0.001).  
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Patients classified in the AKI vs no AKI group according to ΔADM>0.3 had a greater severity 
of illness as demonstrated by a higher APACHE II score (p=0.003), a higher need for invasive 
ventilation (p<0.001) and a longer ICU stay (p=0.009). When ΔHIS or ΔEST were used, there 
was a difference in APACHE II score in AKI vs no AKI but not in need for invasive ventilation 
or length of ICU stay (Table 1). The difference between historical and admission sCr was 
larger in the patients with AKI defined by ΔHIS or ΔEST, as compared to ΔADM (p<0.001). 
Based on ΔHIS or ΔEST, there is a steady decrease in sCr vs the admission value in the AKI 
group over the following four days, as opposed to AKI according to ΔADM (Figure 1A, Figure 
1B and Figure 1C). 
 
Mortality in AKI vs no AKI according to different definitions 
In patients with AKI vs no AKI defined according to ΔADM>0.3, ICU mortality, and three 
months, 1 year and 2 years mortality rates were 44.4%,48.1%,63% and 63% vs 
18.7%,27.7%,39.8% and 47.6%, respectively (OR 3.48(1.48-8.18), 2.42(1.06-5.54), 2.58(1.11-
5.97) and 1.87(0.81-4.33)) (Table 1 and Figure 2A). 
When AKI was defined according to ΔHIS>0.3 or ΔEST>0.3, mortality rates were not different 
between AKI and no-AKI respectively at any of the time points (Table 1 and Figure 2A). 
Mortality in AKI vs no AKI in ICU survivors, according to ΔADM,ΔHIS and ΔEST> 0.3 
In ICU survivors (n=150), mortality rates at three months, 1 year and 2 years in AKI vs no-AKI 
according to ΔADM>0.3 were 6.7%, 33.3% and 33.3% vs 11.9%, 25.9% and 35.6% 
respectively (OR 0.53(0.07-4.32), 1.43(0.46-4.47) and 0.91(0.29-2.81) respectively). Based on 
ΔHIS>0.3, mortality rates were 9.6%, 23.3% and 30.1% vs 13%, 29.9% and 40.3% respectively 
(OR 0.71(0.26-1.98), 0.71(0.34-1.48) and 0.64(0.33-1.26)). Based on ΔEST>0.3 these were 
13.4%, 28.4% and 31.3% vs 9.6%, 25.3% and 38.6% in AKI vs no AKI respectively (OR 
1.46(0.53-4.00), 1.17(0.57-2.42) and 0.73(0.37-1.44)) (Figure 2B). 
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Table 1: Demographics in AKI vs no-AKI according to different definitions. 
 ΔADM>0.3   ΔHIS>0.3   ΔEST>0.3   
AKI/noAKI 
(n/%) 
AKI 
(27/13.8) 
no AKI 
(166/85.1) 
p value AKI(98/50.3) no AKI (97/49.7) p value AKI (89/45.6) no AKI (106/54.4) p value 
%male 66.7 61.4 0.6 67.3 57.7 0.17 65.2 60.4 0.49 
Age(y)(mean/sd) 66.2(10.7) 60.7(15.6) 0.08 62.6(14.1) 60.2(15.8) 0.28 65.1(13.5) 58.2(15.5) 0.001 
APACHE II  27(9) 22(9) 0.003 25(8) 19(9) <0.001 25(8) 20(9) <0.001 
Ventilation(%) 92.6 48.2 <0.001 60.2 48.5 0.10 61.8 48.1 0.06 
CKD(%) 25.9 13.9 0.11 18.4 12.4 0.25 28.1 4.7 <0.001 
ICU admission serum 
creatinine (mg/dl) 
1.29(0.66) 1.05(0.89) 0.01 1.67(1.25) 0.79(0.40) <0.001 1.76(1.24) 0.80(0.39) <0.001 
Historical baseline 
creatinine (mg/dl) 
0.98(0.41) 0.83(0.32) 0.18 0.88(0.37) 0.82(0.34) 0.52 0.98(0.35) 0.79(0.32) 0.001 
RRT need(%) 51.9 7.8 <0.001 23.5 4.1 <0.001 27 2.8 <0.001 
ICU LOS(d) in ICU survivors 15(22) 6(8) 0.009 6(9) 5(10) 0.34 7(9) 6(9) 0.24 
ICU Mort(%) 44.4 18.7 0.003 25.5 20.6 0.42 24.7 21.7 0.62 
Mort at three months(%) 48.1 27.7 0.03 32.7 39.9 0.68 33.7 29.2 0.50 
Mort at 1 year(%) 63 39.8 0.024 42.9 44.3 0.84 46.1 41.5 0.52 
Mort at 2 years(%) 63 47.6 0.14 48 52.6 0.52 48.3 51.9 0.62 
AKI: Acute Kidney Injury, ΔADM>0.3= Serum creatinine increase > 0.3 mg/dl based on the difference between the value 24 hours after admission and ICU admission, ΔHIS>0.3=Serum 
creatinine increase > 0.3 mg/dl based on the difference between the highest value during the first 24 hours after ICU admission and a historical baseline value, ΔEST>0.3= Serum creatinine 
increase > 0.3 mg/dl based on the difference between the highest value during the first 24 hours after ICU admission and an estimated baseline value, APACHE II: Acute Physiology and 
Chronic Health Evaluation II score, CKD: Chronic Kidney Disease, RRT: Renal Replacement Therapy, ICU LOS: Intensive Care Unit Length of Stay, Mort: Mortality
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Figure 1: Evolution of serum creatinine over 4 days in patients with Acute Kidney Injury, 
according to different definitions. 
 
 
 
Legend Figure 1: As opposed to Acute Kidney Injury based on ΔADM>0.3(A), there is a steady decrease in serum 
creatinine after admission over the following four days  when AKI is defined according to ΔHIS>0.3(B) or 
ΔEST>0.3(C). 
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Figure 2: Mortality rates (%) in Acute Kidney Injury vs no Acute Kidney Injury according to 
different definitions, in the entire cohort and in ICU survivors separately. 
 
 
 
Legend Figure 2: A: Mortality rates at ICU, 3 months, 1 year and 2 years in the entire cohort in Acute Kidney 
Injury vs no Acute Kidney Injury, either based on ΔADM>0.3, ΔHIS>0.3 or ΔEST>0.3. Only based on ΔADM>0.3, 
there is a higher mortality at ICU, 3 months and 1 year in AKI vs no AKI. At year 2, there is no significant 
different in mortality between AKI and no AKI with either of the  definitions. B: Mortality rates at 3 months, 1 
year and 2 years in ICU survivors in Acute Kidney Injury vs no Acute Kidney Injury, either based on ΔADM>0.3, 
ΔHIS>0.3 or ΔEST>0.3. There is no significant difference in mortality between Acute Kidney Injury and no Acute 
Kidney Injury at the three time points, independent of the definition used. 
Thus with none of the above definitions (ΔADM>0.3, ΔHIS>0.3 or ΔEST>0.3) there was a 
significant difference in mortality rates between AKI and no AKI in septic patients who 
survived their ICU stay, either at three months, 1 year and 2 years.  
Also other variants of calculating ΔsCr were assessed, which confirmed that in sepsis 
patients only the evolution of sCr as compared to admission sCr was prognostic for mortality 
(supplemental table 1, 2 and 3). 
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Prognostic value for mortality of different cut-off values for serum creatinine increase 
Using the different combinations of how to calculate increase of sCr (ΔADM, ΔHIS, ΔEST) and 
different cut-off levels for that increase (0.1mg/dl to 0.5mg/dl with increments of 0.1mg/dl), 
we found that in univariate analysis an increase in sCr of 0.3mg/dl was the lowest robust cut-
off value that was still associated with mortality at three months in the entire cohort (OR 
2.42, 95% CI 1.06-5.54), but only if the difference in increase of sCr was based on ΔADM 
(Figure 3A). At year 1 and 2 an increase in sCr of 0.3mg/dl was also the lowest robust cut-off 
for prediction of mortality in the entire cohort, again only when the definition is based on 
ΔADM (RR 2.11(1.24-3.6) and RR 1.79(1.06-3.03) for mortality at 1 year and 2 years 
respectively) (Figure 3B and Figure 3C). 
 
Figure 3: Odds ratio of incremental cut-off values for serum creatinine increase and mortality 
in the entire cohort. 
 
 
Legend figure 3: A 0.3 mg/dl increase in serum creatinine is the lowest robust cut-off value associated with 3 
months mortality (A), but only if this increase is based on ΔADM>0.3 (OR 2.42(1.06-5.54). At year 1 (B) and year 
2 (C), a serum creatinine increase of 0.3 mg/dl is also het lowest robust cut-off value associated with mortality 
but again only if this increase is based on ΔADM>0.3 (RR 2.11(1.24-3.6) and RR 1.79(1.06-303) at year 1 and 
year 2 respectively).  
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Multivariate analysis for prediction of mortality 
In a logistic regression model adjusted for age and gender, APACHE II score (OR per point: 
1.06, 95% CI 1.01-1.11) and Need for Ventilation (OR 2.89, 95% CI 1.41-5.95) but not AKI 
according to ΔADM, were independent predictors for mortality at three months (Table 2). 
Comparable results were obtained when the other definitions of AKI were used (Table 2). 
 
Table 2: Multivariate logistic regression for prediction of mortality at three months including 
different AKI definitions in the model  
 Exp(B) 95% CI p value 
ΔADM>0.3 1.15 0.46-2.87 0.76 
Age 1.01 0.99-1.04 0.29 
Gender 0.75 0.38-1.49 0.42 
APACHE II  1.06 1.01-1.11 0.02 
Need for Ventilation 2.89 1.41-5.95 0.004 
ΔHIS>0.3 0.62 0.30-1.26 0.18 
Age 1.01 0.99-1.04 0.37 
Gender 0.69 0.35-1.36 0.28 
APACHE II 1.08 1.03-1.14 0.003 
Need for Ventilation 2.97 1.48-5.95 0.002 
ΔEST>0.3  0.64 0.31-1.31 0.22 
Age 1.01 0.99-1.04 0.27 
Gender 0.70 0.36-1.39 0.31 
APACHE II 1.08 1.03-1.14 0.003 
Need for Ventilation 2.96 1.48-5.92 0.002 
ΔADM>0.3=Serum creatinine increase > 0.3 mg/dl based on the difference between the value 24 hours after 
admission and ICU admission, APACHE II: Acute Physiology and Chronic Health Evaluation II score, 
ΔHIS>0.3=Serum creatinine increase > 0.3 mg/dl based on the difference between the highest value during the 
first 24 hours after ICU admission and a historical baseline value, ΔEST>0.3= Serum creatinine increase > 0.3 
mg/dl based on the difference between the highest value during the first 24 hours after ICU admission and an 
estimated baseline value. 
AUC ROC analysis confirmed that ΔADM>0.3 did not add discriminatory value above APACHE 
II score and Need for Ventilation for prognostication of mortality at 3 months (AUC 0.71 
without ΔADM>0.3 and AUC 0.71 with ΔADM>0.3) (Figure  4A and Figure 4B). 
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Figure 4: AUC ROC for predicting mortality at three months, either including or not including 
ΔADM>0.3 in the model. 
 
Legend figure 4: A: AUC ROC for predicting mortality at three months for the model not including ΔADM>0.3 is 
0.71. B:Adding ΔADM>0.3 to the model does not improve discriminative power for prediction of mortality (AUC 
ROC 0.71) 
 
In a Cox regression multivariate model applied to ICU survivors, only age was an 
independent predictor for mortality both at 1 year (RR=1.04, 95% CI: 1.01-1.06) and 2 years 
(RR=1.02, 95% CI: 1.001-1.043)  (Table 3). This suggests that longer term mortality in sepsis 
patients is more influenced by underlying comorbidity such as older age than by AKI or other 
parameters of acute severity of illness. 
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Table 3: Multivariate cox regression analysis for prediction of mortality at 1 year and 2 years 
in ICU survivors. 
1 year mortality in 
ICU survivors 
Exp(B) 95% CI p value 
Age 1.04 1.01-1.06 0.005 
Creatinine day 1 0.69 0.38-1.25 0.22 
CKD 1.73 0.73-4.12 0.21 
ΔADM>0.3 1.38 0.43-4.40 0.59 
Need for Ventilation 1.07 0.55-2.07 0.85 
Gender 0.65 0.32-1.31 0.23 
APACHE II 1.006 0.96-1.05 0.80 
2 years mortality in 
ICU survivors 
   
Age 1.02 1.001-1.043 0.04 
Creatinine day 1 0.47 0.26-0.85 0.01 
CKD 2.17 0.99-4.72 0.05 
ΔADM>0.3 1.17 0.38-3.60 0.78 
Need for Ventilation 1.29 0.73-2.29 0.38 
Gender 0.67 0.37-1.22 0.19 
APACHE II 1.03 0.99-1.07 0.18 
ICU: Intensive Care Unit, CKD: Chronic Kidney Disease, ΔADM>0.3= Serum creatinine increase > 0.3 mg/dl 
based on the difference between the value 24 hours after admission and ICU admission, APACHE II: Acute 
Physiology and Chronic Health Evaluation II score. 
 
2.5 Discussion 
This study demonstrates that the predictive value of AKI for mortality in sepsis only exists if 
the increase in sCr is calculated based on the difference between the sCr value at 24 hours 
and the ICU admission value. AKI in sepsis is not associated with mortality when the increase 
in sCr is calculated as the difference between the highest sCr or when the baseline sCr is 
back-calculated by solving the MDRD formula assuming a GFR of 75 ml/min/1,73m2.7 An 
increase in sCr of 0.3mg/dl according to the ICU admission value is the lowest robust value 
still associated with mortality, confirming previous data in the cardiac surgery setting. 
However, when adjusted for severity of illness, this increase in sCr of 0.3mg/dl was no longer 
associated with mortality. Taken together, our data suggest that, at least in sepsis, 
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definitions of AKI are only robust to predict mortality when they do allow to assess the 
evolution of sCr after initiation of therapy, at least during the first 24 hours.     
Although the definition of AKI has become progressively more uniform since the 
introduction of RIFLE 7, uncertainty and debate on the methodology to calculate the increase 
of sCr remains, and different interpretations are still appearing in the literature.10-13 Most 
guidelines advocate the use of the difference of the highest sCr value and a pre admission 
historical baseline value,15;16 or a back calculated sCr by solving the MDRD formula assuming 
a GFR of 75ml/min/1,73m2 if the preadmission baseline value is unknown.17-20 It has been 
demonstrated that the use of these surrogates as baseline sCr can lead to misclassification 
by either under- or overestimation of AKI.15 Siew et al also investigated the impact of 
different surrogate baseline values in a large cohort of 4863 adults on AKI diagnosis and 
outcome.16 These authors not only demonstrated that the incidence of AKI based on the ICU 
admission value, decreased compared to AKI defined  based on a pre admission historical 
baseline value, as in our cohort, but that mortality rates were higher with increasing AKIN 
stages but were largely different according to the surrogate value that was used.16 As in our 
study, mortality rates were highest when AKI was defined according to the admission value. 
However, Siew et al used a cohort containing mainly non-critically ill patients (only 19% of 
patients were admitted to ICU) and only in-hospital and 60 days mortality were evaluated, 
without adjustment for severity of illness.16 
Another potential point of discussion is the use of the highest sCr value after admission as 
reference value. This strategy does not allow to study the impact of the evolution of sCr 
after admission and after start of therapeutic interventions. In our cohort, AKI was 
associated with mortality, but only if based on the difference between the value 24 hours 
after admission and the value at ICU admission. There was no association with mortality 
when the increase in sCr was calculated as the difference between the highest value in the 
24 hours after admission and either a known historical baseline value or a value that was 
back-calculated assuming a GFR of 75 ml/min/1,73m2. These findings suggest that the 
evolution of sCr in the first 24 hours at the ICU, and thus very likely the response to fluid 
challenge, is more predictive for outcome than the admission value itself, which is in line 
with previous observations.21 Definitions comparing the highest value after admission with a 
pre-existing value probably also include a relatively high number of patients with so called 
"functional" or prerenal AKI, who have a good response to treatment and thus a more 
benign prognosis. This is reflected in the fact that AKI as defined by these criteria, called 
ΔHIS or ΔEST in our study, was more prevalent than when defined by ΔADM, and that length 
of ICU stay was not different in AKI vs no AKI when based on the ΔHIS or ΔEST definition, but 
was much longer in AKI vs no AKI patients when defined by ΔADM.  
Although it is generally accepted that AKI is associated with increased mortality22, this topic 
is still a matter of debate, even in the non-critically ill. In a population based study of AKI, no 
association between AKI and outcome was found.23 A higher risk for chronic dialysis need, 
but not mortality, was found in a large cohort of ICU survivors24, in parallel with  another 
study, where a 28-fold risk increase for development of CKD stage 4-5 was observed 
compared to an only twofold increase in mortality for patients with AKI vs no AKI.25 Of note 
however is that several reports indicated that the duration of AKI rather than the diagnosis 
of AKI per se was highly predictive of mortality, an aspect that was not evaluated in the 
current study. This might explain why, in our cohort, the fact of being diagnosed with AKI, 
was no longer independently associated with mortality after adjustment for severity of 
illness. Our data on the other hand clarify something that is visualized by none of the other 
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definitions, i.e. that the response to treatment in the first 24 hours of observation also 
contributes to the prognosis, probably by unveiling those who respond to volume 
resuscitation. Our findings thus indicate that the response to treatment in the first 24 hours 
also has a contributive prognostic value. Several older and more recent studies also 
demonstrated that the most important predictors for mortality were already present at 
admission to the ICU and included advanced age, the presence of infection, a past history of 
chronic diseases and the presence of other failing organs.26 27 28 29;30 
Although it was demonstrated in the recent literature that even small increases in sCr are 
independently associated with  a higher risk of mortality, these results are mainly obtained 
in cohorts of cardiac surgery patients, after coronarography and after myocardial infarction1-
4;31;32,33,  and can therefore not necessarily be extrapolated to other situations, such as sepsis. 
The latter can be considered as a complex often multifactorial variant of AKI with a largely 
unknown pathophysiology which in turn might translate into a different impact of AKI on 
mortality risk assessment. Our results confirm that, even in a cohort of sepsis patients, a 
0.3mg/dl increase in sCr 24 hours after admission compared to the ICU admission value, 
seems to be the lowest robust threshold for increased risk.  
The strong points of our prospective study are the availability of longer term outcomes and 
the detailed patient information that is included, and that the results were obtained in a well 
defined homogenous patient category (patients with sepsis admitted to ICU). More 
specifically, we have the historical baseline creatinine of all patients, as well as 2 year 
mortality data.  
Our study is the first to consider that the evolution of sCr after start of therapy, rather than 
an absolute highest value over a time period might be important for prognostic purposes in 
sepsis patients.  
A limitation of this study is the observational  nature so that causal assumptions can not be 
made, but this is unavoidable in this setting. Furthermore, it is single centre, and describes 
only a relatively small cohort of patients. Further prospective studies on long term outcome 
in septic AKI are warranted. 
 
2.6 Conclusion 
In sepsis patients, the AKI diagnostic criterion of sCr increase of >0.3mg/dl should for 
prognostic purposes be calculated referring to the ICU admission value, rather than by the 
difference between a highest value and a known or estimated historical baseline value.  
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3.1 Abstract 
Objective: Acute Kidney Injury (AKI) remains associated with high morbidity and mortality 
despite progress in medical care. Although the RIFLE and AKIN criteria, based on serum 
creatinine (Screa) and urine output, were a step forward in diagnosing AKI, a reliable tool to 
differentiate between true parenchymal and prerenal azotemia in clinical practice is still 
lacking. In the last decade, many papers on the use of new urinary and serum biomarkers for 
diagnosis and prognostication of AKI have been published. Thus, the question arises which 
biomarker is a reliable differential diagnostic tool under which circumstances.  
Design: We searched Medline from inception to April 2012 using medical subject heading 
and textwords for AKI and biomarkers (NGAL, KIM-1, Cystatin C, IL-6, IL-8, IL-18, NAG, 
glutathione transferases and LFABP) to identify relevant papers in 5 different settings 
(pediactrics, cardiac surgery, emergency department, critically ill, and contrast induced 
nephropathy).  
Results: We included 87 relevant papers, reporting on 74 studies. Depending upon the 
setting, 7 to 27 different definitions of AKI were used. Reported diagnostic performance of 
the different biomarkers was variable from poor to excellent, and no consistent 
generalizable conclusions can be drawn on their diagnostic value. 
Conclusion: Early diagnosing of AKI in clinical conditions by using new serum and urinary 
biomarkers remains cumbersome, especially in those settings where timing and etiology of 
AKI are not well defined. Putting too much emphasis on markers that have not convincingly 
proven reliability might lead to incorrect interpretation of clinical trials. Further research in 
this field is warranted before biomarkers can be introduced in clinical practice .  
 
3.2 Introduction 
Acute Kidney Injury (AKI) remains associated with high morbidity and mortality, despite 
progress in medical care1-3. In the last decade, many papers on the use of new urinary and 
serum biomarkers for AKI were published, mostly concluding that these biomarkers will lead 
to a new era with earlier diagnosis, better prognostication of outcome in terms of need for 
renal replacement and/or mortality, and finally better survival.4 Nevertheless, there remains 
a gap between the fascinating findings at the basic science level and the clinical application 
of this knowledge. Objective evaluation of the available literature shows a rather 
disappointing picture.5 Before we throw out the baby with the bathwater, we should 
evaluate what we reasonably can expect from biomarkers, what they provide today, and 
why their performance is currently suboptimal.  
 
3.3 Methods 
To identify relevant studies, we searched MEDLINE (through OvidSP) from inception to April 
2012, using medical subject headings and textwords for AKI and biomarkers. The full search 
strategy is outlined in item S1, provided as online supplementary material. To locate studies 
not indexed in Medline, we checked by hand the bibliography of relevant publications. We 
included both cohort and case-control studies evaluating the potential of biomarkers to 
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detect AKI early, or to predict the need for renal replacement therapy in both adults and 
children. We excluded studies published as abstracts only and restricted to those published 
in English. Papers were excluded as "invalid intervention" when they did not analyse AKI, or 
where not performed in humans, and as "inappropriate design" when they did not 
investigate the differential diagnosis AKI vs non AKI. Mostly, the latter studies just reported 
means/medians in subgroups rather than discriminatory values on the individual patient 
level, or insufficient data were present to calculate these.We allowed for any definition of 
AKI. Biomarkers included in the search strategy were neutrophil gelatinase associated 
lipocalin (NGAL), kidney injury molecule 1 (KIM-1), interleukin 6 (IL-6), interleukin 8 (IL-8), 
interleukin 18 (IL-18), Cystatin C, N-acetyl-glucosaminidase (NAG), liver fatty acid binding 
protein (LFABP) and the glutathione transferases (GST), measured either in plasma, serum or 
urine. 
Two authors (JVM, WVB) independently screened all titles and abstracts and assessed all 
selected full papers for eligibility. Any disagreements were resolved by face to face 
discussion. Using a structured data extraction template, we collected details on biomarker(s) 
studied, outcome, AKI definition, number of patients/events and diagnostic test 
characteristics. Results are reported in overview tables 2 to 6. When not available, Positive 
Predictive Value (PPV) and Negatieve Predictive Value (NPV) were calculated if enough 
information was provided and if the study design allowed this.  
Because of the heterogeneity of studies in different clinical settings, a meta-analysis or 
pooling of the data was deemed to be methodologically inappropriate. 
 
3.4 Results 
1532 potentially relevant papers were identified by the search strategy. Based on title and 
abstract, 149 papers were selected for full paper review. After checking the bibliography of 
relevant papers, 6 additional publications were selected for full paper review. 87 papers 
reporting on 74 studies, were included in the review. 68 papers were excluded for reasons 
outlined in figure 1.  
Chapter 3 
77 
Figure 1: Flowchart of retrieval and selection process of papers included in the final review. 
 
All biomarkers and their abbreviations as used further in the text, are summarized in table 1. 
 
Table 1: Biomarkers considered in this review 
Acronym/abbreviation Legend Main source 
AP alcaline phosphatase Liver, bone, intestine, placenta, 
brush border proximal convoluted 
tubules 
α1MG alpha 1 microglobulin Liver. Reabsorption by renal 
proximal tubular cells 
α1acidGP alpha 1 acid glycoprotein Liver. Reabsorption by renal 
proximal tubular cells 
AST Aspartate aminotransferase Liver, heart, muscle, brain, red 
blood cells, kidney 
Β2MG beta 2 microglobulin All nucleated cells. Reabsorption 
by renal proximal tubular cells 
Cystatin C Cystatin C All nucleated cells. Reabsorption 
by renal proximal tubular cells 
FENA Fractional Excretion of Sodium  
GGTP Gamma glutamyl transpeptidase All cells except myocytes. Mainly 
liver and kidney (brush border 
proximal convoluted tubules and 
loop of Henle) 
GST-α Alpha glutathione S transferase Expressed in almost all tissues. 
Kidney: Proximal tubular cells 
(cytoplasmatic) 
GST-π Pi glutathione S transferase Expressed in almost all tissues. 
Kidney: Distal tubular cells 
(cytoplasmatic) 
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Acronym/abbreviation Legend Main source 
HGF  Hepatocyte Growth Factor Mesenchymal cells 
ICAM-1 Intracellular Adhesion Molecule 1 Endothelial cells, leukocytes 
IL-6 Interleukin 6 T lymphocytes, macrophages, 
endothelial cells, monocytes 
IL-8 Interleukin 8 Monocytes, macrophages, 
epithelial cells, endothelial cells 
IL-10 Interleukin 10 Monocytes, lymphocytes, 
macrophages 
IL-18 Interleukin 18 Monocytes, dendritic cells, 
macrophages and epithelial cells 
KIM-1 Kidney Injury Molecule 1 Kidney: Proximal tubular cells 
LDH Lactate dehydrogenase Heart, liver, red blood cells, 
muscle, brain, lung. Kidney: 
proximal tubular cells 
(cytoplasmatic) 
LFABP Liver type Fatty Acid Binding Protein Hepatocytes, Kidney: proximal 
tubular cells 
NGAL Neutrophil Gelatinase Associated 
Lipocalin 
Leucocytes, loop of Henle and 
collecting ducts 
NAG N Acetyl beta Glucosaminidase Several tissues (Liver, brain, 
spleen,…). Kidney: Proximal 
tubular cells (lysosomal) 
PAI-1 Plasminogen Activator Inhibitor 1 Endothelium 
PCX Podocalyxin Podocytes 
RBP Retinol Binding Protein Liver. Reabsorption by renal 
proximal tubula cells 
sTNFR-I Soluble Tumor Necrosis Factor 
Receptor I 
Most cells and tissues (cytotoxic, 
apoptotic and proinflammatory 
effects) 
sTNFR-II Soluble Tumor Necrosis Factor 
Receptor II 
Most cells and tissues 
(proliferative and anti-apoptotic 
effects) 
TNFα Tumor Necrosis Factor alpha Macrophages, lymfoïd cells, renal 
parenchymal cells 
11k-TXB2 11-keto-Thromboxane B2 Platelets 
vWF Von Willebrand Factor Endothelium, megakaryocytes, 
subendothelial connective tissue 
 
Results of the data extraction of the 87 selected papers are presented in tables 2 to 6. We 
organised papers according to 5 different clinical settings (pediatrics, cardiac surgery, 
emergency department, critically ill patients at ICU, and Contrast Induced Nephropathy(CIN)). 
In the pediatric setting, 16 papers reporting on 11 studies were discussed. Eleven papers 
reporting on 7 studies were conducted post cardiac surgery6-16, 1 studied CIN17, 1 was 
conducted in the emergency department setting18 and 3 papers reporting on 2 studies were 
conducted in critically ill children. Only 1 study in pediatric setting6 explored the use of 
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biomarkers for early prediction of need for RRT (196 patients, 4 events, AUCRoC 0.86, PPV 
and NPV not available). All other studies considered the predictive value for AKI, which was 
defined according to 7 different definitions. The number of patients varied from 23 to 374, 
and the number of events varied from 6 to121. AURoC’s for prediction of AKI varied from 
0.44 to 1.00. PPV’s and NPV’s ranged from 27-100% and from 10-100%.  
In adult cardiac surgery, 26 papers reporting on 22 studies were included. Twenty-seven 
different definitions for AKI were used. Patient number varied from 30-1219 and event 
number varied from 1-85. The AURoC’s varied from 0.27-0.98. PPV’s and NPV’s ranged from 
4-100% and from 61-100% respectively. One study19 reported on the use of biomarkers for 
prediction of need for RRT (100 patients, 4 events, AURoC 0.83, PPV 100%, NPV 99%), 
although another study20 also defined AKI as a 25% increase of Screa or RRT need with 
AURoC’s between 0.54-0.73 and PPV 64-72%, NPV 67-73%.   
In the emergency department setting, 4 studies were included21-24. Patient number varied 
from 616-1635 and event number from 24-130. Three different definitions of AKI were used. 
AURoC’s varied from 0.59-0.95. PPV’s and NPV’s varied from 4-90% and from 84-99.5%. 
In critically ill patients, 33 papers reporting on 29 studies of which 1 was a meta-analysis, 
were included. Twenty-one different definitions were used to define AKI. Patient number 
varied from 26-1345, event number varied from 4-209. AURoC’s for prediction of AKI varied 
from 0.35-0.99 and PPV’s and NPV ranged from 1-100% and from 50-100%. Fifteen papers 
reported on the adverse clinical outcomes of AKI (Failure of Recovery, RRT or the composite 
outcome of RRT and mortality). AURoC’s for prediction of adverse clinical outcomes varied 
from 0.51-0.92 (PPV 5-75% and NPV 86-99.5%). 
Eight studies exploring the use of biomarkers in CIN were included. Seven different 
definitions of CIN were used. Patient number ranged from 30-410 and event number from 2-
34. AURoC’s varied from 0.73-0.93. PPV’s and NPV’s ranged from 20-68% and from 96-100%.  
 
3.5 Discussion 
This paper evaluated the state of the art on the diagnostic usefulness of biomarkers in AKI. 
Most striking was the wide array of definitions used for AKI. With regard to the diagnostic 
usefulness of biomarkers, a variety of results ranging from overtly negative to very optimistic 
was found.  
There are different explanations for this wide range of results. First, widely different clinical 
settings are investigated, from pediatric post cardiac bypass, where timing and amount of 
renal impact are exactly known, to patients with septic shock, where timing of renal insult is 
unknown. Overall, diagnostic performance of biomarkers appears to be better in situations 
with a known timing and etiology of renal injury. Second, most of these markers are not only 
associated with kidney damage, but also with the underlying conditions causing the AKI, 
such as sepsis, diabetic nephropathy , systemic lupus erythematosus and hemolytic uremic 
syndrome.25-28 Some of these markers are also increased in chronic kidney disease29;30, 
blurring the differential diagnosis between CKD and AKI. The reference baseline creatinine of 
a given patient is not always available, so in these patients, it is unclear whether an 
increased creatinine is due to AKI or chronic kidney disease (CKD). The behavior of most 
biomarkers in patients with CKD is however largely unknown. Usefulness of biomarkers 
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should thus be addressed differently for different clinical settings, as it is apparent that 
performance is strongly dependent on the underlying circumstances. As such, results in one 
setting cannot be generalised. 
Third, one should be cautious for some statistical pitfalls when translating studies to clinical 
practice. Most studies report higher values for the biomarker in patient with AKI, but with 
substantial overlap between AKI and non AKI patients, hampering discrimination in the 
single case.  Area under receiver operating characteristic (AURoC) curves are mostly used to 
circumvent this problem; however, the use of this instrument is troublesome in conditions 
with rather low prevalence, so also positive and negative predictive value should be 
provided, to allow good judgement on the accuracy of the biomarker. The use of odds ratios 
should be avoided in cases with low prevalence. In a study on performance of uNGAL for 
example, an impressive 16.4 higher odd's ratio to need RRT was reported; however, still only 
2.5% of patients in this NGAL+/Screa- group end up on RRT, implicating that 97.5% did not. 
One should be cautious that, based on the high odds ratio, people become tempted to use 
NGAL cut-off levels to decide on start of RRT, as this would lead to unnecessary RRT in 97.5% 
of cases. 31-33  
Fourth, many studies use circular reasoning to define AKI by new markers. They start from 
the premise that an increase in the biomarker without a rise in Screa indicates AKI34;35, thus 
increasing sensitivity, but at the expense of specificity and PPV. This confusion is due to the 
lack of a gold standard to diagnose AKI, and the difficulty to make a distinction between 
intrinsic renal damage (histological AKI) and physiologic decrease in renal perfusion 
(functional AKI) in the clinical setting. Undoubtedly, there is also a gray zone, where 
functional and histological AKI co-exist in a varying mix. Recent work by Nejat et al indicated 
that even in cases of transient AKI, markers of tubular damage can be present, 
demonstrating that "functional" and "intrinsic" AKI are probably gradations of an evolving 
spectrum of AKI.36 Urinary markers will probably be more sensitive for true histological 
damage, whereas serum levels of markers are probably more sensitive for changes in 
clearance. In research conditions, e.g. to evaluate potential nephrotoxicity, use of high 
sensitivity markers is excellent. However, in clinical practice, we need to define what degree 
of subclinical damage as detected by biomarkers we will accept. Therefore, we need studies 
linking acute tubular damage to long term outcomes. Several studies make the link between 
AKI, even when apparently fully recovered, and progressive chronic kidney disease, but in all 
these, the classic definition of AKI, based on creatinine, was used, and to our knowledge, 
these data are lacking for biomarkers. 37;38 
Lastly, some studies advertise the use of biomarkers in situations where the outcome 
already seems predictable using standard parameters, such as clinical appraisal and oliguria.  
In the study of Koyner et al, 7 patients needed RRT, 5 of them within 27 hours after cardiac 
surgery, making it plausible that RRT need in these patients could have been predicted by 
bedside clinical appraisal.20 Also, the value of biomarkers to predict need for RRT should be 
evaluated compared to other available standards, such as clinical appreciation, time on 
cardiopulmonary bypass, or urinary output.39 Singer et al used uNGAL to separate intrinsic 
from pre-renal AKI40, but 32 out of 104 patients were esteemed "unclassifiable", and were 
thus not incorporated in the evaluation of the diagnostic accuracy of uNGAL.  This means 
that only patients in whom the distinction between prerenal azotemia and AKI could already 
be established based on clinical grounds were included. From the provided graphs, it is clear 
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that the biomarker in these "unclassifiable" cases also was “intermediate”, and thus not 
discriminative. 
Not taking into account all these reflections can lead to erroneous conclusions on the value 
of biomarkers, resulting in incorrect diagnoses, and thus incorrect therapeutic interventions.  
It is clear from our survey that, whereas RIFLE and AKIN form a giant leap forward, the 
definition of AKI is still problematic, and that both RIFLE as AKIN are applied differently in 
every individual study in clinical practice, resulting in differences in classification.  
The studies of Mishra et al  and Bennett et al showed excellent performance for NGAL under 
ideal circumstances: children without comorbidities after cardiopulmonary bypass (CPB).6;12 
When more heterogenic populations were studied  such as critically ill patients, results 
became more ambiguous.41-43 Septic pediatric patients have higher uNGAL and IL-18 levels 
than non septic patients, indicating that the association between uNGAL and AKI in septic 
patients might more reflect the association between severity of disease and AKI rather than 
true renal damage.  
Reported results on biomarkers in cardiac surgery are disappointing and conflicting, with 
AURoC’s for uNGAL comparable to the predictive power of clinical parameters such as 
duration of cardiopulmonary bypass and aortic cross–clamp time.44-46 KIM-1 has been 
reported to have the best AURoC for the prediction of AKI. However, the low PPV  showed 
that three out of four patients are being mislabeled as having AKI.47 Plasma NGAL  and IL-18 
also performed poorly.48;49 Serum cystatin C performed reasonably when AKI was defined as 
an increase in Screa of 50% , but poorly when based on RIFLE. More importantly, also Screa 
distinguished accurately between the AKI and non- AKI group within 24hs after arrival at 
ICU.50 In subjects with a baseline eGFR < 60 ml/min/1.73m2, uNGAL was not able to predict 
the development of evolving AKI.51 The discriminatory ability of uNGAL was less with 
decreasing RIFLE class.19 The major challenge in the emergency setting, is to distinguish fluid 
responsive from non-fluid responsive AKI, and AKI from CKD. As we do not have an 
established clinical definition of "pre-renal" AKI, discrimination of this condition always 
remains somewhat subjective. 
In a study with 635 patients, 411 had normal kidney function, 80 had prerenal azotemia, 30 
AKI, and 106 non-progressive CKD.21 This implicates that a patient with increased Screa at 
the emergency department has a six-fold higher odds to have either CKD or pre-renal kidney 
dysfunction than to have AKI. Despite the significant difference in median uNGAL levels 
between the different groups, there was a substantial overlap. Most of the patients with AKI 
had already very high Screa levels at presentation (mean 5.6 mg/dl, standard deviation 5.5 
mg/dl). In patients presenting at the emergency department with suspected sepsis, median 
NGAL levels were higher in patients with vs. without AKI, but with substantial overlap, 
making discrimination per individual patient impossible.23 In addition, patients who died 
without AKI had pNGAL levels comparable to the range of the AKI group, again indicating 
that the discriminative power of pNGAL for AKI is more related to the fact that it is a marker 
of severity of disease than of kidney injury.  
In a prospective cohort study of 616 patients admitted to a tertiary care emergency 
department, both sCysC and Screa but not uCysC, differentiated between AKI and non-AKI. 
Authors state that sCysC distinguishes between AKI and prerenal azotemia. Neither 
biomarker discriminated between AKI and CKD.24  
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The application of biomarkers is most cumbersome in critically ill patients. As in this setting 
the timing of the renal insult is unknown, multiple samplings will have to be taken, which all 
have the potential of being false positive, and may lead to logistical and cost-effectiveness 
problems. The pathophysiology of AKI in sepsis patients is complex and not merely due to 
ischemia/reperfusion injury, but also to inflammatory processes.52 It is likely that the levels 
of many biomarkers, e.g. IL-18, or NGAL, will be influenced by these processes, irrespective 
of AKI.32 Plasma markers are thus in these patients more an indication of severity of disease 
than of true kidney damage.53 54 33;55 Finding a biomarker or a panel of biomarkers that takes 
into account these different underlying pathological processes while still discriminating AKI is 
challenging. In most studies, there was no attempt to evaluate the discriminative power of 
the biomarker on top of other parameters, such as severity of sepsis, or urinary output. 
Although in a large cohort, uNGAL remained an independent predictor for AKI in a 
multivariate logistic regression model, the addition of uNGAL did not significantly improve 
discriminative power of the model. Overall, the clinical model performed better than 
uNGAL.56 In ICU patients, uNGAL and pNGAL did perform worse than admission eGFR , and 
adding pNGAL and uNGAL to a multivariate model with eGFR only improved reclassification 
for AKI insignificantly.57 Adding sCysC to a clinical model did not improve the diagnostic 
performance of the clinical model.58  Urinary CysC predicted AKI, with a model including 
uCysC, uCrea, age, hypotension and APACHE II subcategory scores, in 444 critically ill 
patients, but when excluding patients with overt AKI on admission based on clinical grounds 
and Screa , the AURoC was only 0.54.59 The predictive performance of urinary IL-18 in 
critically ill patients was poor60, and uLFABP did not perform well to diagnose established 
AKI61.  
Some authors showed a better diagnostic performance of biomarkers when stratifying 
patients according to presence of pre-existing CKD. 60;62  
Another strategy to optimize the performance of biomarkers in ICU patients was to use a  
marker pattern (20 urinary peptides) rather than individual biomarkers.63 However, a panel 
of 20 peptides measured by capillary electrophoresis-mass spectrometry, with high cost and 
long turn-around time, might not be realistic in clinical conditions.  
Also in CIN, the use of biomarkers is prone to problems. The risk for CIN increases in patients 
with comorbid conditions, such as diabetes or older age, and in patients with pre-existing 
kidney disease, all of which influence on themselves biomarker levels. In patients without 
pre-existing CKD, the incidence of CIN is very low.  In children, plasma and serum uNGAL 
were reported to be better predictors for CIN than Screa.17 Diagnosis of AKI was made using  
NGAL and IL-18 in adults undergoing elective coronarography, PTCA or angioplasty, up to 
24h before diagnosis by Screa, but this was not confirmed in another study.64;65  
Interestingly NGAL is known to be increased in atherosclerotic plaques and might be 
released from these plaques during PCI without being related to kidney injury.66 It can also 
be questioned whether CIN in patients with arteriography versus simple intravenous 
contrast administration, is the same condition, as the former can also be induced by 
cholesterol embolism.  
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3.6 Conclusion 
Whereas biomarkers can increase our understanding of the pathophysiology of AKI, it 
appears that the promising results with new biomarkers for early detection and differential 
diagnosis of AKI in clinical practice can only be confirmed in the setting of children without 
comorbidities and with a well defined timing of renal injury. Results are far less robust when 
we search for validation in adult heterogenic populations, including patients with comorbid 
conditions such as diabetes mellitus, vascular disease and chronic kidney disease. Whereas 
AURoC values sometimes look impressive, applying levels of urinary or serum biomarkers for 
discrimination in individual patients is hampered by wide overlap between groups, which 
might result in many false positives. Biomarkers reflect a general degree of severity of 
disease, rather than being specific for kidney injury. Before biomarkers can be advocated to 
diagnose AKI, further research on the implications of "subclinical" AKI, i.e. diagnosed by the 
biomarker but not by an increase of creatinine or decrease of diuresis, should be performed 
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Table 2: Pediatric setting 
Author PY Biomarker U/S/P Outcome AKI def/Outcome def Patients/Events AURoC PPV 
(%) 
NPV (%) 
Mishra12 2005 NGAL U 
S 
AKI Screa * 1.5 
 
71/20 0.99 
0.91 
95 
82 
100 
89 
Hirsch17 2007 NGAL 
 
U 
P 
CIN Screa * 1.5 91/11 0.92 
0.91 
100 
80 
96 
96 
Zappitelli43 2007 NGAL U AKI 
Persistent 
AKI 
pRIFLE crea 
AKI lasting > 48h 
140/106 
140/? 
0.78  
0.79 
NA 
NA 
NA 
NA 
Dent8  2007 NGAL P AKI Screa * 1.5 120/45 0.96 84 93 
Bennet6 2008 NGAL U AKI 
RRT 
Screa * 1.5 196/99 
196/4 
0.95 
0.86 
89 
NA 
83 
NA 
Wheeler42 2008 NGAL S AKI BUN>100mg/dl, 
Screa>2mg/dl in 
absence of CKD or RRT 
143/22 0.68  
 
39 94 
Krawczeski10  2011 NGAL U 
 
P 
AKI Neonates:↑Screa 
>0.3mg/dl  
Children: Screa *1.5  
within 48h after CPB 
374/112 0.95(neonates)  
0.92 (others) 
0.95 (neonates) 
0.94 (others) 
80 
73 
78 
77 
100 
93 
96 
95 
Portilla14 2008 NGAL U AKI Screa * 1.5 40/21 1.00 100 100 
Du18  2011 NGAL U AKI pRIFLE crea 252/18 0.66-0.67 NA NA 
Parikh13  2011 NGAL U 
P 
AKI Progression of 
established AKI 
311/53 0.71 
0.56 
30 
20 
93 
86 
Parikh13  2011 IL-18 U AKI Progression of 
established AKI 
311/53 0.72 30 92 
Parikh16 2006 IL-18 U AKI Screa * 1.5 55/20 0.75 65 76 
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Author PY Biomarker U/S/P Outcome AKI def/Outcome def Patients/Events AURoC PPV 
(%) 
NPV (%) 
Du18  2011 IL-18 
IL-18 
U 
U 
AKI 
RIFLE-I 
pRIFLE crea 252/6 0.44-0.54 
0.48-0.64 
NA 
NA 
NA 
NA 
Washburn41 2008 IL-18 U AKI pRIFLE crea 137/103 
 
0.54 27 85 
Portilla14 2008 LFABP 
 
U AKI Screa * 1.5 40/21 0.81 71 68 
Dennen7 2010 IL-6 U AKI Screa*1.5 23/10 NA 60 10 
Liu11  2009 IL-6 
IL-8 
S 
S 
AKI Screa *1.5 within 3 
days 
39/18 0.76 
0.74 
69 
52 
87 
78 
Zappitelli15 2011 Clinical 
Model(CM) 
Cystatin C + CM 
Screa + CM 
S AKI Screa*1.5 288/121 0.71 
 
0.81 
0.83 
NA 
 
NA 
NA 
NA 
 
NA 
NA 
Krawczeski9  2010 Cystatin C S AKI Screa *1.5 within 48h 374/119 0.81 
 
70 87 
Du18  2011 KIM-1 
β2-MG 
KIM-1 
β2-MG 
U 
U 
U 
U 
AKI 
 
RIFLE-I 
pRIFLE crea 252/18 
 
252/6 
0.61 
0.59 
0.73 
0.80 
 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
 
 
 
 
Abbreviations: PY: Publication Year, U/S/P: Urine/Serum/Plasma, AKI def: definition of Acute Kidney Injury, AURoC: Area Under the Receiver Operating Characteristic Curve, PPV: Positive 
Predictive Value, NPV: Negative Predictive Value, NA: Not Available or Not Applicable, NGAL: Neutrophil Gelatinase-Associated Lipocalin, IL-18: Interleukin 18, LFABP: Liver Fatty Acid Binding 
Protein, IL-6: Interleukin 6, IL-8: Interleukin 8, KIM-1: Kidney Injury Molecule 1, β2MG: β2-microglobulin, Screa: Serum Creatinine, BUN: Blood Urea Nitrogen,AKI: Acute Kidney Injury, CKD: 
Chronic Kidney Disease, CIN: Contrast Induced Nephropathy, RRT: Renal Replacement Therapy, pRIFLE: pediatric modified Risk Injury Failure Loss of Kidney Function and End stage renal 
disease classification, pRIFLE crea: pRIFLE criteria based on the creatinine criterium (omitting the diuresis criterion), CPB: Cardiopulmonary bypass time 
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Table 3: Cardiac Surgery 
Author PY Biomarker U/S/P Outcome AKI def/Outcome def Patients/Events AURoC PPV (%) NPV (%) 
Parikh
67
  2011 NGAL 
 
Screa immediate 
postop 
U 
P 
P 
AKI Doubling of Screa 1219/60 0.67 
0.70 
0.72 
NA 
NA 
NA 
NA 
NA 
NA 
Xin
68
  2008 NGAL U AKI AKIN both 33/9 0.88 58 91 
Wagener
69
 2007 NGAL U AD Scra *1.5 81/6 0.8 4 9 
Wagener
46
 2008 NGAL  U AKI AKIN crea 426/85 0.61 31 84 
Haase-
Fielitz
50 
 
 
 
2009 NGAL 
 
NGAL 
NGAL 
NGAL 
NGAL 
 
P 
 
P 
P 
P 
P 
 
AKI 
 
AKI 
AKI RIFLE 
RRT+M 
RRT+M 
Screa *1.5 within 5 days 
postoperatively 
RIFLE  
100/23 
eGFR > 60 
ml/min/1.73m
2
 
100/5 
 
eGFR > 60 
ml/min/1.73m2 
0.80/0.87  (ICU 
arr/24h post) 
0.80/0.87   
0.73/0.70   
0.95 
NA 
 
52/53 
 
69/57 
73/69 
57 
NA 
 
93/97 
 
94/95 
69/61 
99 
NA 
 
Haase-
Fielitz
19
 
2009 NGAL P AKI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-Screa * 1.25 within 48h 
 
-Screa * 1.25 within 72h 
 
-Screa * 1.25 within 120h 
 
-Screa * 1.25 within 168h 
 
-↑ Screa 0.3mg/dl or 
*1.5 48h 
-Screa * 1.25 or RRT 
within 72h 
-Screa * 1.5 within 48h 
 
-Screa * 1.5 within 72h 
 
-Screa * 1.5 within 120h 
 
-Screa * 1.5 within 168h 
 
100/36 
 
100/38 
 
100/39 
 
100/40 
 
100/32 
 
100/42 
 
100/20 
 
100/21 
 
100/23 
 
100/23 
 
0.66 
 
0.64 
 
0.67 
 
0.64 
 
0.66 
 
0.68 
 
0.78 
 
0.79 
 
0.80 
 
0.80 
 
58 
 
55 
 
55 
 
57 
 
51 
 
66 
 
44 
 
46 
 
51 
 
51 
 
78 
 
74 
 
76 
 
72 
 
80 
 
75 
 
92 
 
92 
 
92 
 
92 
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RIFLE R 
RIFLE I 
RIFLE F 
AKIN I 
AKIN II 
AKIN III 
RRT 
RIFLE both 
 
 
AKIN both 
100/31 
100/13 
100/6 
100/29 
100/11 
100/6 
100/4 
0.72 
0.79 
0.80 
0.75 
0.78 
0.81 
0.83 
52 
33 
100 
53 
33 
100 
100 
84 
97 
98 
87 
97 
98 
99 
Tuladhar
70
 2009 NGAL U 
P 
AKI ↑ Screa 0.5mg/dl within 
48h 
50/9 0.96 
0.85 
47 
33 
97 
93 
Perry
49
 2010 NGAL P AKI Screa *1.5 within 4 days 879/75 0.64 16 93 
Prabhu
71
 2010 NGAL P AKI RIFLE crea 30/8 0.98 79 100 
McIllroy
51
 2010 NGAL U AKI AKIN crea 
-eGFR<30  
-eGFR 30-60 
-eGFR 60-90 
-eGFR 90-120 
-eGFR > 120 
 
426/85 
21/9 
101/20 
142/35 
109/13 
53/8 
 
0.34 
0.51 
0.55 
0.88 
0.27 
 
44 
22 
29 
40 
4 
 
60 
86 
85 
99 
74 
Koyner
20
 2008 NGAL 
 
NGAL 
P 
 
U 
AKI Screa *1.25 or RRT need 
within 72h 
72/34 
 
0.54 
 
0.69 
NA 
 
64 
NA 
 
67 
Haase
72
 2009 NGAL 
NGAL+CysC 
P 
S 
AKI AKIN both 100/46 0.77 
0.81 
71 
78 
77 
75 
Koyner
73
  2012 NGAL U 
P 
 
AKI AKI progression 380/45 NA NA NA 
Koyner
45
 2010 NGAL 
NGAL 
NGAL 
NGAL 
NGAL 
NGAL 
U 
U 
U 
U 
U 
U 
AKI stage 1 
AKI  
AKI  
AKI stage 3 
AKI stage 3 
AKI stage 3 
AKIN  
-eGFR>60  
-eGFR<60 
 
-eGFR>60 
-eGFR<60 
 
123/36 
74/27 
49/19 
123/9 
74/4 
49/5 
0.72 
0.81 
0.58 
0.88 
0.97 
0.73 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
Heise
74
 2011 NGAL U AKI AKIN both 
 
47/38 0.77 94 50 
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Author PY Biomarker U/S/P Outcome AKI def/Outcome def Patients/Events AURoC PPV (%) NPV (%) 
Han
44
 2009 NGAL 
 
 
NGAL 
 
NGAL 
U 
 
 
U 
 
U 
AKI 
 
 
Early AKI 
 
Late AKI 
↑ Screa 0.3mg/dl or 2 to 
3 fold increase in Screa 
within 72h 
↑ Screa 0.3mg/dl within 
24h 
 
90/36 
 
 
90/16 
 
90/20 
0.59/0.65 (imm/3h 
postop) 
 
0.51/0.58 
 
0.66/0.71 
47/57 
 
 
NA 
 
NA 
69/77 
 
 
NA 
 
NA 
Liangos
47
 2009 NGAL U AKI Screa *1.5 within 72h 103/13 0.50 15 90 
Koyner
20
 2008 Cystatin C 
 
Cystatin C 
P 
 
U 
AKI Screa *1.25 or RRT need 
within 72h 
 
 
 
72/34 
 
0.62 
 
0.73 
NA 
 
72 
NA 
 
73 
Haase-
Fielitz
50 
 
 
 
2009 Cystatin C 
Creatinine 
Ureum 
Cystatin C 
Creatinine 
Ureum 
Cystatin C 
Creatinine 
Ureum 
Cystatin C 
Creatinine 
Ureum 
Cystatin C 
Creatinine 
Ureum 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
S 
AKI 
 
 
AKI 
 
 
AKI RIFLE 
 
 
RRT+M 
 
 
RRT+M 
Screa *1.5 within 5 days 
postoperatively 
 
 
 
 
RIFLE  
100/23 
 
 
eGFR > 60 
ml/min/1.73m
2
 
 
100/5 
 
 
 
 
 
eGFR > 60 
ml/min/1.73m
2
 
0.83/0.84 
0.68/0.86 
0.60/0.79 
0.78/0.84 
0.69/0.86 
0.61/0.79   
0.75/0.73 
0.58/0.73 
0.55/0.76 
0.99 
NA 
NA 
NA 
NA 
NA 
62/43 
47/56 
32/53 
64/53 
54/49 
35/36 
75/69 
56/75 
54/76 
36 
NA 
NA 
NA 
NA 
NA 
93/96 
85/93 
90/88 
93/96 
86/97 
89/100 
69/71 
53/65 
55/62 
100 
NA 
NA 
NA 
NA 
NA 
Haase
72
 2009 Cystatin C S AKI AKIN both 100/46 0.76 65 75 
Ristikankare
75
  2010 Cystatin C 
 
Creatinine 
S 
 
P 
AKI RIFLE both POD1 
 
RIFLE crea POD2 
110/62 0.71/0.77 
(POD1/POD2) 
0.66/0.74 
(POD1/POD2) 
 
NA 
 
NA 
NA 
 
NA 
Wald
76
  2010 Cystatin C P AKI Screa *1,5 or ↑ 0,3 
mg/dl within 72h 
 
150/47 0.68 NA NA 
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Author PY Biomarker U/S/P Outcome AKI def/Outcome def Patients/Events AURoC PPV (%) NPV (%) 
Heise
74
 2011 Cystatin C 
α1MG 
U 
U 
AKI AKIN both 47/38 
 
0.59 
0.61 
 
NA 
NA 
NA 
NA 
Koyner
45
 2010 Cystatin C 
Cystatin C 
Cystatin C 
Cystatin C 
Cystatin C 
Cystatin C 
U 
U 
U 
U 
U 
U 
AKI stage 1 
AKI  
AKI  
AKI stage 3 
AKI stage 3 
AKI stage 3 
AKIN  
-eGFR>60  
-eGFR<60 
 
-eGFR>60 
-eGFR<60 
123/36 
74/27 
49/19 
123/9 
74/4 
49/5 
0.72 
0.70 
0.70 
0.85 
0.93 
0.81 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
Liangos
47
 2009 CystatinC U AKI Screa *1.5 within 72h 103/13 0.50 31 91 
Xin
68
  2008 IL-18 U AKI AKIN both 33/9 0.89 78 92 
Liangos
47
 2009 IL-18 U AKI Screa *1.5 within 72h 103/13 0.66 25 95 
Liang
77
 2010 IL-18 
 
 
U 
 
 
AKI 
Progr AKI 
 
RIFLE crea 
RIFLE R → I or RIFLE ≥ I 
from start 
122/30 
Progr AKI: 122/11 
0.62 
0.91 
 
27 
17 
79 
100 
Haase
48
 2008 IL-18 U RIFLE ≥ R 
 
 
RIFLE ≥ I 
 
AKI 
 
 
 
 
 
AKI 
Sustained 
AKI (At least 
two 
consecutively 
increased 
Screa levels) 
RIFLE within 120h.  
Urine output criterion 
only during first 24h 
-Screa * 1.25 within 24h 
-Screa * 1.25 within 48h 
-Screa * 1.25 within 72h 
-Screa * 1.25 within 120h 
-Screa * 1.5 within 24h 
-Screa * 1.5 within 48h 
-Screa * 1.5 within 72h 
-Screa * 1.5 within 120h 
AKIN ≥ Stage1 
-Screa * 1.25 within 48h 
-Screa * 1.25 within 120h 
-Screa * 1.5 within 48h 
-Screa * 1.5 within 120h 
-RIFLE ≥ R 
-RIFLE ≥ I 
100/50 
 
100/19 
100/? 
100/? 
100/? 
100/? 
100/? 
100/20 
100/? 
100/? 
100/32 
100/? 
100/? 
100/? 
100/? 
100/50 
100/19 
0.61/0.57 (ICU 
arr/24h post) 
0.52/0.58 
0.58/0.56 
0.59/0.56 
0.60/0.58 
0.60/0.59 
0.56/0.57 
0.53/0.55  
0.58/0.55 
0.52/0.56 
0.48/0.59 
0.58/0.56 
0.59/0.56 
0.56/0.57 
0.51/0.57 
0.61/0.57 
0.52/0.58 
NA 
 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
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Author PY Biomarker U/S/P Outcome AKI def/Outcome def Patients/Events AURoC PPV (%) NPV (%) 
Han
44
 2009 KIM-1 
NAG 
Panel of 3 
KIM-1 
NAG 
Panel of 3 
KIM-1 
NAG 
Panel of 3 
U 
U 
U 
U 
U 
U 
U 
U 
U 
AKI 
 
 
Early AKI 
 
 
Late AKI 
↑ Screa 0.3mg/dl or 2 to 
3 fold increase in Screa 
within 72h 
↑ Screa 0.3mg/dl within 
24h 
 
↑ Screa 0.3mg/dl within 
24-72h 
90/36 
 
 
90/16 
 
 
90/20 
 
0.68/0.65 
0.61/0.63 
0.75/0.78 
0.79/0.73 
0.60/0.59 
0.80/0.84 
0.61/0.60 
0.62/0.65 
0.72/0.74 
61/72 
50/54 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
71/68 
75/69 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
Liangos
47
 2009 KIM-1 
KIM1/NAG/IL18 
KIM-1/CPB time 
KIM-1/CCF  
U 
 
 
 
AKI Screa *1.5 within 72h 103/13 0.78 
0.78 
0.78 
0.88 
24 
NA 
NA 
NA 
98 
NA 
NA 
NA 
Liang
77
 2010 KIM-1 
 
 
KIM-1+IL-18 
U 
 
 
U 
AKI 
Progr AKI 
 
Progr AKI 
RIFLE crea 
RIFLE R → I or RIFLE ≥ I 
from start 
122/30 
Progr AKI: 122/11 
0.88 
0.70 
 
0.90 
57 
19 
 
35 
96 
97 
 
90 
Koyner
45
 2010 KIM-1 
KIM-1 
KIM-1 
KIM-1 
KIM-1 
KIM-1 
U 
U 
U 
U 
U 
U 
AKI stage 1 
AKI  
AKI  
AKI stage 3 
AKI stage 3 
AKI stage 3 
AKIN  
 
-eGFR>60  
-eGFR<60 
-eGFR>60 
-eGFR<60 
123/36 
74/27 
49/19 
123/9 
74/4 
49/5 
0.67 
0.68 
0.64 
0.82 
0.80 
0.82 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
Jörres
78
 1994 βNAG 
α1MG 
Albumine 
Transferrin 
IgG 
11k-TXB2 
U 
U 
U 
U 
U 
U 
Renal Injury Screa > 1.3 mg/dl 36/12 NA NA NA 
da Silva 
Magro
79
 
2004 α GST 
FENA 
Creatinine 
Urea 
CrCl 
U 
U 
P 
P 
ARF ↓CrCl<75ml/min  
within 72h 
41/20 < 0.80 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
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Author PY Biomarker U/S/P Outcome AKI def/Outcome def Patients/Events AURoC PPV (%) NPV (%) 
Eijkenboom
80
 2005 αGST 
πGST 
U 
U 
ARF 
 
Screa *1.5 84/1 NA NA NA 
Wagener
46
 2008 CPB time 
AXT  
U AKI AKIN crea 426/85 0.59 
0.59 
NA 
NA 
NA 
NA 
Liangos
47
 2009 NAG 
α1MG 
CPB perf time 
CCF score 
U 
 
 
 
AKI Screa *1.5 within 72h 103/13 0.62 
0.62 
0.67 
0.83 
26 
21 
NA 
NA 
91 
94 
NA 
NA 
Liangos
81
 2009 IL-8 P AKI 1. Screa *1,5 or  
↑ 0,3 mg/dl 
2. Screa *1.5within 72h 
143/41 
 
143/18 
0.62 
 
0.72 
NA 
 
NA 
NA 
 
NA 
Gueret
82
 2009 IL-6 P ARD Faint ARD: Screa *1.25 
Moderate ARD: Screa 
*1.5 
Severe ARD: Screa *2 
within 48h 
63/36 NA NA NA 
Koyner
45
 2010 HGF 
αGST 
πGST 
FENA 
FEUrea 
HGF 
αGST 
πGST 
FENA 
FEUrea 
HGF 
αGST 
πGST 
FENA 
FEUrea 
HGF 
αGST 
πGST 
FENA 
FEUrea 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
AKI stage 1 
 
 
 
 
AKI  
 
 
 
 
AKI  
 
 
 
 
AKI stage 3 
 
 
 
 
AKIN  
 
 
 
 
-eGFR>60  
 
 
 
 
-eGFR<60 
 
 
 
 
 
 
 
 
 
123/36 
 
 
 
 
74/27 
 
 
 
 
49/19 
 
 
 
 
123/9 
 
 
 
 
0.53 
0.62 
0.60 
0.49 
0.59 
0.52 
0.66 
0.61 
0.50 
0.52 
0.54 
0.57 
0.56 
0.46 
0.51 
0.65 
0.68 
0.78 
0.65 
0.57 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
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Abbreviations: Same as in table 2. Not defined in table 2: ARF: Acute Renal Failure, ARD: Acute Renal Dysfunction, Progr AKI: Progressive AKI, ICU: Intensive Care Unit, imm: immediately, ICU arr: ICU arrival, 24h post: 
24h postoperatively, imm/3h: immediately/3 hours after surgery, POD: postoperative day, AKIN: Acute Kidney Injury Network, RIFLE crea: staging according to RIFLE based on the creatinine criterion (omitting the 
diuresis criterion), AKIN crea: staging according to AKIN based on the creatinine criterion (omitting the diuresis criterion); RIFLE/AKIN both: staging according to RIFLE or AKIN based on both criteria (creatinine and 
diuresis)CrCl: Creatinine Clearance, eGFR: estimated Glomerular Filtration Rate, αGST: α-glutathione-S-transferase, πGST: π-glutathione-S-transferase, α1MG: α1 microglobulin , AXT: aortic cross-clamp time, βNAG: N-
acetyl-β-D-glucosaminidase, CysC: Cystatine C, CCF: Cleveland Clinic Foundation Score , CPB time: CPB perfusion time, IgG: Immunoglobulin G, HGF: Hepatocyte Growth Factor, 11k-TXB2: 11-keto-thromboxane B2, 
FENA: Fractional Excretion of Sodium, FEUrea: Fractional Excretion of Urea 
HGF 
αGST 
πGST 
FENA 
FEUrea 
HGF 
αGST 
πGST 
FENA 
FEUrea 
U 
U 
U 
U 
U 
U 
U 
U 
U 
U 
AKI stage 3 
 
 
 
 
AKI stage 3 
-eGFR>60 
 
 
 
 
-eGFR<60 
74/4 
 
 
 
 
49/5 
0.73 
0.75 
0.93 
0.66 
0.60 
0.44 
0.61 
0.56 
0.63 
0.35 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
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Table 4: Emergency department  
Author PY Biomarker U/S/P Outcome AKI def/Outcome def Patients/Events AURoC PPV (%) NPV (%) 
Nickolas21 2008 NGAL U AKI RIFLE crea 635/30 0.95 90 99.5 
Shapiro23 2010 NGAL P 
 
 
 
AKI 
 
≥RIFLE R 
≥RIFLE I 
↑0,5mg/dl or RRT need 
within 72h  
Screa * 1,5 
Screa * 2 
661/24 
 
661/27 
661/15 
0.82 
 
NA 
NA 
7 
 
7 
4 
99 
 
98 
99 
Nickolas22 2012 NGAL 
T0 Creatinine>1.4 
T0 Creatinine>1.1 
IL-18 
KIM-1 
U 
S 
S 
U 
U 
Intrinsic AKI  1635/96 0.81 
0.90 
NA 
0.64 
0.71 
23 
28 
17 
14 
17 
97 
98 
99 
94 
95 
Nickolas21 2008 NAG 
α1MG 
α1acidGP 
FENA 
Creatinine 
U 
U 
U 
U 
S 
AKI RIFLE crea 635/30 0.71 
0.89 
0.83 
0.71 
0.92 
9 
17 
10 
16 
35 
98 
99 
99 
94 
99 
Shapiro23 2010 Creatinine 
 
P ≥RIFLE I 
AKI 
Screa * 1,5 
Screa * 2 
661/27 
661/15 
NA 
NA 
4 
3 
99 
99 
Soto24 2010 Cystatin C 
 
 
 
 
 
Creatinine 
S 
 
 
 
 
U 
S 
U 
AKI 
 
 
 
 
 
AKI 
AKIN crea 
 
 
 
 
 
AKIN crea 
616 
AKI: 130 
Prerenal 
azotemia: 159 
Stable CKD: 15 
 
0.87 
 
 
 
 
0.59 
0.9 
0.62 
48 
 
 
 
 
32 
54 
NA 
94 
 
 
 
 
84 
95 
NA 
Abbreviations: Same as in tables 2 and 3. Not defined in tables 2 and 3: α1acidGP: α1 acid glycoprotein; T0: at admission 
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Table 5: Critically ill patients at ICU  
Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Ahlström
83
  2004 Cystatin C S ARF RIFLE F both 202/54 0.89 NA NA 
Herget-
Rosenthal
84
 
2004 Cystatin C U RRT patients with 
non oliguric 
ATN 
73/26 0.92 75 95 
Herget-
Rosenthal
85
 
2004 Cystatin C 
 
 
Cystatin C 
S 
 
 
S 
ARF 
 
 
RRT 
RIFLE  crea 85/44 
 
 
85/17 
Rday-2/-1: 
0.82/0.97 
Iday-2/-1: 
0.92/0.98 
Fday-2/-
1:0.97/0.99 
Rday-2/-
1:0.69/0.75 
92/95 
 
100/100 
 
100/100 
 
45/76 
66/83 
 
63/81 
 
76/93 
 
86/93 
Mazul-
Sunko
86
 
2004 Cystatin C P ARF Screa ≥ 267 
µmol/l or 
diuresis < 
30ml/h in 
patients 
without CKD 
29/10 NA NA NA 
Hei
87
  2008 Cystatin S 
 
ARF ↑Screa to 132 
µmol/l or 
↑BUN to 18 
mmol/l 
60/10 NA 42 85 
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Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Perianayagam
58
  
2009 Cystatin C 
Clinical  
model + 
Cystatin C 
Clinical  
Model +  
Creatinine 
Clinical  
Model + 
Urea 
Clinical Model 
+ Urine output 
Clinical model 
alone 
S RRT or M Inlcusion of 
patients with 
ARF defined 
asBL 
≤1.9mg/dl: 
↑Screa 0.5 
mg/ dl 
 
200/84 0.65 
 
0.83 
 
0.83 
 
 
0.84 
 
 
0.84 
 
0.82 
NA 
 
NA 
 
NA 
 
 
NA 
 
 
NA 
 
NA 
NA 
 
NA 
 
NA 
 
 
NA 
 
 
NA 
 
NA 
Portal
88
  2010 Cystatin C 
Cystatin C 
S 
S 
AKI 
Severe AKI 
 AKIN crea 
Severe AKI: ≥ 
stage 2 
80/30 
80/19 
0.78 
0.78 
NA 
NA 
NA 
NA 
Nejat
89
 2010 Cystatin C 
Creatinine 
Cystatin C 
Creatinine  
Cystatin C 
Creatinine 
 
Cystatin C 
Creatinine 
P 
S 
P 
S 
P 
S 
 
P 
S 
-AKI 
 
-AKI 7d  
 
-AKI sust 
 
 
-RRT 
 
AKIN crea 
 
AKIN crea 
within 7 days 
Screa*1,5 
within 7 days 
and ≥24h 
 
444/198 
 
319/73 (no 
AKI on entry) 
319/19 (no 
AKI on entry) 
 
319/? (no AKI 
on entry) 
 
0.78 
0.87 
0.65 
0.61 
0.80 
0.57 
 
0.84 
0.77 
NA 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
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Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Nejat
59
 2010 Cystatin C U 
 
U 
 
 
P 
 
 
U 
 
 
P 
AKI 48h 
 
AKI 48h 
 
 
AKI 48h 
 
 
AKI 48h 
 
 
AKI 48h 
AKIN crea 319/73 (no 
AKI on entry) 
51/? (sepsis, 
no AKI on 
entry) 
268/? (no 
sepsis, no AKI 
on entry) 
268/? (no 
sepsis, no AKI 
on entry) 
0.54 
 
0.71 
 
 
Not predictive 
 
 
0.45 
 
 
NA 
NA 
 
NA 
 
 
NA 
 
 
NA 
 
 
NA 
NA 
 
NA 
 
 
NA 
 
 
NA 
 
 
NA 
Metzger
63
 2010 Cystatin C S AKI AKIN both  
2/16 
20/9 0.67 NA NA 
Endre
62
 
 
 
2011 Cystatin C 
 
Cystatin C 
 
 
Cystatin C 
 
 
 
 
 
 
 
Cystatin C 
U 
 
U 
 
 
U 
 
 
 
 
 
 
 
U 
AKIN48 
 
RIFLE 24hrs 
 
 
AKIN48 
 
 
 
 
 
 
 
RRT 
AKIN crea  
 
RIFLE crea, 
sustained  for 
≥24h  
-eGFR < 
60ml/min 
-eGFR 60-<90 
ml/min 
-eGFR 90-<120 
ml/min 
-eGFR > 120 
ml/min 
 
381 (no AKI on 
entry)/82 
381/27 
 
 
69/20 
 
116/25 
 
128/26 
 
66/11 
 
128/26 
0.55 
 
0.63 
 
 
0.64 
 
0.54 
 
0.58 
 
0.35 
 
0.66 
NA 
 
NA 
 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
NA 
 
NA 
 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
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Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Royakkers
90
 2011 Cystatin C U 
 
 
 
S 
 
U 
S 
AKI 
 
 
 
AKI 
 
RRT 
RIFLE both 
 
 
 
RIFLE both 
151 
No-AKI: 60 
AKI at adm.: 
56 
AKI after 
adm.: 35 
151/14 
day-2: 0.49 
day-1: 0.46 
 
 
day-2: 0.72 
day-1: 0.62 
0.61 
0.66 
NA 
NA 
 
 
NA 
NA 
NA 
NA 
NA 
NA 
 
 
NA 
NA 
NA 
NA 
Niemann
91
 2009 NGAL S AKI RIFLE crea 59/27 
45 (Screa 
baseline < 
1.5mg/dl)/24 
NA 
0.79 
NA 
NA 
NA 
NA 
Makris
92
 2009 NGAL 
Creatinine 
U 
S 
AKI RIFLE both 31/11 0.98 
0.79 
91 
NA 
95 
NA 
Aghel
93
 2010 NGAL 
BUN 
eGFR 
S 
S 
Worsening 
renal function 
↑Screa≥0.3m
g/dl within 5 
days 
91/35 0.70 
0.56 
0.61 
54 
NA 
NA 
86 
NA 
NA 
Bagshaw
55
 2010 NGAL 
 
P 
 
U 
Worsening 
AKI/RRT 
RIFLE  
 
83 
(sepsis:43)/20 
RRT:13 
0.71/0.78 
 
0.70/0.70 
NA 
 
NA 
NA 
 
NA 
Märtensson
94
 2010 NGAL 
 
NGAL 
U 
P 
U 
P 
AKI RIFLE or AKIN 
both 
45/18 
 
25(only septic 
shock)/18  
0.86 
0.85 
0.86 
0.67 
100 
79 
100 
81 
84 
88 
58 
54 
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Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Siew
56
 2009 NGAL 
Clinical  
Model 
NGAL+clinical 
model 
NGAL 
NGAL 
 
NGAL 
U 
 
 
 
 
U 
U 
 
U 
 
 
U 
AKI 24h 
 
 
 
 
AKI 24h 
AKI 48h 
 
Sust AKI 24h 
 
 
Sust AKI 48h 
AKIN crea 
 
 
 
 
AKIN crea, 
eGFR ≥ 75 
ml/min 
Persistent AKI 
24h post 
detection 
Persistent AKI 
24h post 
detection 
451/64 
 
 
 
 
275/18 
451/86 
 
451/47 
 
 
451/52 
0.71 
0.81 
0.82 
 
 
0.77 
0.64 
 
0.70 
 
 
0.66 
NA 
NA 
NA 
 
 
NA 
NA 
 
NA 
 
 
NA 
NA 
NA 
NA 
 
 
NA 
NA 
 
NA 
 
 
NA 
Constantin
32
 2010 NGAL P AKI 
 
 
RRT 
RIFLE  crea 88/52 
56/20 (no AKI 
on admission) 
88/7 
0.93 
0.96 
 
0.79 
97 
94 
 
21 
80 
92 
 
98 
Cruz
33
 2010 NGAL P AKI 
AKI 48h 
RRT 
RIFLE both 
within 5 
daysAKI within 
48h 
301/133 
301/? 
133/15 
O.67 
0.78 
0.82 
26 
24 
12 
91 
97 
99 
Yang
95
  2010 NGAL U Failure of 
recovery 
Failure to 
return to 
baseline or 
RRT need 
Inclusion of 
AKI patients 
according to 
RIFLE crea 
100/35 0.88 72 93 
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Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Endre
62
 
 
 
2011 NGAL 
 
NGAL 
NGAL 
 
 
 
 
 
 
 
 
 
NGAL 
U 
 
U 
U 
 
U 
 
U 
 
U 
 
U 
AKIN48 
 
RIFLE 24hrs 
AKIN48 
 
 
 
 
 
 
 
 
 
RRT 
AKIN crea  
 
RIFLE crea, 
sustained  for 
≥24h 
-eGFR  
< 60ml/min 
-eGFR 60- 
<90 ml/min 
-eGFR 90- 
<120 ml/min 
-eGFR > 120 
ml/min 
 
381 (no AKI on 
entry)/82 
381/27 
 
 
69/20 
 
116/25 
 
128/26 
 
66/11 
0.55 
 
0.68 
 
 
0.71 
 
0.53 
 
0.53 
 
0.44 
 
0.78 
NA 
 
NA 
 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
NA 
 
NA 
 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
Haase
31
  2011 NGAL 
 
Creatinine 
U 
P 
S 
RRT 
RRT 
RRT 
 1345/29 
977/30 
1345/29 
NA 
NA 
NA 
5 
6 
6 
99.5 
99 
99 
De Geus
57
  2011 NGAL 
 
 
 
 
 
eGFR 
 
 
NGAL 
 
 
 
 
 
 
 
P 
 
 
U 
 
 
 
 
 
P 
 
 
U 
 
 
S 
 
RIFLE R 
RIFLE I 
RIFLE F 
RIFLE R 
RIFLE I 
RIFLE F 
RIFLE R 
RIFLE I 
RIFLE F 
RIFLE I/F 
 
 
RIFLE I/F 
 
 
RIFLE I/F 
 
RIFLE crea 
 
 
 
 
 
 
 
 
RIFLE crea, 
eGFR > 60 
ml/min 
RIFLE crea, 
eGFR > 60 
ml/min 
RIFLE crea, 
eGFR > 60 
632/67 
632/48 
632/56 
632/67 
632/48 
632/56 
632/67 
632/48 
632/56 
632/104 
 
 
632/104 
 
 
632/104 
 
0.77 
0.80 
0.86 
0.80 
0.85 
0.88 
0.84 
0.87 
0.92 
0.75 
 
 
0.79 
 
 
0.65 
 
40 
NA 
NA 
35 
NA 
NA 
NA 
NA 
NA 
NA 
 
 
NA 
 
 
NA 
 
97 
NA 
NA 
95 
NA 
NA 
NA 
NA 
NA 
NA 
 
 
NA 
 
 
NA 
 
Chapter 3 
100 
 
NGAL 
 
 
Creatinine 
eGFR 
Clinical Model 
Clinical Model 
+NGAL 
Clinical Model 
Clinical 
Model+NGAL 
NGAL 
Creatinine 
eGFR 
 
P 
 
 
 
 
 
U 
 
 
U 
 
P 
S 
 
 
RIFLE I/F 
 
 
RIFLE F 
RIFLE F 
RIFLE F 
RIFLE F 
 
RRT 
RRT 
 
RRT 
ml/min 
RIFLE crea, 
eGFR > 60 
ml/min 
RIFLE crea 
RIFLE crea 
RIFLE crea 
RIFLE crea 
 
632/104 
 
 
632/56 
632/56 
632/56 
632/56 
 
632/28 
 
0.67 
 
 
0.95 
0.96 
0.94 
0.95 
 
0.89 
0.88 
 
0.90 
0.91 
 
NA 
 
 
NA 
NA 
NA 
NA 
 
NA 
NA 
 
NA 
NA 
 
NA 
 
 
NA 
NA 
NA 
NA 
 
NA 
NA 
 
NA 
NA 
Metzger
63
 2010 NGAL  U AKI AKIN crea 20/9 0.54 NA NA 
Siew
60
 2010 NGAL 
NGAL+IL-18 
U 
U 
AKI 24h 
 
AKIN crea 451/64 0.71 
0.71 
NA 
NA 
NA 
NA 
Portal
88
  2010 NGAL 
 
NGAL 
 
NGAL 
P 
U 
P 
U 
S 
AKI 
 
Severe AKI 
 
RRT 
 AKIN crea 
 
Severe AKI: ≥ 
stage 2 
80/30 
 
80/19 
0.79 
0.76 
0.87 
0.84 
0.84 
71 
NA 
61 
NA 
NA 
81 
NA 
91 
NA 
NA 
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Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Endre
62
 
 
 
2011 IL-18 
 
IL-18 
 
 
IL-18 
 
 
 
IL-18 
U 
 
U 
 
 
U 
 
U 
 
U 
 
U 
 
U 
AKIN48 
 
RIFLE 24hrs 
 
 
AKIN48 
 
 
 
 
 
 
 
RRT 
AKIN crea  
 
RIFLE crea, 
sustained  for 
≥24h  
-eGFR < 
60ml/min 
-eGFR 60-<90 
ml/min 
-eGFR 90-<120 
ml/min 
-eGFR > 120 
ml/min 
381 (no AKI on 
entry)/82 
381/27 
 
 
69/20 
 
116/25 
 
128/26 
 
66/11 
0.55 
 
0.72 
 
 
0.65 
 
0.48 
 
0.57 
 
0.49 
 
0.70 
NA 
 
NA 
 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
NA 
 
NA 
 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
Siew
60
 2010 IL-18 
IL-18 
 
 
IL-18 
IL-18 
IL-18 
IL-18 
U 
U 
 
 
U 
U 
U 
U 
AKI 24h 
AKI 24h 
 
 
AKI 48h 
AKIN I 
AKIN II+III 
RRT 
AKIN crea 
AKIN crea, 
eGFR ≥ 75 
ml/min 
AKIN crea 
AKIN crea 
AKIN crea 
451/64 
275/18 
 
 
451/86 
451/61 
451/25 
451/17 
0.62 
0.67 
 
 
0.60 
0.59 
0.62 
NA 
NA 
NA 
 
 
NA 
NA 
NA 
NA 
NA 
NA 
 
 
NA 
NA 
NA 
NA 
Metzger
63
 2010 IL-18  U AKI AKIN crea 20/9 0.57 NA NA 
Parikh
96
 2005 IL-18 U AKI Screa * 1.5 
within 6 days 
 
138/52  24h before 
↑Screa: 0.73 
48h before 
↑Screa: 0.65 
62 
 
NA 
78 
 
NA 
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Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Endre
62
 
 
 
2011 KIM-1 
 
KIM-1 
 
 
KIM-1 
 
 
 
 
 
 
 
KIM-1 
U 
 
U 
 
 
U 
 
U 
 
U 
 
U 
 
U 
AKIN48 
 
RIFLE 24hrs 
 
 
AKIN48 
 
 
 
 
 
 
 
RRT 
AKIN crea  
 
RIFLE crea, 
sustained  for 
≥24h  
-eGFR < 
60ml/min 
-eGFR 60-<90 
ml/min 
-eGFR 90-<120 
ml/min 
-eGFR > 120 
ml/min 
381 (no AKI on 
entry)/82 
381/27 
 
 
69/20 
 
116/25 
 
128/26 
 
66/11 
 
381/12 
0.55 
 
0.64 
 
 
0.66 
 
0.44 
 
0.65 
 
0.37 
 
0.63 
NA 
 
NA 
 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
NA 
 
NA 
 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
Metzger
63
 2010 KIM-1  U AKI AKIN crea 20/9 0.71 NA NA 
Liangos
39
 2007 KIM-1 
NAG+KIM-1 
Apache + KIM-1 
U 
U 
RRT +M 
 
 ↑Screa 0.5 
mg/ dl 
 
201/96 0.61 
0.71 
0.80 
NA 
NA 
NA 
NA 
NA 
NA 
Westhuyzen
97 
2003 α GST 
π GST 
GT 
AP 
NAG 
LDH 
Cr Cl 
U 
U 
U 
U 
U 
U 
 
ARF Screa * 1.5 
and ↑ ≥ 0.15 
mmol/l 
26/4 0.89 
0.93 
0.95 
0.86 
0.85 
0.69 
0.80 
60 
67 
67 
67 
50 
100 
50 
95 
100 
100 
90 
100 
96 
91 
Iglesias
98
 2003 IL-6 
TNF-α 
sTNFR-I 
sTNFR-II 
U 
U 
U 
U 
ARF Screa > 3,5 
mg/dl or RRT 
need 
If baseline 
Screa 1.8-
3mg/dl: 
Screa*2 or 
RRT need 
537/112 NA NA NA 
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Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Herget-
Rosenthal
84
 
2004 α GST 
GT 
NAG 
α1MG 
RBP 
β2MG 
LDH 
Liano score 
U 
U 
U 
U 
U 
U 
U 
U 
RRT patients with 
non oliguric 
ATN 
73/26 0.64 
0.64 
0.81 
0.86 
0.80 
0.51 
0.59 
0.83 
NA 
NA 
55 
72 
NA 
NA 
NA 
63 
NA 
NA 
88 
93 
NA 
NA 
NA 
85 
Liangos
39
 2007 NAG 
Screa 
enrollment 
Urine output 
Apache score 
Apache + NAG 
U 
 
RRT +M Inclusion of 
patients with 
ARF defined  
as 
BL  
≤1.9mg/dl: 
↑Screa 0.5 
mg/ dl 
BL 2-4.9mg/dl: 
↑Screa 1 
mg/dl 
BL ≥5mg/dl: 
↑Screa 1.5 
mg/dl 
201/96 0.71 
0.60 
 
0.65 
0.78 
0.79 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
Liu
99
  2007 Clinical model 
 
Clinical model 
+biomarkers 
PAI-1 and 
sTNFR-I (not 
included in 
model, because 
not predictive:  
IL-6,IL-8,IL-
10,TNF 
alfa,vWF,sTNRF
-II, 
IADM-1) 
 
 
P 
AKI 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screa * 1.5 
within 4 days 
 
 
 
 
 
 
 
 
 
 
 
 
876/209 0.66 
 
0.70 
 
 
 
 
 
 
 
 
 
 
 
NA 
 
NA 
 
 
 
 
 
 
 
 
 
 
 
NA 
 
NA 
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Clinical Model 
Clinical Model + 
biomarkers 
 
 
AKI 
 
 
Screa*1.5 day 
1 
 
 
0.72 
0.77 
 
 
NA 
NA 
 
 
NA 
NA 
Chawla 
Lakhmir
54
 
2007 IL-6 P AKI Screa*1.25 or 
↑0.3mg/dl  
during first 
week 
547/127 NA NA NA 
Hei
87
  2008 β2-MG 
NAG 
β2-MG 
Creatinine 
U 
U 
S 
S 
ARF ↑Screa to 132 
µmol/l or 
↑BUN to 18 
mmol/l 
60/10 NA 
NA 
NA 
NA 
15 
21 
24 
100 
79 
90 
87 
88 
Walshe
100
 2009 αGST 
GST 
U AKI AKIN both 38/19 Biomarker not 
a good 
predictor of 
AKI 
NA NA 
Portal
88
  2010 Creatinine 
eGFR 
APACHEII 
SOFA 
Creatinine 
eGFR 
APACHE II 
SOFA 
S 
 
 
 
P 
U 
S 
AKI 
 
 
 
Severe AKI 
 AKIN crea 
 
 
 
Severe AKI: ≥ 
stage 2 
80/30 
 
 
 
80/19 
 
 
 
0.72 
0.71 
0.74 
0.67 
0.81 
0.77 
0.87 
0.75 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
NA 
Metzger
63
 2010 MP ICU-T 
 
MP ICU-V 
U 
 
U 
AKI AKIN both  
2/16 
AKIN crea 
30/16 
 
20/9 
0.91 
 
0.84 
94 
 
80 
93 
 
90 
Chapter 3 
105 
Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Matsui
101
 2010 LFABP 
NAG 
Albumine 
PCX 
U 
U 
U 
U 
AKI AKIN crea 25/14 0.95 
0.63 
0.70 
0.42 
1 
70 
77 
80 
85 
53 
67 
50 
Endre
62
 
 
 
2011 GT 
 
AP 
 
GT 
 
AP 
 
GT 
 
 
 
 
 
AP 
 
 
 
 
 
 
 
 
 
GT 
AP 
U 
 
U 
 
U 
 
U 
 
U 
 
U 
 
 
 
U 
 
U 
 
U 
 
U 
 
U 
AKIN48 
 
 
 
RIFLE 24hrs 
 
 
 
AKIN48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RRT 
AKIN crea  
 
 
 
RIFLE crea, 
sustained  for 
≥24h within 7 
days 
-eGFR < 
60ml/min 
-eGFR 60-<90 
ml/min 
-eGFR 90-<120 
ml/min 
-eGFR > 120 
ml/min 
-eGFR < 
60ml/min 
-eGFR 60-<90 
ml/min 
-eGFR 90-<120 
ml/min 
-eGFR > 120 
ml/min 
381 (no AKI on 
entry)/82 
 
 
381/27 
 
 
 
69/20 
 
116/25 
 
128/26 
 
66/11 
 
69/20 
 
116/25 
 
128/26 
 
66/11 
 
381/12 
0.57 
 
0.56 
 
0.61 
 
0.64 
 
0.79 
 
0.48 
 
0.50 
 
0.56 
 
0.71 
 
0.48 
 
0.54 
 
0.55 
 
0.63 
0.72 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
NA 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
 
NA 
NA 
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Author PY Biomarker U/S/P Outcome AKI def / 
Outcome def 
Patients / 
Events 
AURoC PPV (%) NPV (%) 
Blasco
102
  2011 GT 
 
 
Creatinine 
GT + 
Creatinine 
U 
 
 
P 
AKI CrCl 25% 
lower than 
theoretical 
CrCl based on 
age and 
gender 
100/36 0.86  
 
 
0.85  
NA 
80 
 
 
70 
66 
88 
 
 
87 
100 
Abbreviations: Same as in tables 2-4. Not defined in tables 2-4: ATN: Acute tubular Necrosis, AKI sust: sustained AKI, M: Mortality, Rday-2/-1: 1 and 2 days before AKI diagnosed by serum 
creatinine, IDay -2/-1: 1 and 2 days before AKI diagnosed by serum creatinine, FDay -2/-1: 1 and 2 days before AKI diagnosed by serum creatinine, at adm: at admission, after adm: after admission, 
GT:  Glutamyl Transferase, AP: Alkaline Phosphatase, LDH: Lactate Dehydrogenase, RBP: Retinol Binding Protein, PAI-1: Plasminogen Activator Inhibitor-1, sTNFR-I and II: soluble Tumor 
Necrosis Factor receptor I and II, IADM-1: Intracellular Adhesion Molecule 1, TNFα: Tumor Necrosis Factor alpha, vWF; von Willebrand Factor, IL-10: Interleukin-10, MP ICU-T: Marker Pattern ICU 
Training set, MP ICU-V: Marker Pattern ICU Validation Set, pNGAL: plasma NGAL, PCX: podocalyxin, BL: baseline serum creatinine 
 
Table 6: Contrast induced nephropathy  
Author PY Biomarker U/S/P Outcome AKI def/Outcome def Patients/Events AURoC PPV 
(%) 
NPV 
(%) 
Nakamura103 2006 L-FABP U CIN ↑Screa >0.5mg/dl or *1.25 within 2-5 
days  
66/13 NA NA NA 
Bachorzewska-
Gajewska104 
2007 NGAL 
NGAL 
U 
S 
CIN Screa*1.25 within 48h  100/11 NA 
NA 
NA 
NA 
NA 
NA 
Ling64 2008 NGAL U CIN ↑Screa 0.3 mg/dl: or * 1.25 40/13 0.73 20 97 
Shaker105 2010 NGAL S CIN Screa*1.25 30/2 NA NA NA 
Bulent Gul65 2008 IL-18 U CIN ↑Screa >0.5mg/dl or *1.25 51/15 NA NA NA 
Ling64 2008 IL-18 U CIN ↑Screa 0.3 mg/dl or * 1.25  40/13 0.75 20 96 
Kato106 2008 Cystatin C 
Creatinine 
P 
S 
CIN ↑Screa 0,5 mg/dl or * 1.25  within 48h  87/18 0.93 
0.83 
63 
42 
98 
89 
Briguori107 2010 Cystatin C S CIN ↑ Screa 0.3 mg/dl 48h PP or RRT 410/34 0.92 39 100 
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Ishibashi108 2010 Cystatin C 
Creatinine 
S 
S 
CIN ↑Screa 0,5 mg/dl or * 1.25 
within 48h 
100/18 > 0.50 
> 0.50 
68 
NA 
96 
NA 
Bachorzewska-
Gajewska104 
2007 Cystatin C S CIN Screa*1.25 within 48h  100/11 NA NA NA 
Shaker105 2010 Cystatin C S CIN Screa*1.25 30/2 NA NA NA 
 
Abbreviations: Same as in tables 2-5.  Not defined in tables 2-5: PP= Post Procedure 
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4.1 Abstract 
Background: The role of neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic 
marker for Acute Kidney Injury (AKI) in sepsis is still debated. We hypothesized that in sepsis, 
the performance of serum(s) and urinary(u) NGAL can be negatively impacted by severity of 
illness, and that both uNGAL and sNGAL can be increased, even in the absence of AKI. 
Materials and methods: Hundred-seven patients with sepsis were included. Urinary NGAL 
and sNGAL were measured at admission (T0) and 4 hours (T4) and 24 hours later (T24). 
Transient and intrinsic AKI were respectively defined as AKI according to RIFLE, that did or 
did not recover to "no AKI" in the following 5 days. Patients were classified according to 
tertiles of CRP increase (CRP≤20.10mg/dl, CRP 20.11-30.7mg/dl and CRP ≥30.71mg/dl). The 
relationship between sNGAL and uNGAL was assessed by linear regression. 
Results: Fifty-seven patients developed transient and 22 intrinsic AKI. Prevalence of transient 
and intrinsic AKI was higher in patients with vs without septic shock (OR 3.3, p=0.007). 
uNGAL was associated to sNGAL, and this with parallel slopes but different intercepts for AKI 
(Y= 0.87*X+314.3,R²= 0.31) and no AKI (Y= 0.87*X+20.1,R²=0.38). At T4, median uNGAL and 
sNGAL levels were higher in septic patients with vs without shock but this independent of 
AKI (545ng/ml vs 196ng/ml for uNGAL and 474ng/ml vs 287ng/ml for sNGAL (both p=0.003). 
Urinary and sNGAL levels increased with tertiles of CRP increase. Neither uNGAL nor sNGAL 
had discriminating value for differentiating AKI from no-AKI within these categories. 
Conclusion: Serum and uNGAL levels are influenced by severity of illness, independent of AKI. 
There is a strong correlation between sNGAL and uNGAL levels in sepsis. Increased levels of 
uNGAL do not automatically imply tubular damage, but can also be due to overspill from the 
systemic circulation. 
 
4.2 Introduction 
Septic Acute Kidney Injury (AKI) is associated with worse outcome compared to non-septic 
AKI and is regarded as a distinct clinical entity.1 The unacceptably high mortality rates 
associated with septic AKI are partly explained by an incomplete understanding of the 
pathophysiology and a delay in diagnosis.2-6 The adagio that renal vasoconstriction is the key 
pathophysiological pathway in septic AKI has recently been questioned while immunological 
mechanisms and oxidative stress inducing microcirculatory changes and tubular damage 
have gained interest.5;7 Early diagnosis of septic or non-septic AKI remains cumbersome 
because it relies on imperfect parameters such as serum creatinine while introduction of 
new serum and urinary biomarkers could hypothetically allow earlier diagnosis and better 
prognostication.8-10 At present, NGAL (neutrophil-gelatinase-associated-lipocalin) has been 
the most frequently investigated biomarker for early diagnosis of AKI.11  
The shift in paradigm towards a more prominent role for immunological mechanisms and 
microvascular changes rather than renal hypoperfusion and renal vasoconstriction in the 
pathophysiology of septic AKI has created controversy about the existence of so called 
‘transient acute kidney injury’.12  The latter is considered to be a physiological response to a 
decrease in glomerular capillary perfusion without structural tubular injury. This controversy 
has been amplified by the fact that some studies found increased urinary NGAL levels in 
patients classified as having transient AKI, suggesting presence of subtle tubular structural 
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injury.13;14 In addition, studies where a rise in biomarker level (either in serum or urine) 
without a rise in serum creatinine or a decrease in urinary output was found, resulted in 
speculation on the existence of a new entity called subclinical AKI.12;15 However, serum NGAL 
levels can be increased in many other conditions beside acute kidney injury, such as 
inflammation.16 Moreover, serum NGAL is filtered at the glomerular level so that its 
presence in urine can reflect either glomerular overspill and/or local tubular production 
induced by structural injury.17-19 
The present study aims to characterize the origin of the raised serum and urine levels of 
NGAL in septic patients. We hypothesized that, as in sepsis patients the prevalence of AKI is 
related to severity of sepsis, which in turn is associated with an increase in urinary and 
serum NGAL levels, a correlation between both urinary and serum NGAL, and severity of 
illness could exist, independent of the presence of AKI.  
 
4.3 Material and methods 
Study cohort: 
One hundred and seven consecutive patients with sepsis, severe sepsis or septic shock, 
admitted to the Ghent University Hospital between 12/01/2010 and 05/09/2010, were 
prospectively enrolled. Sepsis, severe sepsis or septic shock were defined according to the 
American College of Chest Physicians/Society of Critical Care Medicine Consensus 
Conference guidelines.20 Briefly, sepsis was defined when two or more of the following 
conditions were present as a result of infection: 1) temperature > 38° or < 36°, 2) heart 
rate > 90 beats/min, 3) respiratory rate > 20 breaths/min or PaCO2 < 32 mmHg (<4,3 kPa) or 
4) white blood cell count > 12000 cells/mm3  or <  4000 cells/mm3 , or > 10% immature (band) 
forms. Severe sepsis was defined as sepsis associated with organ dysfunction, hypoperfusion 
or hypotension. Sepsis with shock was defined as sepsis with hypotension despite adequate 
fluid resuscitation or vasopressor need. Since only 4 patients were not classified as having 
either severe sepsis or septic shock, we combined sepsis and severe sepsis in a new 
cumulative category "sepsis without shock". Exclusion criteria were 1) a history of liver 
and/or kidney transplantation, 2) ICU stay less than 24 hours, 3) patients treated with 
chronic hemodialysis and 4) age< 17 years.  
Fluid management and decision making for need of RRT were done by intensivists, who were 
blinded to the study, and according to protocols applied in the study hospital. The study was 
approved by the ethical committee of the Ghent University Hospital. Written informed 
consent was obtained from the patient or their next of kin. Research was adhered to the 
tenets of the Declaration of Helsinki. 
Study definitions: 
We defined AKI based on the worst of either serum creatinine or urinary output criteria 
according to RIFLE. 21 The urinary output criterion was based on 6 hour blocks, as described 
by Macedo et al. 22 Baseline serum creatinine was based on the most recent value before 
admission or was estimated with the MDRD equation if the latter was not available. 21 
Transient acute kidney injury was defined as presence of AKI according to RIFLE, occurring in 
the first three days after admission and returning to no AKI within 5 days. Intrinsic AKI was 
defined as presence of AKI according to RIFLE in the first three days of admission that did not 
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improve to no AKI in the following days. Patients who left ICU before 5 days after admission 
were followed-up at the department where they were transferred to. 
Sample collection: 
Urine and blood samples were collected at the moment of admission (T0), four hours later 
(T4) and 24 hours later (T24). Blood samples were centrifuged at 1500g for 10 minutes 
within 20 minutes after collection, and serum was aliquoted and  stored at -80°C for later 
batch analysis. Urine was collected in a sterile way and centrifuged at 500g for 10 minutes, 
urine samples were aliquoted and stored  at -80°C for later batch analysis. 
Serum and Urinary Neutrophil-Gelatinase-Associated-Lipocalin (NGAL) were measured using 
an ELISA kit (BioportoR Diagnostics Denmark).  
Data collection: 
After informed consent, demographics and medical history were obtained. Laboratory and 
cilinical data were gathered. APACHE II scores were calculated over the first 24 hours of 
admission. 
The highest CRP value in the first 5 days after admission was retained and patients were 
classified according to tertiles of CRP increase: CRP≤20.10mg/dl, CRP 20.11-30.70mg/dl and 
CRP ≥30.71mg/dl. 
Statistical Analysis: 
Results are reported as medians and interquartile ranges  (IQR) for continuous variables, 
unless otherwise specified. Discrete variables are reported as numbers and/or percentages. 
All statistical analyses were performed using SPSS® 19. All consecutive patients fulfilling the 
inclusion criteria, were included, irrespective of their course or duration of stay at ICU. 
Demographic characteristics of the study cohort were compared using using Mann-Whitney 
U test (two groups) or Kruskal Wallis (>two groups) in case of continuous variables that are 
not normally distributed. In case of continuous variables with a normal distribution, 
Student’s t test (two groups) or one way ANOVA (>two groups) were used to compare 
means.  
Patients were classified according to sepsis status (either sepsis without shock or sepsis with 
shock) and AKI status (no AKI vs transient AKI vs intrinsic AKI). The Kruskall Wallis test was 
used to compare median uNGAL and sNGAL levels between groups at the three different 
time points (T0,T4 and T24). For each sepsis category separately (sepsis without or with 
sohck), uNGAL and sNGAL levels were compared between no-AKI, transient AKI and intrinsic 
AKI at the different time point, using the Kruskall Wallis test. Dichotomous variables were 
compared between groups using Chi Square analysis. 
Regression analysis was used to assess association between serum and urinary NGAL. 
 
4.4 Results 
Demographics and clinical background of the 107 included patients are presented in tables 1 
and 2 as partially published elsewhere.23 (Table 1 and Table 2). Four patients had sepsis 
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(3.7%), 38 had severe sepsis (35.5%) and 65 septic shock (60.7%). Twenty-eight (26.2%) 
patients were classified as having no-AKI versus 57(53.3%) and 22(20.6%) as having transient 
and intrinsic AKI, respectively. Median APACHE II score was 21 in patients without shock and 
23 in those with shock (p=0.22) and increased from no-AKI over transient AKI to intrinsic AKI 
(p=0.08). 
More sepsis patients with shock vs without shock had transient or intrinsic AKI (35/65 vs 
22/42 and 19/65 vs 3/42, respectively, p=0.007). There was also an increasing positive fluid 
balance, need for ventilation, length of ICU stay and mortality from no AKI over transient AKI 
to intrinsic AKI and in patients with versus those without shock. Fourteen patients needed 
RRT. (Table 1 and Table 2) Median urinary and serum NGAL levels were higher in sepsis 
patients with vs those without shock. (Figure 1 A, Figure 1B, Figure 1 C and Table 3)  
Table 1: Clinical and demographic characteristics of the study cohort comparing patients with 
no AKI vs transient AKI vs intrinsic AKI. 
 no-AKI 
(n=28) 
transient AKI 
(n=57) 
intrinsic AKI 
(n=22) 
p value 
Gender male(%) 52 54 59 0.93 
Age(years,mean/sd) 55.4(17.3) 62.6(13.2) 63.1(14.9) 0.08 
CKD on admission (eGFR according 
to MDRD <60ml/min/1,73m2) (%) 
11 9 9 1 
APACHE II score on the first day of 
admission 
21(10) 22(8) 24.5(9) 0.08 
Fluid balance  first 24 hours 
(mean/sd) 
2.2(1.8) 3.1(1.9) 5.4(2.7) <0.001 
Use of diuretics on the first day of 
admission (%) 
7 14 23 0.29 
RRT need during ICU stay (%) 0 2 59 <0.001 
Vasopressor use (%) 32 61 86 <0.001 
Total dose of Noradrenaline first 24h 
in mg/kg (mean/sd) 
0.08(0.16) 0.13(0.17) 0.29(0.32) 0.001 
Maximum dose of Noradrenaline 
during first 24h in µg/kg/min 
(mean/sd) 
0.12(0.23) 0.25(0.31) 0.54(0.55) 0.002 
Need for ventilation during ICU stay 
(%) 
39 51 86 <0.001 
LOS in the ICU (days) 5(6) 5(10) 38(32) 0.014 
ICU mortality (%) 21 16 54 0.002 
Mortality at 90 days(%) 29 25 59 0.012 
AKI: Acute Kidney Injury, CKD: Chronic Kidney Disease, eGFR according to MDRD equation: estimated 
glomerular filtration rate according to modification of diet in renal disease equation, APACHE II: Acute 
Physiology and Health Care Evaluation II, RRT: Renal Replacement Therapy, ICU: Intensive Care Unit, LOS: 
Length of Stay. 
Chapter 4 
121 
Table 2: Clinical and demographic characteristics of the study cohort comparing sepsis 
patients without vs with shock. 
 sepsis without shock 
(n=42) 
sepsis with shock 
(n=65) 
p value 
Gender male(%) 50 60 0.31 
Age(years,mean/sd) 57.(15.6) 62.9(14.3) 0.07 
CKD on admission (eGFR according to 
MDRD <60ml/min/1,73m2) (%) 
17 5 0.04 
APACHE II score on the first day of 
admission 
21(9) 23(9) 0.22 
AKI (transient or intrinsic) (%) 25(60) 54(83) 0.007 
Fluid balance first 24 hours (mean/sd) 2.06(2.21) 3.8(2.58) <0.001 
Use of diuretics on the first day of 
admission (%) 
10 17 0.28 
RRT need during ICU stay (%) 0 22 0.001 
Total dose of Noradrenaline first 24h 
in µg/kg/min (mean/sd) 
N/A 0.17(0.16) N/A 
Maximum dose of Noradrenaline 
during first 24h in µg/kg/min 
(mean/sd) 
N/A 0.44(0.41) N/A 
Need for ventilation during ICU stay 
(%) 
39 74 <0.001 
LOS in the ICU (days) 4(6) 7(16) 0.03 
ICU mortality (%) 14 32 0.04 
Mortality at 90 days(%) 19 42 0.02 
AKI: Acute Kidney Injury, CKD: Chronic Kidney Disease, eGFR according to MDRD equation: estimated 
glomerular filtration rate according to modification of diet in renal disease equation, APACHE II: Acute 
Physiology and Health Care Evaluation II, RRT: Renal Replacement Therapy, N/A: Not Applicable, ICU: Intensive 
Care Unit, LOS: Length of Stay. 
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Figure 1: Urinary and serum NGAL in sepsis without vs with shock  
 
Figure legends: A: Urinary NGAL(ng/ml) at time point T0 is higher in sepsis with vs without shock (p=0.003). 
There is a trend for higher serum NGAL levels (ng/ml) in sepsis with vs without shock (p=0.083). B: Serum and 
urinary NGAL (ng/ml) at time point T4  are  higher in sepsis with shock vs without shock (both p=0.003). C: 
Serum NGAL(ng/ml) at time point T24 is higher in sepsis with vs without shock (p=0.011). There is a trend for 
higher urinary NGAL levels (ng/ml) in sepsis with vs without shock (p=0.082). (°=outliers; *=extreme outliers (> 
three times the height of the boxes)) 
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Table 3: Urinary NGAL and serum NGAL (ng/ml) in no-AKI vs transient and intrinsic AKI.  
 Sepsis without shock  Sepsis with shock   
 no AKI      
(n=17) 
transient 
AKI 
(n=22) 
Intrinsic 
AKI 
(n=3) 
p 
value 
no AKI 
(n=11) 
 
transient 
AKI 
(n=35) 
intrinsic 
AKI (n=19) 
p 
value 
overall 
p 
value 
uNGAL T0 125(262) 262(350) 1276 0.27* 178(457) 649(1164) 1775(2108) 0.08* 0.001# 
uNGAL T4 116(256) 234(310) 1044 0.27* 269(511) 523(1384) 1802(2046) 0.03* 0.009# 
uNGAL T24 122(218) 239(383) 1245 0.27* 137(612) 405(1523) 2372(2308) 0.11* 0.084# 
sNGAL T0 220(269) 288(477) 235 0.44* 290(221) 493(579) 962(894) 0.003* 0.03# 
sNGAL T4 218(193) 336(338) 284 0.17* 267(192) 469(604) 975(940) 0.011* 0.002# 
sNGAL T24 203(189) 295(364) 184 0.44* 283(188) 475(435) 1052(670) 0.001* 0.001# 
* p values refer to the difference between no AKI, transient AKI and intrinsic AKI, separately for patients with vs 
without shock. 
#
 p values refer to the difference between no AKI, transient AKI and intrinsic AKI either with or without shock at 
each time point. 
All no-AKI patients had serum NGAL levels above the generally accepted cut-off of 150 ng/ml 
at all time points. All sepsis patients with shock had urinary NGAL levels above 150 ng/ml at 
admission and four hours later, even if they did not have AKI. Urinary and serum NGAL levels 
were higher in intrinsic vs transient vs no AKI patients, but there was substantial overlap 
limiting discriminative value. (Table 3)  When classified according to sepsis without vs with 
shock, discriminative value of NGAL for AKI further decreased. (Figure 2 A, Figure 2 B and 
Figure 2 C) 
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Figure 2: Urinary NGAL in no-AKI, transient AKI and intrinsic AKI, stratified according to sepsis 
severity. 
 
 
Figure legend: (A) At time point T0, urinary NGAL(ng/ml) is not significantly different between no-AKI, transient 
AKI and intrinsic AKI in sepsis without shock (p=0.27) and sepsis with shock (p=0.08). (B) At time point T4, 
urinary NGAL(ng/ml) is not significantly different between no-AKI, transient AKI and intrinsic AKI in sepsis 
without shock (p=0.27).(C) At time point T24, urinary NGAL(ng/ml) is not significantly different between no-AKI, 
transient AKI and intrinsic AKI in sepsis without shock (p=0.27) and sepsis with shock (p=0.11). 
(°=outliers; *=extreme outliers (> three times the height of the boxes)) 
Urinary and serum NGAL levels increased with tertiles of CRP (175ng/ml vs 229ng/ml vs 
563ng/ml, for uNGAL and 245ng/ml vs 296ng/ml vs 512ng/ml for sNGAL (p=0.006 and 
p=0.04, respectively). (figure 3 A and Figure 3 B) Neither uNGAL or sNGAL had a 
discriminative  value for differentiating AKI (transient or intrinsic) from no AKI. (Figure 3 C 
and Figure 3 D) 
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Figure 3: Influence of inflammation on serum and urinary NGAL 
 
Figure legend: (A): Urinary NGAL(ng/ml) increases together with increasing levels of CRP. (B): Serum 
NGAL(ng/ml) increases together with increasing levels of CRP. (C): Urinary NGAL(ng/ml) is not significantly 
different between AKI (transient or intrinsic) and no AKI, when stratified according to tertiles of CRP increase. (D) 
Serum NGAL(ng/ml) is not significantly different between AKI (transient or intrinsic) and no AKI in the two lower 
tertiles of CRP increase. (°=outliers; *=extreme outliers (> three times the height of the boxes)) 
We found a strong correlation between sNGAL and uNGAL, both in patients without and 
with AKI (R²=0.38 for no AKI and R²= 0.31 for AKI), but with different relationships in no AKI 
(Y= 0.87*X+20.1) vs AKI (Y= 0.87*X+314.3), respectively (p< 0.001). The slopes of the 
regression lines followed a parallel course. (Figure 4) 
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Figure 4: Linear regression between serum NGAL and urinary NGAL in no AKI and AKI  
 
 
Legend figure 4: For no AKI: y=0.87*x + 20.1 and for AKI: y=0.87*x+314.3. R
2
 for AKI=0.31 and R2 for no-
AKI=0.38 (p<0.001). 
Analyses of the correlation between sNGAL and uNGAL levels at the time points 4 and 24 
hours demonstrated comparable findings. (data not shown) 
There was also a correlation between the APACHE II score and uNGAL (p=0.002, p<0.001 and 
p=0.003 at T0, T4 and T24) and between the APACHE II score and sNGAL (p=0.007, p=0.003 
and p=0.07 at T0,T4 and T24.  Median urinary NGAL levels increased with increasing tertiles 
of  APACHE II (179ng/ml vs 355ng/ml vs 405ng/ml for APACHE II<20, 20-25 and >25 
respectively). There was an increasing trend in serum NGAL levels over the first two tertiles 
(Figure 5). 
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Figure 5: Influence of severity of illness on serum and urinary NGAL 
 
 
Legend Figure 5: (A): Urinary NGAL(ng/ml) increases together with tertiles of APACHE II score increase. (B): 
There is a trend for increasing serum NGAL(ng/ml) together with APACHE II score increase,  in the two lower 
tertiles of APACHE II score increase. (C): Urinary NGAL(ng/ml) is not significantly different between AKI 
(transient or intrinsic) and no AKI, in the two lower tertiles of APACHE II score  increase. 
 
4.5 Discussion 
In this cohort of septic ICU patients, we confirmed that the risk for AKI increased with 
severity of sepsis. Serum and urinary levels of NGAL increased with severity of illness and 
inflammation, as assessed by APACHE II and CRP, and this irrespective of presence of AKI. In 
addition, there was a strong correlation between urinary and serum levels of NGAL, again 
irrespective of presence of AKI. Although there was a significant difference in uNGAL levels 
between no-AKI, transient AKI and intrinsic AKI, this difference did not remain when patients 
were stratified according to severity of sepsis (sepsis with or without shock) or to tertiles of 
CRP increase or APACHE II score, except at time point T4 in patients with shock.  
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As such, it remains unclear whether in sepsis patients, increased urinary NGAL is a marker of 
structural tubular injury, the result of overspill from the systemic circulation or just a marker 
of severity of illness.  
NGAL is a 25 kD molecule which is filtered into the primary urine and almost completely 
reabsorbed by the tubular epithelium via the megalin receptor under normal circumstances 
24. One of the concerns of using NGAL as a biomarker for AKI is that  even in the absence of 
AKI, NGAL levels can increase during inflammation.16;25-29  We demonstrated  that in patients 
with sepsis, serum NGAL levels increase in parallel with the severity of sepsis, severity of 
illness and severity of inflammation, irrespective of the presence of AKI. Because the 
prevalence of AKI is associated with severity of illness, a clear judgement on whether NGAL  
reflects severity of illness and/or inflammation rather than presence of AKI, is difficult.  
High levels of serum NGAL can overwhelm the reabsorptive capacity of the proximal tubule 
so that urinary NGAL levels might increase, even in the absence of structural tubular injury. 
We found a strong correlation between serum and urinary NGAL levels, both in patients 
without and with AKI. The  value of urinary NGAL for differentiating between AKI and no AKI 
was low due to  overlap between the two groups, and this irrespective of severity of illness, 
sepsis or inflammation.  
Thesefindings underline that the concept of "subclinical AKI" should be used with caution, 
however,they do not contradict the existence of this conceptin certain patients. Indeed, 
urinary NGAL was well correlated with serum NGAL (R² = 0.37), but the regression line went 
through the origin for no AKI patients, whereas it did not in AKI patients. This suggests that 
in AKI, there is some degree of either local tubular production, or reduced reabsorption, 
both of which may reflect tubular injury.  
Although the question whether a patient has true "subclinical tubular injury" or just overspill 
from the circulation due to severity of illness and its associated risk for AKI might seem 
purely semantic, it has some consequences for clinical practice. The current evolution 
towards an increasing use of NGAL for diagnostic purposes because of its proposed 
discriminating role in differentiating AKI from no AKI should, based on the current data, be 
considered with care at least in patients with sepsis. In addition, if patients classified as 
having "subclinical AKI", based on NGAL positivity only, would be included in an 
interventional trial, interventions that only focus on preventing or healing tubular injury will 
appear to be less useful because in a substantial part of patients, the increased urinary NGAL 
will not be the result of tubular damage but rather of overspill from the circulation as a 
consequence of high circulating levels induced by inflammation.  
A limitation of this observational study is that it describes a relatively small cohort of septic 
patients. However, to our knowledge, this is the first study providing information on 
prospectively collected serum and urinary NGAL levels at different time points during the 
first 24 hours after admission in septic patients.  
 
4.6 Conclusion 
In patients with sepsis, levels of urinary and serum NGAL and the prevalence and severity of 
AKI are strongly associated with severity of illness and inflammation as expressed by APACHE 
II and CRP. There is a strong correlation in sepsis patients between serum and urinary levels 
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of NGAL, and this irrespective of presence of AKI. Therefore, presence of NGAL in the urine 
does not automatically imply tubular injury in sepsis patients. 
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5.1 Abstract 
Introduction: The pathophysiology of acute kidney injury (AKI) in sepsis is ill defined. We 
investigated parameters associated with low glomerular filtration, and their predictive value 
to discriminate transient from intrinsic septic AKI.  
Methods: In 107 sepsis patients, AKI was defined by the RIFLE urinary output or serum 
creatinine criterion, or both. Transient AKI (TAKI) vs intrinsic AKI was defined as RIFLE R, I or 
F on the first day evolving to no AKI or not, respectively, over the following five days. 
Fractional excretion of sodium (FENa), urea (FEUrea) and NGAL (FENGAL) at admission (d0t0), 
4 (d0t4) and 24 hours (d1) were determined. 
Results: Including vs not including the urinary output criterion of RIFLE increased AKI from 43 
to 64,5%. Median uNGAL levels and FENGAL were lower in no AKI versus transient AKI when 
AKI was defined based on creatinine (p=0.002 and p=0.04 respectively) but not when based 
on urinary output (p=0.9 and p=0.49 respectively). FENa<1% and FEUrea <35% was present 
in 77.3 and 63.2 of patients. Urinary NGAL was higher (p<0.001) in those with high vs low 
fractional sodium excretion, but this only in patients with transient or intrinsic AKI (p<0.001 
in subgroups), and not in patients without AKI. The negative predictive value for either 
intrinsic AKI or not restoring diuresis in patients with FENa>0.36% and FEUrea>31.5% was 
92% and 94.5% respectively. 
Conclusions: A low FENa and FEUrea is highly prevalent in the first hours of sepsis. In sepsis, 
oliguria is an earlier sign of impending AKI than increase in serum creatinine. A combination 
of a high FENa and a low FEUrea is associated with intrinsic AKI, whereas a combined high 
FENa and FEUrea are strongly predictive of transient AKI. 
 
5.2 Introduction 
There is controversy about the role of low glomerular filtration pressure in the pathogenesis 
of septic Acute Kidney Injury (AKI)1-3. Tubular damage due to inflammatory cascades is also 
forwarded as a potential underlying pathophysiological mechanism 4-7. Recently, it was 
demonstrated that transient azotemia can be more than a physiologic response to low 
glomerular filtration pressure, as it can also be associated with transient low grade tubular 
injury, as defined by presence of Neutrophil Gelatinase-Associated Lipocalin (NGAL)8 or Liver 
Fatty Acid Binding Protein (LFABP)9. Whereas these findings enhance our understanding of 
the pathophysiology of AKI, they are not always very helpful in clinical practice, where the 
most important dilemma is to differentiate those cases where restoration of glomerular 
filtration pressure can potentially still reverse AKI from those where it will only lead to fluid 
overload. This is important, as there is increasing evidence that links blind fluid loading to 
higher mortality.10;11 
Although most definitions of AKI are based on both an increase in serum creatinine and a 
decrease in urinary output, the latter criterion has been neglected in many studies12-15. 
Recent work has demonstrated that urinary output is important, as it is associated with 
morbidity and mortality16. A low urinary output can be used as an early warning parameter 
of developing AKI, maybe even before tubular damage arises.  
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We hypothesized that the combined interpretation of a reduced urinary output, and a low 
fractional excretion of sodium and urea, and especially the evolution of these parameters, is 
an early indicator of incipient AKI in sepsis patients, at a moment that it is still reversible if 
glomerular filtration pressure is restored. We also hypothesized that a high fractional 
sodium excretion can be an indicator of active sodium secretion by damaged tubular cells 
and reduced proximal tubular reabsorption, whereby extent of tubular damage was 
assessed by (fractional excretion of) urinary neutrophil gelatinase associated lipocalin 
(NGAL). 
 
5.3 Materials and methods 
Ethics statement: The study was approved by the ethical committee of the Ghent University 
Hospital. Written informed consent was obtained from the patients or their next of kin. 
107 consecutive patients with sepsis admitted to the intensive care unit (ICU) of a tertiary 
university hospital were included between 12/01/2010 and 5/09/2010. Sepsis, severe sepsis 
and septic shock were defined according to the American College of Chest Physicians/Society 
of Critical Care Medicine Consensus Conference guidelines17. Exclusion criteria were 1) a 
history of liver and/or kidney transplantation, 2) ICU stay less than 24 hours, 3) patients 
treated with chronic hemodialysis and 4) age< 17 years.  
Acute Kidney Injury (AKI) was defined according to RIFLE classification (Risk, Injury, Failure, 
Loss of kidney function, and End stage renal disease)13. Baseline creatinine was based on the 
most recent value before admission or was calculated if the latter was not available13. The 
urinary output criterion was based on 6 hour blocks, as described by Macedo et al16. As we 
wanted to assess the impact of the creatinine and the urine output criterion separately, we 
defined AKI based on both criteria (AKIboth) together, versus on the urinary output criterion 
only (AKIuo), or the serum creatinine criterion alone (AKIc). Transient AKI (TAKI) was defined 
as RIFLE R, I or F on day 1 that improved to "no AKI" in the following five days, whereas 
"intrinsic AKI" was defined as patients with RIFLE R, I or F who did not evolve to no AKI in the 
following five days.  
Urine and blood samples were collected at the moment of admission (time point d0t0), and 
also four hours later (time point d0t4) and 24 hours later (time point d1), to assess the 
evolution of the parameters. Blood samples were centrifuged within 20 minutes after 
collection at 1500g for 10 minutes, and serum was aliquoted and  stored at -80°C for later 
batch analysis. Urine was collected in a sterile way and centrifuged at 500g for 10 minutes; 
urine samples were aliquoted and stored  at -80°C for later batch analysis. 
Serum and Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) were measured using 
an ELISA kit (BioportoR Diagnostics Denmark).  
Fractional excretion of sodium, urea and NGAL was calculated according to the formula 
(UxxScrea)/(UcreaxSx)x100 with x=either sodium, urea or NGAL. Patients were classified 
according to FEUrea and FENa quartiles. We also defined FENA and FEUrea dichotomously as 
"high" (two upper quartiles) and "low" (two lower quartiles). 
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Statistical analysis 
Results are reported as medians and interquartile ranges  (IQR) for continuous variables, 
unless otherwise specified. Discrete variables are reported as numbers and/or percentages. 
All statistical analyses were performed using SPSS® 19. All consecutive patients were 
included, irrespective of their course or duration of stay at ICU. 
Continuous variables were compared between groups using Mann-Whitney U test (two 
groups) or Kruskal Wallis (>2 groups), as appropriate, using the non-parametric section of 
SPSS®19. When the overall p-value was <0.05, post-hoc analysis between different pairs was 
performed using Mann-Whitney U tests, taking into account correction for multiple testing.  
Dichotomous variables in groups were compared using Chi Square analysis. Positive and 
negative predictive values were calculated for high and low fractional excretion of sodium 
and urea, whereby "high" and "low" where based on the median value. We performed 
Receiver Operating Characteristics (RoC) curves to assess the performance of fractional 
excretion of sodium and urea to predict transient or intrinsic AKI. 
Performance of the combined interpretation of fractional excretion of sodium and urea was 
evaluated by calculating positive and negative predictive power of the different 
combinations for restoration of diuresis and for development of intrinsic AKI.  
 
5.4 Results 
107 consecutive patients were included. Demographic and clinical data are shown separately 
for AKI vs no AKI patients as defined by RIFLE on the first day of admission in table 1.  
 
Table 1: Clinical and demographic characteristics of the study cohort comparing patients 
without vs with AKI as defined by RIFLE on the first day of admission. 
 No AKI (n=38) AKI (n=69) p value 
Gender male(%) 57.9 55.1 0.78 
Age(years,mean/sd) 57.5(16.0) 62.7(14.2) 0.09 
CKD on admission 
(MDRD 
<60ml/min/1,73m2) 
(%) 
10.5 8.7 0.76 
APACHE II score on the 
first day of admission 
21(10) 23(9) 0.19 
Positive fluid balance 
first 24 hours 
(mean/sd) 
2.5(2.1) 4.0(2.3) 0.002 
Use of diuretics on the 
first day of admission 
(%) 
18.4 17.4 0.89 
RRT need during ICU 
stay (%) 
5.3 17.4 0.08 
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Vasopressor use (%)        42.1 68.1 0.009 
 No AKI (n=38) AKI (n=69) p value 
Total dose of 
Noradrenaline first 24h 
in µg/kg/min 
0.15(0.25) 0.13(0.20) 0.83 
Maximum dose of 
Noradrenaline during 
first 24h in µg/kg/min 
0.32(0.44) 0.34(0.51) 0.83 
Need for ventilation 
during ICU stay (%) 
47.4 59.4 0.23 
LOS (days) 5(9) 6(12) 0.82 
ICU mortality (%) 21.1 27.5 0.46 
Mortality at 90 days(%) 26.3 36.2 0.30 
 
Demographic and clinical data for no AKI vs transient AKI vs intrinsic AKI are shown in table 2.  
Table 2: Clinical and demographic characteristics of the study cohort comparing patients with 
no AKI vs transient AKI vs intrinsic AKI. 
 No AKI (n=28) Transient AKI (n=57) Intrinsic AKI(n=22) p value 
Gender male(%) 51.7 54.4 59.1 0.93 
Age(years,mean/sd) 55.4(17.3) 62.6(13.3) 63.1(14.9) 0.08 
CKD on admission 
(MDRD 
<60ml/min/1,73m2) 
(%) 
10.7 8.8 9.1 0.96 
APACHE II score on 
the first day of 
admission 
21(10) 22(8) 24.5(9) 0.08 
Positive fluid balance 
first 24 hours 
(mean/sd) 
2.2(1.8) 3.3(1.9) 5.4(2.7) <0.001 
Use of diuretics on 
the first day of 
admission (%) 
7.1 19.3 27.3 0.16 
RRT need during ICU 
stay (%) 
0 1.8 59.1 <0.001 
Vasopressor use (%)        32.1 61.4 86.4 <0.001 
Total dose of 
Noradrenaline first 
24h in µg/kg/min 
0.13(0.22) 0.12(0.19) 0.16(0.28) 0.65 
Maximum dose of 
Noradrenaline during 
first 24h in 
µg/kg/min 
0.28(0.34) 0.32(0.47) 0.49(0.68) 0.66 
Need for ventilation 
during ICU stay (%) 
39.3 50.9 86.4 0.003 
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LOS (days) 5(6) 5(10) 38(32) 0.014 
ICU mortality (%) 21.4 15.8 54.2 0.002 
Mortality at 90 
days(%) 
28.6 24.6 59.1 0.012 
 
Based on both RIFLE criteria combined (AKIboth), 35.5% of patients had no AKI, and 20.6%, 
31.8% and 12.1% had RIFLE R, I and F. When AKI was defined based on urinary output alone 
(AKIuo), 58.9% patients were classified as having no-AKI, and 10.3%, 27.1% and 3.7% as 
RIFLE-R, I or F respectively. When defining AKI based on the creatinine criterion alone (AKIc), 
57%  had no AKI, and 17.8%, 15% and 10.3% were classified as RIFLE R, I and F (figure1). So, 
omitting the urinary output criterion leads to underdiagnosis of AKI. 
Figure 1: Distribution of RIFLE class based on a single or both criteria.  
 
Legend Figure 1: Based on the urinary and the creatinine criteria together (AKIboth), 35.5% of patients had no 
AKI, versus 20.6%, 31.8% and 12.1% with RIFLE R, I and F. Based on the urinary output criterion only (AKIuo), 
58.9% patients were classified as having no-AKI, versus 10.3%, 27.1% and 3.7% as RIFLE-R, I or F respectively. 
Based on the creatinine criterion only (AKIc), 57%  had no AKI, versus 17.8%, 15% and 10.3% classified as RIFLE R, 
I and F (p 0.03). 
Upper cut-off values for the FENa quartiles based on the values of d0t0 were 0.15%, 0.36%, 
0.95%. At time points d0t0, d0t4 and d1, 77.3, 74.5 and 71.1% of patients had a fractional 
excretion of sodium (FENa) < 1%, the currently used cut-off value. 
Upper cut-off values for the FEUrea quartiles were 21%, 31.5%, and 42.0%. At time points 
d0t0, d0t4 and d1, 63.2%, 50.9% and 41.3% of patients had a fractional excretion of urea 
(FEUrea) <35%.  
There was a stepwise increase in prevalence of AKI based on urinary output with quartiles of 
decreasing FENa and FEUrea at d0t0 (p 0.05 and p 0.01) and d0t4 (p < 0.001 for both), but 
not at d1 for FENa (p=0.18). There was no such association for AKI based on creatinine  
(table 3). 
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Table 3: Prevalence of AKIuo and AKIc (% of all patients classified in that category) in 
different FENa and FEUrea quartiles 
FENa quartiles AKIuo d0t0   p=0.05 AKIuo d0t4   p<0.001 AKIuo d1   p=0.18 
<0.15 57.7 72.4 53.3 
0.15-0.36 48.1 34.6 46.7 
0.36-0.95 33.3 39.1 33.3 
>0.95 23.1 14.3 28.1 
FEUrea quartiles AKIuo d0t0   p=0.01 AKIuo d0t4   p<0.001 AKIuo d1   p=0.01 
<21 59.3 77.8 83.3 
21.35 48.1 55.5 38.1 
31.5-42 37.5 22.2 30 
>42 17.9 23.5 34.1 
  
FENa quartiles AKIc d0t0   p=0.76 AKIc d0t4   p=0.66 AKIc d1   p=0.09 
<0.15 34.6 37.9 33.3 
0.15-0.36 40.7 46.2 40 
0.36-0.95 48.1 34.8 29.6 
>0.95 46.2 50 59.4 
FEUrea quartiles AKIc d0t0   p=0.06 AKIc d0t4   p=0.17 AKIc d1   p=0.72 
<21 55.6 61.1 33.3 
21.35 51.9 44.4 33.3 
31.5-42 20.8 44.4 46.7 
>42 39.3 29.4 43.9 
p values represent Chi square over the quartiles. 
The values for FENa and FEUrea in the different  AKI stages based on urinary output are 
illustrated in figure 2A and figure 2B, respectively. FENa was <1% in the majority of patients 
at all time points, except in patients classified as ‘F’ at timepoint d1, where the median was 
2.16%. There was a U-shaped pattern of FENa over the different AKI stages based on urinary 
output (p=0.07, 0.016 and 0.01 at d0t0, d0t4 and d1 respectively)(figure 2A). There was a 
decreasing trend in FEUrea at d0t0,d0t4 and d1 across different AKI stages based on urinary 
output (figure 2B). Patients with stage 'F'AKIuo  had a persistent FEUrea <20% at the three 
time points (figure 2 B).  
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Figure 2: FENa(%)(A) and FEUrea(%)(B)  at the different time points in AKIuo   
 
Legend Figure 2: A: U-shaped form of FENa over the different AKIuo classes(N= no AKI, R=Risk, I=Injury and 
F=Failure).  (p=0.07, 0.016 and 0.01 at d0t0, d0t4 and d1 respectively). B: Decreasing trend in FEUrea(%) across 
AKIuo classes at the different time points with persistently low FEUrea(%) in RIFLE ‘F’ class at the three time 
points (p 0.029, p0.001 and p 0.098). 
 
To analyse the discriminative power of fractional excretion of sodium and urea and of 
urinary NGAL to discriminate transient and intrinsic AKI, we performed Receiver Operating 
Characteristic curves, yielding areas under the curves of 0.59, 0.36 and 0.67 respectively, 
pointing out that none of these parameters had sufficient power to discriminate intrinsic 
from transient AKI.     
We wanted to assess the predictive value of a combined interpretation of fractional 
excretion of sodium and urea for the evolution of diuresis and AKI. Therefore, a categorical 
representation of percentages of patients with no AKI, transient AKI and intrinsic AKI in 
different subgroups of high and low fractional excretion of sodium and urea at 4 hours is 
cross tabulated in table 4 (A: based on urinary output: p<0.001, B: based on creatinine: 
p=0.01, C: based on both urinary output and creatinine: p<0.001).  
 
Table 4: cross tabulation of FENa<0.36%/FEurea<31.5% vs  FENa>0.36%/FEurea<31.5% vs 
FENa<0.36%/FEurea>31.5% vs FENa>0.36%/FEurea>31.5% in AKIuo (Table 4A),  
AKIc (Table 4B) and AKIboth (Table 4C). 
A 
AKIuo 
% within 
FENA/FEUrea 
category 
FENa<0.36% 
FEUrea<31.5% 
FENa>0.36% 
FEUrea<31.5% 
FENa<0.36% 
FEUrea>31.5% 
FENa>0.36% 
FEUrea>31.5% 
Total 
No AKI 18.8 7.7 43.5 71.8 42.1 
Transient AKI 62.5 38.5 52.2 23.1 43.0 
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Intrinsic AKI 18.8 53.8 4.3 5.1 15.0 
B 
AKIc 
% within 
FENA/FEUrea 
category 
FENa<0.36% 
FEUrea<31.5% 
FENa>0.36% 
FEUrea<31.5% 
FENa<0.36% 
FEUrea>31.5% 
FENa>0.36% 
FEUrea>31.5% 
Total 
No AKI 46.9 30.8 65.2 56.4 52.3 
Transient AKI 34.4 15.4 21.7 35.9 29.9 
Intrinsic AKI 18.8 53.8 13.0 7.7 17.8 
 
C 
AKIboth 
% within 
FENA/FEUrea 
category 
FENa<0.36% 
FEUrea<31.5% 
FENa>0.36% 
FEUrea<31.5% 
FENa<0.36% 
FEUrea>31.5% 
FENa>0.36% 
FEUrea>31.5% 
Total 
No AKI 9.4 0.0 30.4 46.2 26.2 
Transient AKI 68.8 38.5 52.2 46.2 53.3 
Intrinsic AKI 21.9 61.5 17.4 7.7 20.6 
AKIuo, AKIc, AKIboth: Acute kidney injury based on urinary output(uo), serum creatinine(c) or both 
criteria(both).A: p<0.001, B: p=0.01 and C: p<0.001 
The negative predictive value for intrinsic AKI for patients with both high fractional excretion 
of sodium and urea was 92.0%; the negative predictive value that urinary output would not 
restore in patients with this combination was 94.9%. In contrast, the positive predictive 
value of a high fractional sodium excretion in combination with a low fractional urea 
excretion for persisting oliguria was 54%. Thus, a high fractional sodium and urea excretion 
are nearly always associated with transient AKI and restoration of diuresis, whereas in 
patients with a high fractional sodium excretion in combination with a low fractional urea 
excretion, there is substantial risk for persisting oliguria. The same evaluation for the same 
parameters at admission showed the same trend (data not shown). 
Urinary NGAL values at 4 hours in patients with no AKI, transient AKI and intrinsic AKI are 
represented in figure 3, and this separately for AKI defined on urinary output (figure 3A), on 
creatinine (figure 3B) or both criteria (figure 3C) (p value overall<0.001).  
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Figure 3: uNGAL in no-AKI, transient AKI and intrinsic AKI based on AKIuo(A), AKIc(B) and 
AKIboth(C). 
 
 
Legend Figure 3: Overall p value was <0.001 for the difference in uNGAL levels between groups, in figure 3A,3B 
and 3C. There was no significant difference (p=0.9) in uNGAL levels between transient AKI and no-AKI if 
diagnosis was based on the urinary output criterion (figure 3A). If diagnosis was based on the creatinine 
criterion (figure 3B), there was a significant difference between no-AKI and transient AKI (p 0.002). 
 
In post hoc analysis, there was a difference in median NGAL levels between no AKI and 
transient AKI when AKI was defined based on creatinine (p=0.002) whereas there was no 
difference when it was based on urinary output (p=0.9).   There was a similar gradual 
increase in the fractional excretion of NGAL in no-AKI versus transient AKI (p=0.04) versus 
intrinsic AKI when AKI was defined based on the creatinine criterion but again, there was no 
significant difference between no-AKI and transient AKI (p=0.49) when AKI was defined 
according to the diuresis criterion only (graphic illustration similar to figure 3; not shown).  
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Urinary NGAL levels and fractional excretion of urea in patients with no AKI vs transient vs 
intrinsic AKI, and this separately for those with a fractional sodium excretion below or above 
0.36% are depicted in figure 4A and 4B respectively. Median urinary NGAL was higher in the 
overall group in those with high (>0.36%) versus low (<0.36%) fractional sodium excretion 
(median 1005 vs 314 µg/g creatininine respectively, p 0.025). In those with high fractional 
sodium excretion (>0.36%), urinary NGAL was higher in those with intrinsic AKI vs in those 
with transient AKI (median 4146 vs 1544 µg/g creatinine, p= 0.001). In those with a low 
fractional sodium excretion <0.36%, the difference was not significant (917 vs 286 µg/g 
creatinine, p=0.29) (figure 4A). Median fractional excretion of urea was higher (39.6% vs 
28.6%, p=0.02) in the overall group in those with high (>0.36%) versus low (<0.36%) 
fractional sodium excretion. In those with high fractional sodium excretion (>0.36%), 
fractional urea excretion was lower in those with intrinsic AKI vs those with transient AKI 
(28,8% vs 38,7%, p 0.04). A RoC analysis of fractional urea excretion in patients with a 
fractional sodium excretion >0.36 yielded an AUC of 0.76 for discrimination between 
transient and intrinsic AKI. In those with a low fractional sodium excretion <0.36, the 
difference was not significant (21,6% vs 27,6%, p=0.49) (figure 4B) 
The median volume of HES administered in no-AKI vs transient AKI based on urinary output 
was 0.5L vs 0.53L (p=0.15). Based on the creatinine criterion this was 0.5L and 0.5L in no-AKI 
vs transient AKI (p=0.64).  
Figure 4: uNGAL(µg/g creatinine) and FEUrea(%) according to FENa (either < 0.36 or > 0.36%) 
in patients with noAKI, transient AKI and intrinsic AKI respectively. 
 
Legend Figure 4: A: For patients with FENa <0.36%, uNGAL(µg/g creatinine) levels were not significantly 
different between no-AKI, transient AKI and intrinsic AKI. For patients with FENa >0.36%, uNGAL levels were 
significantly different between transient AKI and intrinsic AKI (p 0.001).  B: For patients with FENa <0.36%, there 
was no significant difference in fractional excretion of urea between no-AKI, transient AKI and intrinsic AKI. For 
patients with FENa >0.36% there was a significant difference between patients with transient AKI and intrinsic 
AKI (p 0.04)  
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5.5 Discussion 
When urinary output was used on top of serum creatinine in this cohort of sepsis patients to 
define AKI, more cases of AKI were detected as compared to when AKI was only based on 
the creatinine criterion. More importantly, transient AKI based on the RIFLE urinary output 
criterion was not associated with tubular damage as assessed by urinary NGAL, whereas 
there was tubular damage when diagnosis of transient AKI was based on the RIFLE creatinine 
criterion. Our data indicate that in patients with incipient sepsis, FENa is far below the 
proposed cut-off of 1%, which might explain the poor performance of the FENa<1% criterion. 
Unexpectedly, a persisting very low fractional urea excretion <31.5% was associated with 
intrinsic rather than transient AKI. A combined interpretation of high fractional sodium and 
urea excretion yielded a high negative predictive value for intrinsic AKI (92%) and persisting 
oliguria (95%), whereas a high fractional sodium and low fractional urea excretion had a 54% 
positive predictive value for patients remaining oliguric or developing intrinsic AKI.  
Progress in the field of Acute Kidney Injury has been hampered by lack of a uniform 
definition. In the last decade, several recommendations for a consensus definition have been 
proposed13-15. However, although all these definitions are based on both serum creatinine 
and urinary output criteria together, the latter parameter has been neglected in many 
studies. This is mainly because urinary output is mostly not available in administrative 
databases, or because people believe it is difficult to register urinary output. As a 
consequence, there is ongoing debate on the value of urinary output for defining AKI18-23. 
However, oliguria is also associated with hard outcomes such as mortality24, so it is now 
stressed that also urinary output should be taken into account when classifying AKI15. In our 
cohort, prevalence of the diagnosis of AKI decreased from 64.5 to 43% when urinary output 
was not taken into account. Whereas patients with transient AKI based on urinary output 
had similar levels of urinary NGAL production as patients without AKI, patients with transient 
AKI based on creatinine had levels of urinary NGAL production intermediate between no AKI 
and established AKI (figure 3), in line with the findings of Nejat et al, where only the 
creatinine criterion was used8. These results were confirmed when the fractional excretion 
of NGAL was used instead of urinary NGAL alone. These findings underline the concept that 
an increase in creatinine lags behind for early diagnosis of AKI, and that making a diagnosis 
based on urinary output might increase the potential for intervention at a stage when there 
is no tubular damage yet. Recently it was demonstrated in a post hoc analysis of the Chest 
study that fluid resuscitation with HES vs saline was more favorable when AKI was defined 
according to the diuresis criterion only, whereas saline was more favorable than HES when 
AKI was defined according to the creatinine criterion only25, In our cohort the volume of HES 
administered was not different between no-AKI and  transient AKI and between transient 
AKI based on the diuresis criterion vs transient AKI based on the creatinine criterion.  
Recently, it was demonstrated that assessment of urinary output can be easily and 
accurately achieved by registering it in 6-8 hour blocks16. This approach would make it 
possible to even monitor urinary output in patients without an indwelling bladder catheter, 
and maybe even outside the intensive care care unit, at the hospital ward. This would be of 
importance, as it has been demonstrated that the majority of (fatal) cases of AKI develop 
unnoticed on the ward, and are diagnosed with much delay.26  
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There is discussion on the discriminatory value of fractional sodium excretion for the 
diagnosis of transient AKI. Usually, a cut off of <1% is forwarded as diagnostic discriminant.27-
29 Our data indicate that this cut off might be far too high, at least in sepsis, as 75% of the 
patients in our cohort had FENa<1%, and 50% even had a value <0.36%. Bagshaw et al 
recently reported an admission FENa below 1% in 57% of septic patients, being not different 
from non-septic patients30. Darmon et al reported a median FENa on admission of 0.50%.31 
Using RoC curve analysis, the same authors also found that a fractional excretion of 0.58% 
had the best discriminative power, resulting in a positive and negative predictive power for 
persistent AKI of 0.71 and 0.47 respectively.31 In our cohort we used the median, being 
0.36%.  
Our data highlight some other pitfalls for the interpretation of a high fractional sodium 
excretion. First, a high fractional excretion of sodium can also be a marker of tubular damage, 
due to active tubular secretion and reduced proximal tubular reabsoption. In our cohort, 
potentially in line with presumed tubular damage, we indeed found higher urinary NGAL 
levels in patients with a high vs low  fractional sodium excretion, and this most expressed in 
those who develop intrinsic AKI. Interestingly, in our cohort, patients with transient AKI had 
only higher urinary NGAL levels when they also had high fractional excretion of 
sodium >0.36% (figure4A), suggesting that some patients with transient AKI indeed develop 
some (minor) degree of tubular damage, whereas others do not. This also underpins that an 
increase in fractional sodium excretion is not always a positive sign, but can also be an 
indicator of subclinical tubular damage, which further adds to the low discriminative power 
of fractional sodium excretion, even when assessed in consecutive samples. 
Second, a high fractional excretion of sodium might be caused by interference with use of 
diuretics. In our cohort, only a minority of patients were treated with diuretics, and those 
were equally distributed between AKI and no AKI. De Witte et al found much higher values 
of fractional sodium excretion in their cohort, but only a minority of their patients had sepsis, 
whereas 60% were treated with diuretics.32  Because of these two reasons, a high FENa can 
thus not be interpreted by itself. Third, although the fractional excretion of sodium mainly 
decreases due to reduced urinary output and stimulation of sodium reabsorption, it can be 
speculated that fractional excretion of sodium also decreases when glomerular filtration 
decreases, e.g. because of tubular obstruction. Therefore, although in our cohort a very low 
fractional sodium excretion below <0.36% yielded a negative predictive value for intrinsic 
AKI of 87.3%, it is probably not  a strong discriminative parameter, as was also suggested by 
Darmon et al31.   
Surprisingly, and against our initial hypothesis, a low (<31.5 %) fractional urea excretion at 4 
hours was associated with intrinsic rather than with transient AKI, especially when it was 
persistent over time, whereas a value higher than 31.5% had a very high negative predictive 
value for intrinsic AKI. In patients with a fractional sodium excretion above 0.36%, the 
discriminatory value of fractional urea excretion was even more pronounced (figure 4B).  
Darmon et al reported a FEUrea of 39% in the no AKI vs 41% in the transient AKI vs 32% in 
the intrinsic AKI group, and concluded that FEUrea had a low value for discriminating 
intrinsic AKI.31 They based their analysis on admission FEUrea, whereas we used the value 4 
hours after admission, when some attempts to restore low glomerular filtration pressure 
(e.g. by a fluid challenge or start of vasopressors) have already been installed. However, data 
based on FEUrea and FENa at admission showed comparable results, though less impressive 
(data not shown). Our findings are in line with those of De Witte et al, who also found a 
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reasonable value of FEurea<40% as a parameter to discriminate transient from intrinsic 
AKI.32 As a low fractional excretion of urea apparently represents a low glomerular filtration, 
we hypothesized that a combination of fractional sodium and urea excretion would yield the 
most optimal prediction of patients with a substantial chance to respond positively to 
attempts to restore glomerular filtration. Indeed, in our cohort, a combination of a high 
fractional sodium and urea excretion yielded a 95% probability of restoring diuresis, and the 
AKI being transient rather than intrinsic, whereas a persistently low fractional urea excretion 
in combination with a high fractional sodium excretion was suggestive for intrinsic AKI.  
There is debate on the discriminatory value of NGAL to predict or diagnose AKI in clinical 
conditions, as there is much overlap in NGAL levels between patients with vs. without AKI.33 
NGAL is a 25 kD molecule, that is filtered into the primary urine at the glomerular level. In 
sepsis, serum levels of NGAL increase exponentially34;35, even in the absence of AKI36, which 
can as such result in increased urinary levels as well37. Once filtered, NGAL is reabsorbed by 
the tubular epithelium through the megalin receptor and this through competitive binding38.  
 Although a recent study indicated that urinary NGAL stems from local production in the 
thick ascending limb of the loop of Henle when stress factors are applied, there is also 
evidence that urinary NGAL can derive from the systemic circulation37;39. This indicates that 
the presence of NGAL in the urine in sepsis patients cannot automatically be considered as a 
marker of tubular damage per se. In addition, also some patients with transient AKI might 
have some degree of tubular damage, which might explain the relatively low value of NGAL 
to discriminate transient from intrinsic AKI in this cohort of septic patients. 
A strength of this study is that it describes one of the largest cohorts of sepsis patients in 
detail for different patho-physiologic aspects of AKI, such as urinary and serum biomarkers, 
and urinary output. A limitation on the other hand is that it is observational and hence no 
causal assumptions can be made.  
 
5.6 Conclusion 
Urinary output is an early and sensitive marker of AKI, which might incite intervention before 
tubular damage has occurred. Low fractional excretion of sodium (<1%) and urea (<35%) is 
very frequent in septic patients and it might be necessary to define lower discriminatory cut-
off values as an indication of maximal tubular reabsorption and thus intact tubular function 
as the ones used at present. A combination of high fractional excretion of sodium and urea 
has a high negative predictive value for intrinsic AKI, whereas a high fractional sodium 
excretion and a low fractional urea excretion are associated with intrinsic AKI in 54% of cases. 
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6.1 Abstract 
Purpose: The pathophysiology of septic Acute Kidney Injury (AKI) is incompletely understood 
and there is controversy on the role of renal hypoperfusion in early sepsis. We hypothesized 
that renal hypoperfusion plays a role in early sepsis and that there is a continuum between 
transient AKI without tubular damage, transient AKI with minor tubular damage and intrinsic 
AKI.  
Methods: 107 consecutive patients with sepsis were included. Fractional excretion of sodium 
(FENa), urinary and serum Neutrophil gelatinase-associated Lipocalin (NGAL) were measured 
at admission(T0) and 4 hours(T4) and 24 hours later(T24). Patients were classified according 
to FENa quartiles. Transient and intrinsic AKI were respectively defined as AKI that did or did 
not recover  to no AKI in the following 5 days.  
Results:  57 developed transient AKI, 22 intrinsic AKI, and 28 did not have AKI. Of the 10 
patients with transient AKI classified in the two lowest FENa quartiles (FENa<0.36%) and 
without signs of local tubular damage, 7 still did not show signs of tubular damage 24h later. 
Also, 50% of patients with intrinsic AKI classified in the same FENa quartiles, did not show 
signs of local tubular damage at admission but did so 24 hours later.  
Conclusions:  There is a continuum between transient AKI without tubular damage, transient 
AKI with minor tubular damage and intrinsic AKI in sepsis. Renal hypoperfusion seems to be 
the instigator for development of AKI in the majority of patients with early sepsis. Other 
mechanisms in some patients cannot be excluded. 
 
6.2 Introduction 
Septic Acute Kidney Injury (AKI) is associated with worse outcome compared to non-septic 
AKI and can be regarded as a distinct clinical entity.1 The lack of significant progress in this 
field is partly related to an incomplete understanding of the pathophysiology of septic AKI.2 
The role of renal hypoperfusion in the pathogenesis of septic AKI is controversial and there is 
increasing evidence that inflammatory cascades and oxidative stress with microcirculatory 
changes play an important role as well. 3-6 
In recent years the idea has been put forward that transient acute kidney injury is also 
associated with a certain degree of tubular damage and is thus not merely a physiological 
response to a decrease in glomerular capillary perfusion. These assumptions are based on 
findings that showed an increase in biomarkers for diagnosis of tubular damage, in patients 
classified as having transient acute kidney injury. This has also led to the generation of a new 
subgroup of AKI, namely subclinical AKI, defined as a rise in biomarker level without a rise in 
serum creatinine or a decrease in urinary output.7 
We hypothesized that renal hypoperfusion in early sepsis is an important underlying 
mechanism in the pathophysiology of septic AKI and that there is a continuum between 
transient AKI without tubular damage, transient AKI with minor tubular damage and intrinsic 
AKI.  
 
 
Chapter 6 
152 
6.3 Material and methods 
107 consecutive patients admitted with sepsis, severe sepsis or septic shock were 
prospectively included at ICU in a tertiary university hospital between 12/01/2010 and 
05/09/2010. The study was approved by the ethical committee of the Ghent University 
Hospital. Written informed consent was obtained from the patient or their next of kin. Sepsis, 
severe sepsis or septic shock were defined according to the American College of Chest 
Physicians/Society of Critical Care Medicine Consensus Conference guidelines.8 Briefly, sepsis 
was defined as two or more of the following conditions being present as a result of infection: 
1) temperature > 38° or < 36°, 2) heart rate > 90 beats/min, 3) respiratory rate > 20 
breaths/min or PaCO2 < 32 mmHg (<4,3 kPa) or 4) white blood cell count > 12000 cells/mm3  
or <  4000 cells/mm3 , or > 10% immature (band) forms. Severe sepsis was defined as sepsis 
associated with organ dysfunction, hypoperfusion or hypotension. Septic shock was defined 
as sepsis with hypotension despite adequate fluid resuscitation or vasopressor need. 
Exclusion criteria were 1) a history of transplantation, 2) ICU stay less than 24 hours, 3) 
patients treated with chronic hemodialysis,  4) age< 17 years and 5) obstructive Acute 
Kidney Injury. 
The urinary output criterion was based on 6 hour blocks, as described by Macedo et al. 9 We 
defined AKI based on the worst of either creatinine or urinary output criteria according to 
RIFLE.10 Baseline creatinine was based on the most recent value before admission or was 
estimated with the MDRD equation if the latter was not available. 10 
Transient AKI was defined as RIFLE R, I or F that improved to "no AKI" in the following five 
days, whereas "intrinsic AKI" was defined as patients with RIFLE R, I or F who did not evolve 
to no AKI in the following five days.  
Fluid management and decision making for need of RRT was done by intensivists, blinded to 
the study, according to protocols applied in the hospital where the study was conducted.  
Urine and blood samples were collected at the moment of admission (T0), four hours later 
(T4) and 24 hours later (T24). Blood samples were centrifuged within 20 minutes after 
collection at 1500g for 10 minutes, and serum was aliquoted and  stored at -80°C for later 
batch analysis. Urine was collected in a sterile way and centrifuged at 500g for 10 minutes, 
urine samples were aliquoted and stored  at -80°C for later batch analysis. 
Fractional excretion of sodium was calculated according to the formula 
(UxxScrea)/(UcreaxSx)x100 with x=sodium. Patients were classified according to FENa quartiles.  
Serum and Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) were measured using 
an ELISA kit (BioportoR Diagnostics Denmark).  
Since we previously found an important correlation between serum NGAL and urinary NGAL 
(unpublished data) we assessed the origin of urinary NGAL e.i. either serum NGAL after 
systemic generation, reduced tubular reabsorption of filtered NGAL  or local NGAL release at 
distal tubular level, by using two parameters, namely "delta NGAL" and "diff NGAL". We 
defined "delta NGAL" as the urinary value minus the serum value, both expressed in ng/ml. 
Using delta NGAL might not be an exact numerical reflection of the final result of this 
complex process but one can easily appreciate that in case of an intact tubule, filtered NGAL 
can be integrally reabsorbed, and no local production of NGAL occurs, resulting in a net 
negative delta NGAL.11;12 We also defined "diff NGAL" as the difference in urinary NGAL 
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between time points T4 and T0 and between time points T24 and T4. The urinary NGAL 
levels used to calculate diff NGAL were normalized for urinary creatinine, in order to correct 
for urinary flow. Since we were interested in parameters that could indicate tubular integrity, 
we defined both a deltaNGAL level ≤0 and a diffNGAL level ≤0 as absence of local NGAL 
production and thus absence of tubular damage, as the amount of NGAL entering the 
tubular system could not be retrieved down the road. If delta NGAL and diffNGAL were > 0 
we considered that local NGAL production, and thus tubular damage could not be ruled out.  
Results are reported as medians and interquartile ranges  (IQR) for continuous variables, 
unless otherwise specified. Discrete variables are reported as numbers and/or percentages. 
All statistical analyses were performed using SPSS® 19. All consecutive patients were 
included, irrespective of their course or duration of stay at ICU. 
 
6.4 Results 
For demographics of the study cohort, including 107 patients with sepsis, severe sepsis or 
septic shock, we refer to a previously published paper.13  In brief, 3.7% of patients had sepsis 
and 35.5% and 60.7% had severe sepsis and septic shock respectively. Also, 28(26.2%) were 
classified as having no-AKI, 57(53.3%) and 22(20.6%) as having transient and intrinsic AKI 
respectively13. The evolution of the serum creatinine values in patients with no-AKI, 
transient AKI and intrinsic AKI are described in table 1.  A history of arterial hypertension was 
present in 41.3% of patients and 18.3%, 9.2%, 6.4% and 14.7% had a history of diabetes, 
stroke, peripheral arterial disease or coronary artery disease respectively. 10.1 and 15.6% 
suffered from heart failure or cardiac arythmia respectively. Cirrhosis and Chronic 
Obstructive Pulmonary Disease (COPD) were present in 5.5% and 11% respectively. 37% 
were either currenly or in the past treated for an oncological disease. The focus of infection 
was predominantly ‘respiratory’ in 40.2% of patients, followed by ‘abdominal’ (30.8%), 
‘urinary’ (6.5%), ‘endocarditis’ (4.7%), ‘catheter related’ (3.7%) and ‘neurological’ (2.8%). The 
focus of infection was related to other causes or unknown in 12 patients (11.2%). 
 
Table 1: Evolution of serum creatinine (median/IQR) over the first three days after ICU 
admission in no-AKI vs transient AKI vs intrinsic AKI. 
 T0 T4 T24 T48 T72 
No-AKI 0.67(0.35) 0.62(0.41) 0.66(0.40) 0.60(0.40) 0.59(0.34) 
Transient 
AKI 
1.0(0.75) 0.94(0.71) 0.88(0.57) 0.75(0.45) 0.71(0.45) 
Intrinsic AKI 1.45(1.61) 1.84(1.22) 1.92(1.38) 1.77(1.53) 1.90(1.68) 
Legend: T0=sCr at study inclusion, T4= sCr 4 hours after study inclusion, T24=first sCr value at day 1, T48= first 
sCr value at day 2, T72=first sCr value at day 3 
We previously demonstrated that FENa<1% is prevalent in early sepsis.13 Twelve out of 28 
(42.9%), 29/57 (50.9%) and 12/22 (54.5%) of patients classified as having no-AKI, transient 
AKI and intrinsic AKI respectively, were classified in the lowest two sodium quartiles 
(FENa<0.36%) at admission(T0).  
At admission, 7 of the 10 patients who were classified as having transient AKI with a FENa 
less than 0.36% (FENa quartile 1 and FENa quartile 2) and both DeltaNGAL and DiffNGAL ≤0, 
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indicating tubular integrity, still did not show signs of tubular damage 24 hours later 
illustrating that some patients classified as having transient AKI do not have signs of tubular 
damage in the first 24 hours after admission (figure 1). 
Fifty % of patients classified as having intrinsic AKI with a FENA less than 0.36% and both 
DeltaNGAL and DiffNGAL≤0 at admission, did show an increase in FENa and positive values 
for both diffNGAL and deltaNGAL 24 hours later (figure 1), suggesting that intrinsic AKI might 
start of as renal hypoperfusion before displaying signs of progressive tubular damage. 
Figure 1: Tubular integrity defined as diffNGAL≤0 in patients with no-AKI, transient AKI and 
intrinsic AKI, classified in the lower sodium quartiles (FENa<0.36%). 
 
Legend Figure 1: A substantial part of patients with transient AKI, classified in the lower sodium quartiles at 
T0(FENaQT0=1 or 2), indicating maximal tubular sodium reabsorption, do not show local NGAL production at 
admission and still don’t have signs of local NGAL production, as illustrated by diffNGAL≤0, 24 hours later. Some 
patients with intrinsic AKI do not show signs of tubular damage at T0, but do so 24 hours later. (Similar results 
for deltaNGAL, figure not shown) 
To further illustrate that the continuum of "no AKI", “transient AKI without tubular damage”, 
“transient AKI with minor tubular damage”, "evolution to intrinsic AKI (intrinsic a)" and 
“intrinsic AKI from the start (intrinsic b)”, is a reality in patients with sepsis, a  graphic 
illustration of DeltaNGAL, diffNGAL and FENa, at the different time points (T0,T4 and T24) in 
five representative patients classified in one of the groups mentioned above is presented in 
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figure 2. Delta NGAL levels and diffNGAL ≤0 indicate absence of local NGAL production in 
patients with no-AKI, and transient AKI without tubular damage. On the other hand, a 
patient with ‘evolution to  intrinsic AKI’, shows a gradual increase in local NGAL production 
over time together with an increase in FENa (intrinsic a). A patient with ‘intrinsic AKI from 
the start’, shows increased levels of local NGAL production from the beginning (intrinsic b) 
(Figure 2). 
Figure 2: DeltaNGAL, diffNGAL and FENA in patients with no-AKI, transient AKI without 
tubular damage, transient AKI with minor tubular damage, intrinsic AKI type a and intrinsic 
AKI type b, at the different time points.  
 
Legend Figure 2: (a) Delta NGAL levels indicate absence of local NGAL production in patients classified as having 
no-AKI and transient AKI without tubular damage. Patients with intrinsic AKI type a (evolution from renal 
hypoperfusion without tubular damage to intrinsic AKI), show a gradual increase in Delta NGAL over time. The 
patient classified as having intrinsic AKI type b shows increased levels of delta NGAL from the start. Transient 
AKI with minor tubular damage is associated with levels of DeltaNGAL that are lower than in intrinsic AKI. (b) 
DiffNGAL levels indicate absence of local NGAL production in  patients classified as no-AKI and trannsient AKI 
without tubular damage. Patients with intrinsic AKI type a, show a gradual increase in Diff NGAL level over time. 
The patient classified as intrinsic type b shows increased levels of diffNGAL from the start. Transient AKI with 
minor tubular damage is associated with levels of Diff NGAL that are lower than in intrinsic AKI. (c) FENa 
remains below 1% in all patients at all time points except for Intrinsic AKI type a and intrinsic AKI type b, at time 
point T24. 
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6.5  Discussion 
In a cohort of 107 septic patients we showed that there is a continuum between transient 
AKI without tubular damage, transient AKI with minor tubular damage and intrinsic AKI. 
Although there is controversy on the role of renal hypoperfusion in the pathophysiology of 
septic AKI, renal hypoperfusion seems to be the instigator of AKI in the majority of patients 
in this sepsis cohort. 
In this cohort, a substantial part of patients classified as having transient AKI did not show 
signs of tubular damage at admission, as suggested by a very low FENa (FENa quartile 1 or 2 
= FENa <0.36%) and a deltaNGAL and diffNGAL ≤0. Many of them still did not even show 
signs of tubular damage 24 hours later. This underlines the hypothesis that persisting 
prerenal azotemia without tubular damage can exist in early sepsis. In recent literature there 
has been discussion on this topic 14 and the reliance on urinary biomarkers such as NGAL as 
markers for tubular damage has led to the creation of a new entity, called subclinical AKI.7 
The latter is defined as a condition associated with an increase in biomarker level without 
fulfilling the classic RIFLE criteria based on serum creatinine and urinary output.7 Also, in 
view of the search for new ‘troponin-like’ biomarkers there are several reports on the need 
for defining a renal angina syndrome equivalent. The latter is currently based on clinical 
factors such as serum creatinine and oliguria but authors hint that in the future the diagnosis 
of renal angina could  be based on new urinary biomarkers such as NGAL or KIM-1.15  
The consequences of incorrectly classifying patients as having AKI when they actually don’t 
have AKI, can be that studies testing new drugs risk to be falsely negative, because they 
include patients with so called subclinical AKI in the placebo group.  
The emergence of the term ‘subclinical AKI’ has also led to the dismissal of the concept of 
prerenal azotemia, defined as a physiological response to a decrease in renal perfusion 
without structural damage. It created the general impression that there is always a certain 
degree of tubular damage if there is a decrease in GFR and/or if urinary biomarkers are 
present. 
Two recent studies are in favor of presence of structural damage in patients with so-called 
prerenal azotemia.16;17 Doi et al suggested that new AKI biomarkers such as NGAL, LFABP, IL-
18, NAG and albumin can detect mild renal tubular damage in prerenal acute kidney injury in 
a study including 337 critically ill patients and Nejat et al showed that biomarker 
concentrations significantly and progressively increased with the duration of AKI.16;17 
Although the findings in both studies led the authors to conclude that prerenal azotemia is 
associated with a certain degree of tubular damage, some questions remain open. First, 
NGAL levels were not statistically different between prerenal and no-AKI in the study by 
Nejat et al17 and in the volume depleted mice in the study by Doi et al.16 Also in another 
recent study  no increase in NGAL levels in volume depleted animals was demonstrated, 
which led authors to hypothesize that NGAL might be less sensitive to differentiate prerenal 
from no-AKI.18 Although these results at least suggest that in genuine prerenal azotemia 
there is no increase in NGAL levels, still a lot of effort seems to be put in convincing the 
scientific world that a rise in biomarker level (f.e. NGAL) is always a sign of tubular damage, 
even in the absence of AKI diagnosis by classical criteria such as serum creatinine increase of 
oliguria.19;20 A more plausible explanation is that test results indicating biomarker positivity, 
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can be falsely positive and thus that the presence of these biomarkers in the urine is not 
necessarily a sign of tubular damage. 
Second, there are pitfalls in using these molecules as markers for tubular damage. These are 
related to the fact that results can be influenced by several non-renal conditions, such as 
inflammation.21 This is corroborated by the fact that in the studies of Nejat et al and Doi et al 
also no-AKI patients showed increased biomarker levels.16;17 
In our cohort, some patients who were classified as having intrinsic AKI did not show signs of 
tubular damage at the first time point, but did so 24 hours later. These findings suggest that 
septic AKI is a continuum between transient AKI without tubular damage (as evidenced by a 
very low fractional excretion of sodium and no signs of local tubular damage) over transient 
AKI with limited tubular damage, to full blown AKI with extensive tissue damage. As a 
consequence, restoring renal perfusion in the first hours of sepsis is a potentially effective 
way of preventing  AKI. 
However, some patients classified as having intrinsic AKI show signs of tubular damage from 
the beginning and thus other mechanisms besides renal hypoperfusion in the pathogenesis 
of early septic AKI cannot be excluded. 
In the study of Nejat et al and Doi et al, prerenal AKI was defined as recovery of AKI within 
48 hours and a FENa<1%, making it implicitly impossible to demonstrate that intrinsic AKI 
can start off as prerenal azotemia.16;17   
A limitation of this observational study is that it describes  a relatively small cohort of 
patients. However the study provides information on both FENa, serum NGAL and urinary 
NGAL at different time points during the first 24 hours after admission in septic patients. 
Since we were only interested in having strict markers for tubular integrity we used the 
lowest two FENa quartiles (FENa <0.36%) and both diffNGAL and deltaNGAL ≤ 0. We fully 
acknowledge that even more patients could show this continuum since a positive deltaNGAL 
or diffNGAL might arise even in the absence of tubular damage. However, a negative value 
almost certainly excludes the possibility of tubular damage. Since our goal was to illustrate 
that there is a continuum between transient AKI without tubular damage, transient AKI with 
minor tubular damage and intrinsic AKI, we preferred parameters for tubular integrity that 
potentially were too strict vs the opposite. This  resulted in a high degree of certainty 
regarding the presence of tubular integrity when DeltaNGAL and diffNGAL were both ≤0. 
However, if one or both criteria were >0, tubular damage could not be ruled out.  
We also acknowledge that fluid resuscitation before ICU admission could have influenced 
AKI diagnosis. However, this would have weakened rather than strengthened our findings.  
 
6.6 Conclusion 
There is a continuum between transient AKI without tubular damage, transient AKI with 
minor tubular damage and intrinsic AKI in sepsis. Renal hypoperfusion seems to be the 
instigator for development of AKI in the majority of patients with early sepsis. Other 
mechanisms in some patients cannot be excluded. 
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7.1 Study Cohort 
7.1.1  Demographic Data 
We described a cohort of 195 prospectively included patients with sepsis, admitted to the 
Ghent University Hospital between 12/01/2010 and 27/03/2011. Patiënts who developed 
sepsis during their ICU (Intensive Care Unit) stay, were not considered for inclusion. Sepsis, 
severe sepsis and septic shock were defined according to the ACCP/SCCM criteria.1 Exclusion 
criteria were 1) ICU stay less than 24 hours or withdrawal of therapy, 2) no bladder catheter, 
3) patients treated with chronic hemodialysis, 4) patients with RRT need due to AKI upon ICU 
admission, 4) Age < 17 years, 5) a history of organ transplantation, 6) obstructive AKI and 7) 
no central line or arterial catheter.  During the study period, 253 patients were considered 
for inclusion of whom 58 were excluded (18 for not having a bladder catheter, 13 because of 
RRT need upon ICU admission, 10 with a history of organ transplantation, 7 because of the 
decision to withdraw therapy, 5 for being treated with chronic dialysis, 3 who had an ICU 
stay < 24h, 1 with obstructive AKI and 1 who did not have an arterial or central venous line). 
NGAL measurements were performed in the first 107 patients included. 
The demographic data of this cohort are depicted in Table 1. 
Table 1: Demographics of the study cohort 
Age(years, mean/sd) 60.6(15.5) 
Gender(%Male) 61.4(15) 
Sepsis Severity (n/%) 
  Sepsis 
  Severe Sepsis 
  Septic Shock 
 
9(5) 
63(32) 
123(63) 
ICU Mortality (%) 
  Sepsis 
  Severe Sepsis 
  Septic Shock 
 
11 
10 
31 
90 days Mortality (%) 
  Sepsis 
  Severe Sepsis 
  Septic Shock 
 
11 
16 
41 
Reason for admission (%) 
   Respiratory 
   Abdominal 
   Urosepsis/Urological 
   Endocarditis 
   Neurological 
   Catheter 
   Other/Unknown 
 
42 
29 
7 
4 
3 
2 
14 
APACHE II score first 24h after admission 23(9) 
Need for ventilation during ICU stay (%) 54 
Vasopressor need (%) 61 
LOS ICU survivors (days) 6(9) 
CKD (eGFR<60ml/min/1,73m2) (%) 15 
Use of diuretics on the first day of admission (%) 14 
 
Chapter 7 
164 
7.1.2 Prevalence of AKI according to RIFLE 
7.1.2.1  AKI and RIFLE 
According to RIFLE, based on both the serum creatinine (sCr) and urinary output criteria, 131 
patients (67%) developed AKI in the first 24 hours after admission. 201% were classified as 
RIFLE-R (Risk) vs 29% and 17% as RIFLE-I (Injury) and RIFLE-F (Failure), respectively (Table 2). 
Over the next four days after ICU admission, the number of patients diagnosed with AKI 
increased to 152(78%) of whom 23%, 31% and 25% were classified as RIFLE-R, RIFLE-I and 
RIFLE-F, respectively (Table 2). Thus the majority in our cohort of sepsis patients that fulfilled 
the criteria for AKI did so already in the first 24h after admission (Table 2). 
Table 2: Prevalence of AKI according to RIFLE and RRT need 
AKI according to RIFLE first 24h (n(%)) 
  RIFLE-Risk 
  RIFLE-Injury 
  RIFLE-Failure 
Worst RIFLE class during the first 5 days 
after admission (n/%) 
  RIFLE-Risk 
  RIFLE-Injury 
  RIFLE-Failure 
 
40(21) 
57(29) 
34(17) 
 
 
44(23) 
60(31) 
48(25) 
RRT need (%) 27(14) 
 
In a multicenter evaluation of the RIFLE criteria for AKI in critically ill patients, Bagshaw et al 
found that the prevalence of AKI on the first day of admission was 36.1% with 16.3%, 13.6% 
and 6.3% classified as RIFLE-R, RIFLE-I and RIFLE-F respectively.2 A subgroup analysis 
demonstrated a higher prevalence of AKI in septic vs non-septic AKI (42.1% with 16.2%, 
16.3% and 9.6% classified as RIFLE-R, RIFLE-I and RIFLE-F respectively).3 However this was a 
retrospective study, urinary output criteria were modified and baseline sCr values were 
estimated, which might explain the difference in prevalence compared to our study.  
In two other studies4;5, AKI occurred in 11-16% of patients, however the AKI definition that 
was applied also differed from ours. Hoste et al4 defined AKI as an abrupt increase of sCr to 
more than 2 mg/dl in a exclusively surgical ICU and Yegenaga et al5 used the same sCr 
increase criterion and added an a urinary output criterion by defining oliguria as a urinary 
output ≤ 400ml/24h.  
AKI prevalence was around 35% in two retrospective studies by Lopes et al and Ostermann 
et al in patients with sepsis and in the critically ill, respectively6.7 In the study by Lopes et al8, 
authors did not state whether both RIFLE criteria were used for defining AKI. Ostermann et 
al7 used modified urinary output criteria and eGFR, the latter being unreliable in non-steady 
state conditions such as AKI. Oppert et al9 also found a lower AKI prevalence than we did in a 
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prospective cross sectional one-day study including critically ill sepsis patients in 454 ICU’s 
over 310 German hospitals. They defined AKI as a sCr increase above twice the upper limit or 
a urinary output  < 0.5 ml/kg/h for at least 4h despite fluid resuscitation.9 
Several of the above mentioned  studies4;5;9 did not include CKD patients which might also 
have influenced AKI prevalence because CKD patients tend to be more susceptible to 
develop AKI, although this remains controversial in sepsis patients.10-12 
 
7.1.2.2  AKI and RRT 
The prevalence of RRT need in critically ill and/or sepsis patients also varies and depends on 
the AKI severity of the patients included and the hospital and/or physician’s practices for 
starting RRT. In the SOAP study, 7% of patients were treated with hemodialysis and 13% with 
hemofiltration within the sepsis subgroup.13 In a study of Bagshaw et al14, septic AKI resulted 
in RRT need in 8.2% (72/883) of AKI patients and in a study by Hoste et al4, 70% of included 
ARF patients were treated with RRT, comparable to the results of the PICARD study where 
64% of 618 critically ill patients with ARF were treated with RRT.15  
In our cohort, 27(14%) of all included patients were treated with RRT. However 13 patients 
were excluded because they already had RRT need on the time of ICU admission. 10/110(9%) 
and 8/110(7%) of patients were treated with RRT although they were classified on the first 
day of admission as having no AKI according to the urinary output criterion only, or the sCr 
criterion only respectively (Figure 1). Patients classified as having no-AKI based on both 
criteria on the first day of admission received RRT in 5% (3/64) (Figure 1). Of the patients 
classified as having no-AKI on D0 and D4 based on either the urinary output criterion only, 
the sCr criterion only or both criteria, 5% (5/95) , 3% (3/100) and 2% (1/52) respectively, 
were treated with RRT (Figure 1).  Two of the five patients who were treated with dialysis 
although they were not oliguric during ICU stay, only received dialysis on 1 occasion and for 
the following indications: high uremia and therefore anticipated problems for weaning (due 
to confusion of the patient) in one and lactic acidosis in another patient. A third patient who 
was not oliguric during ICU stay developed RRT need only at day 14 after ICU admission and 
was oligo-anuric at that time. Patients classified as RIFLE-F according to the urinary ouput 
criterion on the first day of admission received more frequently RRT compared to patients 
classified as RIFLE-F according to the sCr criterion (9/11(82%) vs 8/27(30%)). Patients with a 
worst RIFLE stage ‘F’ over 5 days according to the urinary output criterion only (n=19) were 
more frequently treated with RRT than when their worst RIFLE stage was RIFLE-F according 
to the serum creatinine criterion (n=42) only (79% vs 50% RRT need respectively) (Figure 1). 
These findings suggest that urinary output is a more specific criterion than sCr for prediction 
of RRT and put emphasis on the fact that both criteria (sCr and urinary output)  should be 
included in the AKI definition. 
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7.1.2.3  Evolution of RIFLE 
Eighty-one percent of patients classified as having no-AKI in the first day of ICU admission, 
according to both the sCr and the urinary output criterion, did not develop AKI during their 
ICU stay. The majority of patients classified as having RIFLE-R on the first day of admission,  
do not progress and are classified as no-AKI on D4 (37/40=93%) (Figure 1). Of the patients 
classified as RIFLE-I (n=57) or RIFLE-F (n=34), 30% (17/57) and 56% (19/34) are still classified 
as RIFLE-I or RIFLE-F on D4. Of those, 6% (1/17) and 68% (13/19) were treated with RRT. Only 
7 of 57(12%) patients classified as RIFLE-I on D0 progressed to RIFLE-F on D4 (Figure 1). 
These results are not corroborated by a retrospective study of Hoste et al16 who found that 
in a cohort of 5383 critically ill patients of whom 67.2% developed AKI during their ICU stay, 
50% progressed from RIFLE-R on the first day of admission to RIFLE-I or RIFLE-F in the 
following days and more than one third of the patients with RIFLE-I progressed to RIFLE-F.  
In their cohort, less than 1% of patients classified as having RIFLE-I and 14.2% of those 
classified as RIFLE-F, were treated with RRT vs 11 and 58% respectively, in our cohort.16 
Altogether, epidemiological data on AKI prevalence and RRT need seem to differ widely, 
even within the same setting. This might be attributable to the lack of a uniform definition 
and/or a uniform application of the RIFLE criteria (different reference/baseline values and 
omitting or modifying the urinary output criteria)(see also chapter 7.2). 
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Figure 1: Evolution of RIFLE according to the urinary output criterion (A), the sCr criterion (B) or both criteria (C), over the first 5 days after ICU 
admission (RIFLE classification on day 5 versus RIFLE classification on the first day ICU admission). 
(N=no AKI, R= Risk, I=Injury, F=Failure, RRT=treatment with RRT during ICU stay, †: patients who died during the first 5 days after ICU admission) 
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7.1.3  Outcome 
We found high overall short and median term mortality rates in this cohort of sepsis patients 
with ICU, 90 days, 1 year and 2 years mortality rates of 23.1%, 31.3%, 43.6% and 50.3% 
respectively. In ICU survivors, 90 days, 1 year and 2 years mortality remained high with rates 
of 11.3%, 26.7% and 35.3%  respectively. (Table 3) 
Of the 27 patients treated with RRT, cumulative mortality was 55.6% during ICU stay. Eighty-
three % of patients who were treated with RRT and survived ICU (n=10/12) survived up to 2 
years. One patient treated with RRT died at three months and another patient died at year 1.  
 
7.1.3.1  Sepsis and mortality 
In a multicenter study of French ICU’s including 546 patients with severe sepsis or septic 
shock, 30 day mortality rate was 35% and hospital mortality rate was 41.9%.17 This French 
cohort differed from ours in age (mean age 65 vs 60.6 years) and in severity of illness with 
also less severily ill patients included in our study (patients with sepsis, severe sepsis or 
septic shock vs only severe sepsis and septic shock in the study by Brun-Buisson).17 In the 
SOAP study, 3147 patients were included over a period of two weeks in 198 ICU’s across 24 
European countries. 37.4% had sepsis with an ICU mortality of 27% vs 14% in non-septic 
AKI.13 There was a correlation between the ICU mortality rate for all patients and the sepsis 
rate in the various countries.13 Also in the SOAP study patients had a higher mean age than 
in our study (again mean age 65 vs 60.6 years). Overall, several reports seem to suggest that 
mortality rates in sepsis are decreasing.18;19 The total number of sepsis related deaths is 
increasing but the case fatality rate is decreasing.20 There are several potential explanations 
for the decrease in case fatality rate. First, there has been a significant improvement in the 
treatment of patients with sepsis in the last decades and technical/surgical procedures and 
skills have improved. Second, there might be a greater awareness for diagnosis of sepsis 
patients among physicians with earlier referral to ICU which might impact outcome. Third, 
due to budgetary reasons physicians might be more strict in registering patients as having 
sepsis in order to increase reimbursement. 
 
7.1.3.2  AKI according to RIFLE and mortality 
Although it is generally accepted that AKI is an independent predictor of mortality21-25, there 
is still controversy on the topic, even in the non-critically ill setting. In a population based 
study by Ali et al, there was no association between AKI and outcome.26 Also, Wald et al 
reported a higher risk for RRT need but not mortality, in a large cohort of ICU survivors.27 Lo 
et al reported a much higher (28-fold) risk increase for CKD 4-5 development than for 
mortality (2-fold) in patients with AKI vs no AKI.28 
In our cohort of sepsis patients, we did not find an increase in mortality rates from no-AKI, 
over RIFLE-R and RIFLE-I to RIFLE-F, either defined according to RIFLE based on both criteria, 
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over the first 24 hours after admission or over the first 5 days after admission (Table 2 and 
Table 3). Defining AKI according to either the urinary output criterion only or the sCr 
criterion only, did not change these findings. Based on both criteria in the first 24h after 
admission, ICU mortality rates in no-AKI, RIFLE-R, RIFLE-I and RIFLE-F were 22%, 15%, 23% 
and 35% respectively and 21%, 18%, 18% and 35% respectively when AKI was defined over 5 
days (Table 3). At 90 days, 1 year and 2 years findings were similar with an absence of 
gradual increase in no-AKI, RIFLE-R, RIFLE-I and RIFLE-F (Table 3). 
Although in a systematic review, Ricci et al29 concluded that there was a gradual increase in 
mortality with increasing stages of AKI, most of the included studies were retrospective and 
RIFLE criteria were being applied differently and often urinary output data were lacking.29  
Also, only 13/16 studies comparing mortality between RIFLE strata of severity reported on 
the mortality rate in the no-AKI group and only 1 paper, which was a letter, including 
exclusively sepsis patients.30 It is also important to note that the RIFLE criteria were originally 
not intended as a tool for prediction of mortality. 
 
Table 3: Mortality in the entire cohort (A) and in ICU survivors (B) and according to AKI status 
(RIFLE based on both criteria) and time span (AKI diagnosis over the first 24h vs over the first 
5 days after ICU admission). 
 
A 
ICU Mortality(%) 
  No AKIfirst24h 
  RIFLEfirst24h-Risk 
  RIFLEfirst24h-Injury 
  RIFLEfirst24h-Failure 
  No AKIfirst5days 
  RIFLEfirst5days-Risk 
  RIFLEfirst5days-Injury 
  RIFLEfirst5days-Failure 
23 
22 
15 
23 
35 
21 
18 
18 
35 
 
90 days Mortality(%) 
  No AKIfirst24h 
  RIFLEfirst24h-Risk 
  RIFLEfirst24h-Injury 
  RIFLEfirst24h-Failure 
  No AKIfirst5days 
  RIFLEfirst5days-Risk 
  RIFLEfirst5days-Injury 
  RIFLEfirst5days-Failure 
31 
31 
23 
32 
41 
33 
23 
30 
40 
1-year Mortality(%) 
  No AKIfirst24h 
  RIFLEfirst24h-Risk 
  RIFLEfirst24h-Injury 
  RIFLEfirst24h-Failure 
  No AKIfirst5days 
44 
48 
33 
44 
47 
44 
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  RIFLEfirst5days-Risk 
  RIFLEfirst5days-Injury 
  RIFLEfirst5days-Failure  
36 
43 
50 
2-years Mortality(%) 
  No AKIfirst24h 
  RIFLEfirst24h-Risk 
  RIFLEfirst24h-Injury 
  RIFLEfirst24h-Failure 
  No AKIfirst5days 
  RIFLEfirst5days-Risk 
  RIFLEfirst5days-Injury 
  RIFLEfirst5days-Failure 
50 
56 
43 
51 
47 
51 
48 
52 
50 
 
B 
90 days Mortality(%) 
  No AKIfirst24h 
  RIFLEfirst24h-Risk 
  RIFLEfirst24h-Injury 
  RIFLEfirst24h-Failure 
  No AKIfirst5days 
  RIFLEfirst5days-Risk 
  RIFLEfirst5days-Injury 
  RIFLEfirst5days-Failure 
11 
12 
12 
11 
9 
15 
8 
14 
7 
1-year Mortality(%) 
  No AKIfirst24h 
  RIFLEfirst24h-Risk 
  RIFLEfirst24h-Injury 
  RIFLEfirst24h-Failure 
  No AKIfirst5days 
  RIFLEfirst5days-Risk 
  RIFLEfirst5days-Injury 
  RIFLEfirst5days-Failure  
27 
34 
21 
27 
18 
29 
22 
31 
23 
2-years Mortality(%) 
  No AKIfirst24h 
  RIFLEfirst24h-Risk 
  RIFLEfirst24h-Injury 
  RIFLEfirst24h-Failure 
  No AKIfirst5days 
  RIFLEfirst5days-Risk 
  RIFLEfirst5days-Injury 
  RIFLEfirst5days-Failure 
35 
44 
32 
36 
18 
38 
36 
41 
23 
 
Several recent studies seem to confirm that AKI is only associated with mortality when it is 
more severe. In a recent study of Abosaif et al31, including critically ill patients, only RIFLE-F 
was associated with mortality. The presence of multiple organ failure seems to be the most 
important determinant of outcome in AKI patients, with increasing mortality as the number 
of failing organs increases.25;32 In studies that did focus on sepsis patients, mostly only ICU, 
hospital or 90 day survival was considered and AKI definitions varied widely. The 
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combination of AKI and sepsis is reported to carry a mortality of 70% whereas the mortality 
of ARF alone is 40-45%.14 
Daher et al found that the RIFLE criterion was not an independent predictor of mortality in 
patients admitted to an infectious disease ICU.33 In a study by Kim et al, RIFLE class on the 
day of admission was not associated with an increased risk of 28 day mortality in patients 
with sepsis and septic shock.34 Bagshaw et al used the ANZINCS (Australian New Zealand 
Intensive Care Society Adult Patient Database) for all adult admissions and found a low 
predictive value of RIFLE for in hospital death (adjusted odds ratio 1.54 (1.45-1.64)).3  
Data on long term outcome in septic AKI/critically ill patients are scarce. In our cohort of 
exclusively sepsis patients we found a 1 year and 2 year mortality rate of 44% and 50% 
respectively, in the entire cohort (Table 3). In ICU survivors these were 27% and 35% 
respectively. There was no increasing trend in mortality from no-AKI over RIFLE-R, RIFLE-I 
and RIFLE-F (Table 3).  
Bagshaw et al35 found a 1 year mortality rate of 24.6% in 5693 retrospectively included 
critically ill patients. In patients with septic AKI, 1-year mortality rate was 49.7%. In a 
prospective study including 243 hospital surviving sepsis patients, Lopes et al found that 
13.7% of patients died after a follow-up period of 21  6.4 months.36 
 
7.1.3.2  RRT and mortality 
In our cohort, patients treated with RRT had a 1-year and 2-years mortality of 63% and 67% 
respectively, comparable to the study of Bagshaw et al who found a mortality rate of 64% at 
1 year in those with severe ARF, defined as RRT need.37 Overall, both short and long term 
outcome after AKI in patients treated with RRT in the ICU is poor with mortality rates varying 
between 40% and 85%.38-53  
Mortality in patients treated with RRT is higher than in patients not treated with RRT.4;54-57 
AKI requiring RRT approximately affects around 6% of critically ill patients and results in a 
hospital mortality rate of 60%.58 In a study by Neveu et al, mortality rate in septic ARF 
treated with RRT compared to non septic ARF treated with RRT was 82.4% vs 48.4%.56 In this 
study, patients were generally more severily ill than in our cohort, as suggested by a higher 
APACHE II score, a longer LOS and a very high hospital mortality rate in the overall cohort 
(74.5%). In the SOAP study, mortality rate was comparable to our study with a rate of 61.9% 
in ARF due to all causes treated with RRT.13 In a study by Clermont et al, critically ill patients 
were treated with RRT in 11% of cases which was associated with a hospital mortality rate of 
57%.55 Metcalfe et al found a 90 days mortality rate of 83% in all ARF patients treated with 
RRT, but mortality was substantially lower (55%) in those who were started in a renal unit 
compared to the ICU.48 In a prospective study including 17126 critically ill patients treated 
with RRT, hospital mortality was 62.8%.59 
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7.2  Different AKI definitions and their impact on incidence and 
outcome 
7.2.1  Impact of urinary output 
Omitting the urinary output criterion in the the AKI definition decreases the prevalence of 
AKI and partly explains why epidemiological data on AKI vary widely between different 
studies and even within the same setting. In our cohort, the prevalence of AKI decreased 
when the urinary criterion was omitted, whichever definition was used (Table 4). 
Although both RIFLE60, AKIN61 and also KDIGO62 include the urinary output criterion in the 
definition for AKI and ERBP again stresses the importance of including the urinary output 
criterion63, the latter has been omitted or modified in several studies on AKI 
epidemiology.29;64;65 There are several explanations for the fact the urinary output criterion 
is often omitted. First, in large databases often only 24 hours urinary output is available 
which drives authors to use modified urinary output criteria.64;65 Second, retrospective 
studies and administrative databases often lack data on urinary output. Third, measuring 
hourly urinary output is time-consuming and requires bladder catheterization which implies 
that hourly urinary output measurement is mostly only available in ICU setting and not in the 
general ward. However, Macedo et al66;67 demonstrated that fixed 6 hour blocks for urinary 
output collection, corresponding to nurses’ shifts, are equivalent to hourly measurements 
and thus can be easily applied both in the ICU and the general ward and in patients either 
with or without bladder catheter. 
Urinary output can be considered as an online biomarker for AKI. As stated before, sCr is an 
imperfect parameter that only starts to increase hours after the initial insult.68 We have 
demonstrated that urinary output is an early parameter that can diagnose AKI in a stage 
where there is no tubular damage yet.69 Prowle et al studied 239 critically ill patients in 7 
ICU’s over 6  countries and found that oliguria of greater than 1h was associated with AKI 
defined as RIFLE≥I according to sCr the next day.70 Leedahl et al found that oliguria of ≥ 3h in 
the first 12h after ICU admission predicted AKI as defined by KIDGO≥stage II based on sCr in 
patients with severe sepsis and septic shock.71 Oliguria of greater than 5h had the best 
performance. APACHE III and sCr were not predictive in the first 12 hours.71 In the study of 
Prowle, the majority of consecutive oliguria episodes was not followed by an AKI diagnosis 
based on sCr later on.70 Although one possible explanation for this finding would be that 
olguria is less specific and can be false positive, another explanation can be that oliguria is a 
sensitive marker that detects AKI in an early stage and that early goal directed therapy 
prevented further evolution to AKI based on sCr.  
Some studies found that the urinary output criterion is less predictive of mortality than the 
sCr criterion.16;29;65;72-75 However, Macedo et al showed that urinary output is a sensitive and 
early marker of AKI and is associated with adverse outcomes in critically ill patients.67 
Oliguria of more than 12 hours and oliguria of 3 and more episodes were associated with an 
increased mortality rate. Cruz et al found that urinary output alone had a lower predictive 
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ability but that both criteria (thus including the urinary output criterion) had the best 
predictive ability.72  
Several factors might influence the relationship between GFR and urinary output. First, 
although septic AKI is predominantly oliguric14, AKI can also be non-oliguric.76 In non-oliguric 
AKI, urinary output remains normal or even increases despite a decrease in GFR. Second, the 
use of diuretics might theoretically disturb the relationship between urinary output and GFR. 
However, Han et al74 demonstrated that urinary output had an additional role in AKI staging 
irrespective of diuretic use. Third, fluid resuscitation can also affect urinary output 
independent of GFR. Pickering et al77 developed a model combining creatinine and volume 
kinetics and studied 49 patients who were resuscitated after cardiac arrest. They showed 
that fluid resuscitation leads to an underestimation of sCr and AKI severity which thus leads 
to a delay in AKI diagnosis based on the sCr criterion. However, 41 of 44 patients classified as 
AKI by the sCr criterion, were oliguric in the first 48h, again underlining the importance of 
the urinary output criterion in the diagnosis of AKI, especially when the sCr can be lowered 
due to fluid dilution.77  
Altogether, these findings stress the importance of urinary output in the diagnosis of AKI. 
Emphasis should be put on the application of both criteria (sCr and urinary output) for 
defining AKI. 
 
7.2.2  Absolute vs relative increases in sCr and the  impact of different 
baseline values 
In our cohort, the prevalence of AKI ranged from 14% to 79% according to which AKI 
definition was used (Table 4). We changed AKI definitions either by 1) including vs not 
including the urinary output criterion, 2) using absolute vs relative increases in sCr, 3) using 
different baseline values (either a historical baseline, the ICU admission value or an 
estimated value) and 4) by changing the time span for AKI diagnosis; and we evaluated the 
impact on prevalence and outcome (Table 4).  
 
Table 4: Influence of changing the AKI definition on prevalence of AKI, RRT need, ICU and 1 
year mortality. 
AKI definition no AKI(n/%) AKI(n/%) p value 
1.RIFLE_24h_sCr 110(56.4) 85(43.6)  
   RRT need    8(7.3)    19(22.4)    0.002 
   ICU M    24(21.8)    21(24.7)    0.64 
   1Y M    48(43.6)    37(43.5)    0.99 
    
2.RIFLE_24h_UO 110(56.4) 85(43.6)  
RRT need    10(9.1)    17(20)    0.03 
ICU M    24(21.8)    21(24.7)    0.64 
1Y M    48(43.6)    37(43.5)    0.99 
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3.RIFLE_24h_sCr_UO 64(32.8) 131(67.2)  
RRT need    3(4.7)    24(18.3)    0.01 
ICU M    14(21.9)    31(23.7)    0.78 
1Y M    31(48.4)    54(41.2)    0.34 
    
4.RIFLE_5days_sCr 96(49.2) 99(50.8)  
noRRT need    3(3.1)    24(24.1)    <0.001 
ICU M    18(18.8)    27(27.3)    0.16 
1Y M    38(39.6)    47(47.5)    0.27 
    
5.RIFLE_5days_UO 73(37.4) 122(62.6)  
RRT need    3(4.1)    24(19.7)    0.002 
ICU M    16(21.9)    29(23.8)    0.77 
1Y M    31(42.5)    54(44.3)    0.81 
    
6.RIFLE_5days_sCr_UO 42(21.5) 153(78.5)  
RRT need    1(2.4)    26(17)    0.02 
ICU M    8(19)    37(24.2)    0.48 
1Y M    18(42.9)    67(43.8)    0.91 
1Y M    
    
7.AKIN_48h_sCr 154(79) 41(21)  
RRT need    9(5.8)    18(43.9)    <0.001 
ICU M    30(19.5)    15(36.6)    0.02 
1Y M    63(40.9)    22(53.7)    0.14 
    
8.AKIN_48h_UO 94(48.2) 101(51.8)  
RRT need    7(7.4)    20(19.8)    0.01 
ICU M    22(23.4)    23(22.8)    0.92 
1Y M    39(41.5)    46(45.5)    0.57 
    
9.AKIN_48h_sCr_UO 85(43.6) 110(56.4)  
RRT need    6(7.1)    21(19.1)    0.02 
ICU M    18(21.2)    27(24.5)    0.58 
1Y M    33(38.8)    52(47.3)    0.24 
    
10.KDIGO_sCr 90(46.2) 105(53.8)  
RRT need    3(3.3)    24(23.1)    <0.001 
ICU M    17(18.9)    28(26.2)    0.20 
1Y M    37(41.1)    48(45.7)    0.52 
    
11.KDIGO_UO 73(37.4) 122(62.6)  
RRT need    3(4.1)    24(19.7)    0.002 
ICU M    16(21.9)    29(23.8)    0.77 
1Y M    31(42.5)    54(44.3)    0.81 
    
12.KDIGO_sCr_UO 42(21.5) 153(78.5)  
RRT need    1(2.4)    26(17)    0.02 
ICU M    8(19)    37(24.2)    0.48 
1Y M    18(42.9)    67(43.8)    0.91 
    
13.ERBP_5days_sCr 141(72.3) 54(27.7)  
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RRT need    7(5)    20(37)    <0.001 
ICU M    23(16.3)    22(40.7)    <0.001 
1Y M    55(39)    30(55.6)    0.04 
    
14.ERBP_5days_UO 73(37.4) 122(62.6)  
RRT need    3(4.1)    24(19.7)    0.002 
ICU M    16(21.9)    29(23.8)    0.77 
1Y M    31(42.5)    54(44.3)    0.81 
    
15.ERBP_5days_sCr_UO 63(32.3) 132(67.7)  
RRT need    3(4.8)    24(18.2)    0.01 
ICU M    11(17.5)    34(25.8)    0.20 
1Y M    25(39.7)    60(45.5)    0.45 
    
16.∆HIS_24h_sCr 97(49.7) 98(50.3)  
RRT need    4(4.1)    23(23.5)    <0.001 
ICU M    20(20.6)    25(25.5)    0.42 
1Y M    43(44.3)    42(42.9)    0.84 
    
17.∆HIS_24h_sCr_UO 59(29.2) 138(70.8)  
RRT need    1(3.7)    26(18.8)    0.002 
ICU M    13(22.8)    32(32.2)    0.95 
1Y M    29(50.9)    56(40.6)    0.19 
    
18.∆HIS_48h_sCr 91(46.7) 104(53.3)  
RRT need    3(3.3)    24(23.1)    <0.001 
ICU M    18(19.8)    27(26)    0.31 
1Y M    39(42.9)    46(44.2)    0.85 
    
19.∆HIS_48h_sCr_UO 47(24.1) 148(75.9)  
RRT need    1(2.1)    26(17.6)    0.008 
ICU M    11(23.4)    34(23)    0.45 
1Y M    22(46.8)    63(42.6)    0.61 
    
20.∆EST_24h_sCr 106(54.4) 89(45.6)  
RRT need    3(2.8)    24(27)    <0.001 
ICU M    23(21.7)    22(24.7)    0.62 
1Y M    44(41.5)    41(46.1)    0.52 
    
21.∆EST_24h_sCr_UO 65(33.3) 130(67.7)  
RRT need    1(1.5)    26(20)    <0.001 
ICU M    16(24.6)    29(22.3)    0.72 
1Y M    30(46.2)    55(42.3)    0.61 
    
22.∆EST_48h_sCr 103(52.8) 92(47.2)  
RRT need    2(1.9)    25(27.2)    <0.001 
ICU M    21(20.4)    24(26.1)    0.35 
1Y M    41(39.8)    44(47.8)    0.26 
    
23.∆EST_48h_sCr_UO 56(28.7) 139(71.3)  
RRT need    1(1.8)    26(18.7)    0.002 
ICU M    14(25)    31(22.3)    0.69 
1Y M    23(41.1)    62(44.6)    0.65 
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24.∆ADM_day1_sCr 166(85.1)  27(13.8)   
RRT need    13(7.8)    14(51.9)    <0.001 
ICU M    31(18.7)    12(44.4)    0.003 
1Y M    66(39.8)    17(63)    0.02 
    
25.∆ADM_day1_sCr_UO 105(53.8) 88(45.1)  
RRT need    9(8.6)    18(20.5)    0.02 
ICU M    20(19)    23(26.1)    0.24 
1Y M    42(40)    41(45.6)    0.36 
(Legend:UO: urinary output criterion, sCr: serum creatinine criterion, 24h: AKI diagnosis over a time span of 24 
hours after ICU admission, 48h: AKI diagnosis over a time span of 48h after ICU admission, 5days: AKI diagnosis 
over a time span of 5 days after ICU admission, ∆EST: creatinine increase based on the difference between the 
highest value over a certain time span and an estimated baseline value according to ADQI, ∆ADM_day 1: 
creatinine increase based on the difference between the value 24 hours after admission and the ICU admission 
value, ∆HIS: creatinine increase based on the difference between the highest value over a certain time span and 
a historical baseline value.) 
 
As described in Chapter 7.1.3.2 on mortality and AKI, we did not find an increase in mortality 
with increasing stages of AKI according to RIFLE (no AKI vs RIFLE-R, RIFLE-I and RIFLE-F). 
Whether AKI is an independent predictor of mortality remains controversial and when an 
association is found, it is mostly for more severe AKI and short term mortality. Poukkanen et 
al found that in a cohort of 918 sepsis patients, only KDIGO stage 3 was associated with 90 
day mortality, whereas stage 1 and 2 were not.78 In a study by Hoste et al4, the excess 
mortality in patients with AKI could be entirely explained by the high mortality in patients 
treated with RRT. Increasing age, need for vasoactive treatment and need for RRT were 
independently associated with mortality in their model.4 Ostermann et al demonstrated that, 
although there is an association between AKI and hospital outcome, associated organ failure, 
non-surgical admission and admission after emergency surgery, all had a greater impact on 
prognosis than severity of AKI.7 In another study, it was demonstrated that the most 
important predictors for mortality were already present at admission to the ICU and 
included advanced age, the presence of infection, a past history of certain chronic diseases 
and the presence of other failing organs.32  
Although in recent literature it was demonstrated that even small increases in serum 
creatinine are independently associated with  a higher risk of mortality, these results are 
mainly obtained in cohorts of cardiac surgery patients, after coronarography and after 
myocardial infarction 21;79-82 and cannot necessarily be extrapolated to sepsis. In our cohort 
we analysed different cut-off levels for absolute sCr increase (0.1 to 0.5 mg/dl with an 
interval of 0.1mg/dl) for association with mortality and we used different reference values to 
calculate this serum creatinine increase (either a historical baseline value, an estimated 
baseline value according to ADQI or the ICU admission value).  
We found that, as in the cardiac surgery setting, a 0.3 mg/dl increase in sCr was associated 
with mortality but only if this increase was calculated based on the difference between the 
value 24 hours after admission and the ICU admission value. Compared to all of the other 
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definitions we used, this is the only definition that incorporates the response to therapy (e.g. 
fluid resuscitation or vasopressor therapy) by comparing the sCr 24h after admission with 
the ICU admission value. These findings suggest that the evolution of sCr in the first 24h is 
more predictive of outcome than the highest value over a certain time span. Most likely, the 
evolution of the sCr in the first 24h is a reflection of the fluid responsiveness, as explained by 
the KDIGO guideline on AKI and confirmed by the ERBP position statement on this topic.62;63 
Although we did find an association between a 0.3mg/dl increase in sCr and mortality, this 
association did not persist after adjustment for severity of illness. This finding was confirmed 
by assessing AUC ROC curves demonstrating no change in discriminatory power by adding vs 
not adding AKI to the model (AUC ROC 0.71 for both).  
In our cohort, 150 patients survived ICU. In a multivariate analysis, including different AKI 
definitions to the model, only age but not AKI, was retained as an independent predictor of 
mortality. These results are corroborated by Sasse et al who demonstrated that the survival 
rate was negatively correlated with the APACHE II score up to 1 month after hospital 
admission, but uncorrelated thereafter.83 Ponte et al also showed that long-term outcome 
seems to be more conditioned by general factors rather than by the acute illness.84 Pereira 
et al found that long term survival of AKI patients was associated with their underlying 
comorbidities and not with severity of AKI.85 In the same line, health related quality of life 
after recovery is more strongly affected by pre-existing diseases and age than by severity of 
illness in ICU.38 Although Bagshaw et al found that 1 year mortality was independently 
associated with advanced age, medical diagnosis, higher APACHE II score and presence and 
severity of kidney function, there was no difference in outcome between those with mild 
versus moderate kidney dysfunction defined as a peak sCr between 1.7mg/dl and 3.4 mg/dl 
versus a peak sCr of >3.4mg/dl but without RRT need, respectively.35 Thus although patients 
with either mild or moderate kidney dysfunction had an increased risk of death vs those 
without kidney dysfunction, use of sCr level alone was poor at discriminating long term 
outcome, suggesting this measure alone should not be used for defining long-term 
prognosis.35 However, our results were not corroborated by Linder et al, who did find an 
association between small increases of sCr and long-term mortality, even after adjustment 
for several covariates.86  
 
7.3  Biomarkers 
7.3.1 Introduction 
The search for new biomarkers has been driven by the fact that AKI diagnosis currently relies 
on imperfect parameters such as sCr which is a functional parameter that only rises hours 
after the initial insult.68 Also, the percentage changes in sCr after severe AKI are highly 
dependent on baseline kidney function. In a study of Waikar et al87, twenty-four hours after 
a 90% reduction in creatinine clearance, the rise in sCr was 246% with normal baseline 
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kidney function, 174% in stage 2 CKD, 92% in stage 3 CKD and only 47% in stage 4 CKD as 
opposed to a nearly identical absolute increase in sCr (1.8 to 2 mg/dl).  
The paradigm that sCr is an imperfect parameter has stimulated the search for a troponin-
like biomarker for AKI diagnosis. An ideal biomarker for AKI should 1) only increase in case of 
tubular damage, 2) correspond to the potential lesions seen on biopsy, 3) follow the clinical 
course, 4) not increase in case of other organ failure besides renal and 5) be easily measured 
at low cost.88 
In the last decade, many papers on the use of new urinary and serum biomarkers for AKI 
were published, mostly concluding that these biomarkers will lead to a new era with earlier 
diagnosis, better prognostication of outcome in terms of need for renal replacement and/or 
mortality, and finally better survival.89 Nevertheless, there remains a gap between the 
fascinating findings at the basic science level and the clinical application of this knowledge 
and objective evaluation of the available literature shows a rather disappointing picture.90 
There are different potential explanations for these disappointing results. First, biomarkers 
are studied in widely different clinical settings, from paediatric post cardiac surgery, where 
timing and amount of renal impact are exactly known, to patients with septic shock, where 
timing of renal insult is unknown. Overall, diagnostic performance of biomarkers appears to 
be better in situations with a known timing and etiology of renal injury. Second, most of 
these markers are not only associated with kidney damage, but also with the underlying 
conditions causing the AKI, such as sepsis, diabetic nephropathy, systemic lupus 
erythematosus and hemolytic uremic syndrome.91-94 Some of these markers are also 
increased in chronic kidney disease95;96, blurring the differential diagnosis between CKD and 
AKI. The reference baseline creatinine of a given patient is not always available, so in these 
patients, it is unclear whether an increased creatinine is due to AKI or chronic kidney disease 
(CKD). The behavior of most biomarkers in patients with CKD is however largely unknown. 
Usefulness of biomarkers should thus be addressed differently for different clinical settings, 
as it is apparent that performance is strongly dependent on the underlying circumstances. As 
such, results in one setting cannot be generalised.  Especially in sepsis, the use of biomarkers 
is hampered by the fact that there is no clear timing of insult and that patients are very 
heterogenous with different comorbidities. AKI is mostly multifactorial, especially in the 
critically ill setting, and thus it is not likely that one single biomarker will cover its entire 
spectrum.97 Some authors have tried to resolve this issue by using a panel of biomarkers 
instead of one single biomarker.98 Although the results seem promising, there remains an 
important overlap between AKI and no AKI patients. Also, the high cost associated with 
these techniques is clearly a limiting factor and in the absence of a clear benefit over more 
traditional markers, their use cannot be justified. Kashani et al99 recently found that 
prediction of AKI in critically ill patients was improved by combining two urinary biomarkers, 
involved in the G1 cell cycle arrest. The two-marker panel performed better than either one 
of the markers separately and also performed better than urinary or plasma NGAL, plasma 
cystatin C and urinary KIM-1, pi-GST, LFABP and IL-18.  In the latter study, AKI was defined as 
KDIGO stage 2 or 3 whereas the focus should e on diagnosing early stages of AKI at a time 
when serum creatinine is not yet increased.99 However, it must also be  acknowledged that 
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as long as we lack a clinical useful gold standard for diagnosing AKI, it remains difficult to 
prove the advantage of any new biomarker over the imperfect parameter that is used (sCr).  
 
7.3.2  Neutrophil gelatinase-associated Lipocalin (NGAL) 
One of the most studied biomarkers in the field of nephrology is Neutrophil gelatinase-
associated Lipocalin (NGAL).100;101 NGAL was first discovered in the granules of neutrophils 
and was originally used for differentiation between bacterial and viral infections.102-104 
However, it can also be induced by distal renal tubular cells in case of kidney injury and is 
expressed by several other epithelia such as the uterus, prostate, salivary glands, lung, liver, 
trachea, stomach and colon.105 Also, in urinary tract infection the presence of urinary 
leucocytes influences urinary NGAL levels. 106 
Several immunoassays have been developed for the measurement of NGAL. Currently, there 
are three commercially available immunoassays: 1) Triage NGAL test from Biosite-Inverness 
Medical which is a point of care fluorescence immunoassay that can be used bedside (result 
after approximately 20 minutes) on whole blood or plasma, 2) NGAL Test from Bioporto, an 
enhanced turbidimetric immunoassay with the advantage of potential use on different 
clinical chemistry analyzers and suitable for testing both plasma and urine with only a small 
amount of sample (3µl) requested (result in 10 minutes), 3) ARCHITECT platform from 
Abbott Diagnostics, a chemiluminescent microparticle enhanced immunoturbidimetric 
immunoassay wich requires a sample volume of 150µl and only operates on urine (result in 
35 minutes). Besides these commercially available automated immune assays there are also 
several non-automated research ELISA’s.107-111  
In humans, NGAL can be found in three different forms: 1) a 25kDa monomer, 2) a 45 kDa 
disulfide-linked homodimer and 3) a 135 kDa  heterodimer where the protein is covalently 
bonded to matrix metalloproteinase 9 (MMP-9). The fact that different forms of NGAL exist, 
implies that the antibody configuration of an immunoassay might affect the clinical 
performance, depending on which form of NGAL is potentially measured. Cai et al 112 
showed that the monomeric form and to some extent the heterodimeric forms are the 
predominant forms produced by tubular epithelial cells, whereas the dimeric form seems 
unique to the neutrophils. In their study, urine levels of NGAL were measured comparing five 
ELISA’s each using different antibodies which reacted with different epitopes and thus 
identifying different molecular structures. Martensson et al 113 tried to ‘remove’ the dimeric 
signal in urine by constructing a ratio of two different ELISA tests, which amplified the 
monomeric signal and almost completely distinguished monomeric from dimeric NGAL. 
However, the currently available immunoassays do not distinguish between the protein 
produced by the renal tubular cell versus the protein synthesized by neutrophils and even if 
such a test would be commercially available, some other issues remain problematic in the 
use of NGAL as a marker of AKI. First, neutrophils (and thus dimeric NGAL) are increasingly 
being recognized as having an important role in the pathophysiology of AKI.114 This implies 
that potentially also dimeric NGAL can indirectly be a reflection of tubular damage. Second, 
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most patients with CKD demonstrate a common pathway of chronic tubulointersitial damage 
and thus increased (supposingly) monomeric NGAL levels even in the absence of acute (on 
chronic) kidney disease. Third, there are insufficient data about biological variability, 
additional pre analytical sources of variation and definitive diagnostic tresholds are 
unavailable. 115 
In sepsis, several studies demonstrated increased levels of NGAL , even in the absence of 
AKI.116;117 Since NGAL is filtered at the glomerular level, its presence in the urine can also be 
due to overflow from the systemic circulation, even in the absence of AKI. In our study, we 
found an important correlation between uNGAL and sNGAL. NGAL levels increased with 
increasing tertiles of CRP and APACHE II score increase, illustrating the relationship between 
NGAL and increasing levels of severity of inflammation and severity of  illness. The latter 
pleads for caution when using NGAL as a diagnostic criterion for AKI in sepsis 
 
7.3.3  Pathophysiology of AKI in sepsis 
7.3.3.1  Transient and intrinsic AKI 
One of the major challenges in clinical nephrology is the differentiation between transient 
and intrinsic AKI. Transient or so called ‘prerenal azotemia’ is considered a physiological 
response to a decrease in glomerular capillary perfusion pressure with little or no tubular 
damage, presumed that the condition is managed in a timely manner by increasing perfusion 
pressure, either by fluid resuscitation or vasopressor therapy.118-122 We demonstrated that 
urinary NGAL levels were not different between no AKI and transient AKI if the diagnosis was 
based on the urinary output criterion, however when based on the sCr criterion, we found a 
gradual increase in uNGAL levels. This suggests that transient AKI without tubular damage 
does exist and at the same time, underlines the importance of urinary output as an online 
biomarker for detecting AKI in a stage where there is no tubular damage yet. The existence 
of transient AKI without tubular damage has been questioned in recent literature. Doi et al 
and Nejat et al123;124 demonstrated that biomarker levels were increased, even in patients 
who were classified as having transient AKI, suggesting that there is always a certain degree 
of tubular damage, even in transient AKI, and that immunological cascades, causing direct 
tubular damage, rather than renal hypoperfusion, are responsible for septic AKI.125 This 
belief has also led to the creation of a new entity called ‘subclinical AKI’ which is defined as a 
condition where the sCr and urinary output criteria of RIFLE, AKIN,KDIGO or ERBP are not 
fulfilled but biomarkers are positive.126;127 As stated above, we found a strong correlation 
between serum and urinary NGAL in sepsis and concluded that biomarker positivity does not 
automatically imply tubular damage, at least in sepsis, and thus can be falsely positive. The 
belief that transient AKI without tubular damage does not exist has also been stimulated by 
the fact that several reports demonstrated that not only intrinsic128 but also transient AKI 
portends a worse prognosis compared to no AKI.79;129;130 131 However, it remains uncertain 
whether this reflects a causal relationship or whether transient AKI is predominantly a 
surrogate marker for severity of disease. In a retrospective study of Uchino et al130, 
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hospitalized patients with transient azotemia, defined as a recovery of kidney function 
within 72h, had higher odds for hospital mortality. However, baseline serum creatinine 
values were not available in the majority of patients and were estimated according to ADQI60 
which might have influenced the classification. Also, data on comorbidities influencing the 
prevalence of AKI, such as diabetes, were not available. 
 
7.3.3.2  Urinary indices 
In our study, we calculated the FENa and FEUrea in 107 septic patients and classified them 
according to FEUrea and FENa quartiles. Our data indicate that in patients with incipient 
sepsis, FENa is far below the proposed cut-off of 1%. Less than 25% of patients had a FENa 
above 1%, whereas 50% had a FENa below 0.36%. This is in line with what we would expect 
in a situation of renal hypoperfusion with tubular integrity, as hypoperfusion at the level of 
the glomerulus will upregulate tubular retention of sodium, leading to a decrease in FENa. 
When tubular damage occurs, the polarization of the tubular cell is reversed, and sodium is 
no longer reabsorbed, but rather actively secreted into the tubular space. It seems likely that 
a very low FENa always is a hallmark of renal hypoperfusion with absence of tubular damage, 
whereas a higher FENa around 1% might be both a sign of improved renal perfusion with 
intact tubuli or of beginning loss of polarization, and thus tubular damage. Bagshaw et al132 
recently reported an admission FENa below 1% in 57% of septic patients, being not different 
from non-septic patients. Darmon et al133 reported a median FENa on admission of 0.50%. 
Using RoC curve analysis, the same authors also found that a fractional excretion of 0.58% 
had the best discriminative power, resulting in a positive and negative predictive power for 
persistent AKI of 0.71 and 0.47 respectively.133 In our cohort, using the median of 0.36%, we 
observed a dose dependent increase in prevalence of AKI based on the urinary 
outputcriterion, with quartiles of decreasing FENa and FEUrea. There was no association for 
AKI based on the sCr criterion. These findings illustrate that patients become more oliguric 
as they retain more salt and water. In this cohort, neither one of the used tools (either FENa, 
FEUrea or NGAL) could differentiate between transient and intrinsic AKI. However, a 
combined use of FENa and FEUrea had a predictive value.  
Several tools, such as urinary indices and urinary microscopic evaluation have been studied 
to differentiate between transient and intrinsic AKI. Espinel et al introduced the use of FENa 
for differentiation between prerenal and intrinsic AKI in 1976.134 In the prerenal state, the 
tubule retains salt and water whereas in intrinsic AKI polarity might be lost which in turn 
leads to active sodium secretion and hence a high FENa. However, differential diagnosis is 
hampered by conditions in which intrinsic AKI is associated with a low FENa (f.e. 
myoglobinuric renal failure, hemoglobinuric renal failure, contrast nephrotoxicity, non 
oliguric ATN, hepatorenal syndrome, heart failure, renal aretery stenosis) and prerenal 
azotemia with a high FENa (volume depletion with ongoing diuretic use, metabolic alkalosis, 
glucosuric states, aldosterone deficiency).135-138 Vaz et al139 included sepsis to the list of 
conditions affecting the reliability of the FENa test.  Their conclusion was based on the 
results of a low FENa in only two septic patients. Authors excluded prerenal azotemia as a 
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possible explanation for their findings because adequate central filling pressures were found 
by Swann Ganz catheterisation. However, there is no reliable tool to estimate volume status 
and a low glomerular perfusion pressure in these patients, despite a general hyperdynamic 
state, cannot be excluded.  
The use of FEUrea could theoretically overcome the problem of a high FENa in conditions of 
volume depletion with continued diuretic use, since tubular urea transport is mainly passive 
and thus less affected by the use of diuretics.136-142 A direct relation between urinary flow 
rate and urea excretion is well known.143 There are conflicting results on the use of FENa and 
FEUrea for dfferential diagnosis between prerenal/transient and intrinsic AKI. Carvounis et 
al144 found that a low FEUrea had a higher sensitivity and specificity for differentiating 
between prerenal azotemia and intrinsic AKI, especially when diuretics were used, in 102 
consecutive adult patients referred to the nephrologist for evaluation. They also 
demonstrated that FEUrea decreased proportionally to urinary output. However, Pepin et 
al145 found that FEUrea is not a better tool than FENa to diagnose transient AKI, regardless of 
diuretic intake. In a systematic review, both in humans and in experimental septic AKI, 
Bagshaw et al146;147 concluded that neither the use of urinary indices or urinary microscopic 
evaluation is of any clear benefit in the differential diagnosis between prerenal and intrinsic 
septic AKI. However, only 52% of patients in their review fulfilled the criteria for sepsis and 
only 54% had clear evidence of AKI.146 Most of the included studies did not have a control 
group and the time frame for diagnosis of sepsis and ARF was highly variable, inconsistent or 
not reported.148  
Surprisingly, and against our initial hypothesis, a low (<31.5 %) fractional urea excretion at 4 
hours was associated with intrinsic rather than with transient AKI, especially when it was 
persistent over time, whereas a value higher than 31.5% had a very high negative predictive 
value for intrinsic AKI. In patients with a fractional sodium excretion above 0.36%, the 
discriminatory value of fractional urea excretion was even more pronounced (figure 4B).  
Darmon et al reported a FEUrea of 39% in the no AKI vs 41% in the transient AKI vs 32% in 
the intrinsic AKI group, and concluded that FEUrea had a low value for discriminating 
intrinsic AKI.133 They based their analysis on admission FEUrea, whereas we used the value 4 
hours after admission, when some attempts to restore low glomerular filtration pressure 
(e.g. by a fluid challenge or start of vasopressors) have already been installed. However, data 
based on FEUrea and FENa at admission showed comparable results, though less impressive 
(data not shown). Our findings are in line with those of De Witte et al149, who also found a 
reasonable value of FEurea<40% as a parameter to discriminate transient from intrinsic AKI. 
As a low fractional excretion of urea apparently represents a low glomerular filtration, we 
hypothesized that a combination of fractional sodium and urea excretion would yield the 
most optimal prediction of patients with a substantial chance to respond positively to 
attempts to restore glomerular filtration. Indeed, in our cohort, a combination of a high 
fractional sodium and urea excretion yielded a 95% probability of restoring diuresis, and AKI 
being transient rather than intrinsic, whereas a persistently low fractional urea excretion in 
combination with a high fractional sodium excretion was suggestive for intrinsic AKI. We also 
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demonstrated that there was a continuum between transient AKI without tubular damage, 
transient AKI with minor tubular damage and intrinsic AKI. 
 
7.4 Limitations 
We fully acknowledge that this work is based on a relatively small cohort of patients. Also, 
due to our inclusion criteria mainly patients with severe sepsis and septic shock were 
included which means that results can not be generalized to patients with less se vere sepsis. 
Although 195 patients were included, NGAL levels were only measured in the first 107 
patients because interim analyses failed to show a benefit for NGAL in diagnosing AKI or 
predicting RRT. This implies that the studies described in chapters 4, 5 and 6 are focusing on 
the first 107 patients only. For the study on robustness of creatinine based AKI definitions 
(chapter 2), all 195 patients were considered. Further prospective studies in sepsis including 
a larger number of patients are warranted to validate our findings. 
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8.1  Definition of AKI 
Despite the fact that several associations and guideline bodies established criteria to define 
AKI, epidemiological data on AKI continue to vary widely, even within the same setting. This 
is predominantly explained by dissimilarity in using the RIFLE, AKIN, KDIGO and ERBP criteria. 
Although these criteria are originally based on both the sCr and the urinary output criterion, 
the latter is often omitted.  
We used different criteria to define AKI, either including vs not including the urinary output 
criterion, using absolute vs relative sCr changes and changing the baseline value (either a 
historical baseline, an estimated baseline value or the ICU admission value). By doing this we 
found a widely different prevalence of AKI ranging from 14% to 79% depending on which 
definition was used. Overall, prevalence decreased from 45-79% till 14%-54% if the urinary 
output was not included, highlighting the importance of using both criteria when defining 
AKI. 
 
8.2  AKI and mortality 
In our sepsis cohort, overall mortality was high, even after ICU survival. We only found an 
association between AKI and mortality if AKI was defined as an absolute sCr increase 
between the value 24 hours after ICU admission and the ICU admission value. However, 
when AKI was defined based on a highest value over a certain span or when referring to a 
historical or an estimated baseline value, no such association was observed. This underlines 
the importance of including a sCr increase that reflects a potential response to specific 
therapy such as fluid resuscitation instead of using the highest sCr value over a certain time 
span without taking into account the evolution of sCr. Also, the ICU admission value should 
be used as the baseline value. 
As in the cardiac surgery setting, the lowest still robust cut-off for sCr increase in sepsis is 
0.3mg/dl. However, although a 0.3mg/dl  increase of sCr was associated with mortality in 
univariate analysis, this was no longer the case after adjusting for severity of illness. This 
indicates that outcome in septic AKI is mainly determined by severity of illness and factors 
that were already present before ICU admission, rather than by AKI itself. 
 
8.3  Biomarkers for diagnosis of AKI 
The difficulties in early diagnosis and the largely unknown pathophysiology of septic AKI, 
partly explain why the successful results in animal studies have not been translated to 
humans. Although the quest for better biomarkers and their allegedly promising results 
might be fascinating from the scientific point of view, their use in daily clinical practice 
currently does not outperform standard markers such as clinical models including sCr and 
urinary output.  
In a systematic review we evaluated the performance of new biomarkers to diagnose AKI 
and found that performance was variable and inconsistent. Overall, biomarkers performed 
better when the exact timing of the renal event was known (e.g. in cardiac surgery) and in 
children without comorbidities. 
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Especially in septic AKI the use of biomarkers becomes complex. First, there is no clear 
timing of the event and second, several biomarkers, such as NGAL and IL-18, can be 
influenced by inflammation, irrespective of AKI. 
It seems highly unlikely that one single biomarker can cover the entire spectrum of AKI. 
However, the use of a panel of biomarkers is expensive, time-consuming and not readily 
available.  
The use of biomarkers for diagnosis of AKI in daily clinical practice is currently not justified 
and a clinical model including sCr and urinary output remains the gold standard. 
 
8.4  Transient vs Intrinsic AKI 
The discrimination between transient and intrinsic AKI and thus between those who would 
potentially benefit from further fluid resuscitation vs those who could rather experience 
harm from it, remains an important issue in clinical nephrology.  
We found a gradual increase in urinary NGAL in patients with no-AKI vs transient AKI vs 
intrinsic AKI, but only if AKI was diagnosed according to the sCr criterion. If based on the 
urinary output criterion, there was no significant difference in NGAL levels between no-AKI 
and transient AKI, demonstrating that recording urinary output might allow for AKI diagnosis 
(and thus treatment) at a stage when there is no tubular damage yet. 
The performance of urinary indices such as FENa and FEUrea to differentiate between 
transient and intrinsic AKI has been questioned. We found that neither FENa, FEUrea or 
NGAL alone, showed a good discriminative value. However, a combination of FENa and 
FEUrea was helpful in differentiating transient and intrinsic AKI. Whereas a high FENa and 
FEUrea is strongly predictive of transient AKI, a high FENa and a low FEUrea is predictive of 
intrinsic AKI. The high prevalence of a very low FENa in early sepsis, questions the value of 
the historically applied 1% cut-off value to differentiate between transient and intrinsic AKI 
and suggests that it should be lower. 
 
8.5  Correlation between sNGAL and uNGAL 
In sepsis, the main determinant of urinary NGAL is serum NGAL, attributed to overflow from 
the systemic circulation and/or reduced tubular reabsorption, irrespective of presence of AKI. 
Both serum and urinary NGAL levels are influenced by severity of illness and inflammation, 
as assessed by APACHE II and CRP. 
Although uNGAL levels were significantly different, but not discriminative, between no-AKI, 
transient and intrinsic AKI, this was no longer the case when classified according to severity 
of illness (sepsis patients without vs with shock). 
These findings caution for the use of NGAL for AKI diagnosis in sepsis. 
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8.6  Pathophysiology of septic AKI 
We found indirect evidence for a role of renal hypoperfusion in early sepsis by 
demonstrating that the majority of patients had a FENa<1% at ICU admission. The latter 
indirectly points to an adequate response of the kidney to a state of decreased glomerular 
perfusion pressure with maximal salt and water retention. This was also corroborated by the 
fact that we found an increase in AKI prevalence, with decreasing quartiles of FENa if AKI 
was defined according to the urinary output criterion, suggesting that as patients are 
retaining more salt and water, they become more oliguric.  
We also found that some patients classified as having transient AKI had no signs of tubular 
injury (as assessed by FENa and NGAL) at admission and still did not have signs of tubular 
injury 24 hours later. Some patients classified as having intrinsic AKI did not have signs of 
tubular injury at admission but did so 24 hours later. These findings are compatible with the 
existence of a continuum between transient AKI without tubular injury, transient AKI with 
minor tubular injury and intrinsic AKI, and underline the role of renal hypoperfusion in the 
pathophysiology of early sepsis. 
 
8.7  Future perspectives 
The importance of uniformity in defining AKI should continue to be stressed. The effect of 
incorporating the evolution of serum creatinine in the AKI definition and of using the ICU 
admission value as a baseline value needs to be validated in larger prospective studies, in 
different settings. 
There is no discussion on the shortcomings of the currently used markers, such as serum 
creatinine, FENa, FEUrea and urinary output for diagnosing AKI. This implies that the search 
for a new troponin-like biomarker with high sensitivity and specificity concerning tubular 
damage, should remain an important target. However, it is unlikely that one biomarker will 
cover the entire spectrum of AKI and different settings such as sepsis, cardiac surgery etc, 
should be individually explored for potential new biomarkers. More emphasis should also be 
put on the analytical issues regarding the method that is being used to quantify the 
biomarker(s) and on standardization of sample collection and preparation, biomarker 
normalization for age, gender and/or urine flow rate and determination of cut-off values to 
distinguish between the diseased and the non-diseased state.  
Long term outcome data in exclusively sepsis patients are scarce. There is an ongoing need 
to investigate long term consequences of septic AKI with regard to increased risk for 
mortality and development of CKD after AKI compared to no-AKI. Although it is generally 
well accepted that AKI is an independent predictor for short and long term mortality and 
increased risk for CKD development, there is still controversy on whether this also stands in 
sepsis, which can be considered as a different clinical entity. Also the association between 
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duration of AKI and outcome should be further explored since several reports indicate that it 
is mainly the duration of AKI that is associated with mortality. 
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